EP1786264A2 - Compositions antiseptiques cationiques et leurs procedes d'utilisation - Google Patents
Compositions antiseptiques cationiques et leurs procedes d'utilisationInfo
- Publication number
- EP1786264A2 EP1786264A2 EP05793861A EP05793861A EP1786264A2 EP 1786264 A2 EP1786264 A2 EP 1786264A2 EP 05793861 A EP05793861 A EP 05793861A EP 05793861 A EP05793861 A EP 05793861A EP 1786264 A2 EP1786264 A2 EP 1786264A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- carboxylic acid
- component
- quaternary ammonium
- antiseptic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 584
- 230000002421 anti-septic effect Effects 0.000 title claims abstract description 200
- 238000000034 method Methods 0.000 title claims description 155
- 125000002091 cationic group Chemical group 0.000 title abstract description 31
- -1 small molecule quaternary ammonium compounds Chemical class 0.000 claims abstract description 192
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 151
- 239000003623 enhancer Substances 0.000 claims abstract description 103
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 101
- 239000004094 surface-active agent Substances 0.000 claims abstract description 88
- 244000005700 microbiome Species 0.000 claims abstract description 79
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 66
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 claims abstract description 52
- 229910052709 silver Inorganic materials 0.000 claims abstract description 45
- 239000004332 silver Substances 0.000 claims abstract description 45
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 40
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims abstract description 33
- 229940123208 Biguanide Drugs 0.000 claims abstract description 25
- 150000004283 biguanides Chemical class 0.000 claims abstract description 22
- 150000004287 bisbiguanides Chemical class 0.000 claims abstract description 22
- 241000700605 Viruses Species 0.000 claims abstract description 15
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical group [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims abstract description 11
- 229960001950 benzethonium chloride Drugs 0.000 claims abstract description 10
- 229960001774 octenidine Drugs 0.000 claims abstract description 7
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960004830 cetylpyridinium Drugs 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 86
- 210000001519 tissue Anatomy 0.000 claims description 60
- 239000003981 vehicle Substances 0.000 claims description 57
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 52
- 238000012360 testing method Methods 0.000 claims description 50
- 241000894006 Bacteria Species 0.000 claims description 45
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 42
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 35
- 239000004599 antimicrobial Substances 0.000 claims description 35
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 35
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 32
- 241000588724 Escherichia coli Species 0.000 claims description 31
- 239000002738 chelating agent Substances 0.000 claims description 29
- 230000009467 reduction Effects 0.000 claims description 29
- 241000191967 Staphylococcus aureus Species 0.000 claims description 22
- 210000003928 nasal cavity Anatomy 0.000 claims description 22
- 150000005846 sugar alcohols Polymers 0.000 claims description 22
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 21
- 229910019142 PO4 Inorganic materials 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 150000002989 phenols Chemical class 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 241000233866 Fungi Species 0.000 claims description 15
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 13
- 125000005233 alkylalcohol group Chemical group 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 239000003242 anti bacterial agent Substances 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 12
- 229920001983 poloxamer Polymers 0.000 claims description 12
- 229940088710 antibiotic agent Drugs 0.000 claims description 11
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 11
- 210000001989 nasopharynx Anatomy 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 11
- 239000010452 phosphate Substances 0.000 claims description 11
- 239000003093 cationic surfactant Substances 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 210000000959 ear middle Anatomy 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 230000000813 microbial effect Effects 0.000 claims description 10
- 210000002345 respiratory system Anatomy 0.000 claims description 10
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 8
- 241000194033 Enterococcus Species 0.000 claims description 8
- 206010021531 Impetigo Diseases 0.000 claims description 8
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 8
- 230000002147 killing effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 7
- 206010033078 Otitis media Diseases 0.000 claims description 7
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 239000000787 lecithin Substances 0.000 claims description 7
- 235000010445 lecithin Nutrition 0.000 claims description 7
- 229940067606 lecithin Drugs 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 241000191940 Staphylococcus Species 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- 208000022760 infectious otitis media Diseases 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 150000002894 organic compounds Chemical class 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- 210000003454 tympanic membrane Anatomy 0.000 claims description 6
- 241000194017 Streptococcus Species 0.000 claims description 5
- 210000002388 eustachian tube Anatomy 0.000 claims description 5
- 230000000415 inactivating effect Effects 0.000 claims description 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 5
- 241000588722 Escherichia Species 0.000 claims description 4
- 150000002195 fatty ethers Chemical class 0.000 claims description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 3
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 238000010227 cup method (microbiological evaluation) Methods 0.000 claims description 2
- 230000037336 dry skin Effects 0.000 claims description 2
- 229960003500 triclosan Drugs 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
- 239000007762 w/o emulsion Substances 0.000 claims description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims 2
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 claims 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 claims 1
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 claims 1
- LKUNXBRZDFMZOK-GFCCVEGCSA-N Capric acid monoglyceride Natural products CCCCCCCCCC(=O)OC[C@H](O)CO LKUNXBRZDFMZOK-GFCCVEGCSA-N 0.000 claims 1
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims 1
- PHMQYKDOTWAOBI-UHFFFAOYSA-N decanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCC(O)=O PHMQYKDOTWAOBI-UHFFFAOYSA-N 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 claims 1
- LKUNXBRZDFMZOK-UHFFFAOYSA-N rac-1-monodecanoylglycerol Chemical compound CCCCCCCCCC(=O)OCC(O)CO LKUNXBRZDFMZOK-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 26
- 238000011282 treatment Methods 0.000 abstract description 22
- 230000000699 topical effect Effects 0.000 abstract description 18
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 abstract description 14
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 abstract description 12
- 229920002413 Polyhexanide Polymers 0.000 abstract description 12
- 229960003260 chlorhexidine Drugs 0.000 abstract description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 5
- 229920000642 polymer Polymers 0.000 description 92
- 229940064004 antiseptic throat preparations Drugs 0.000 description 62
- 238000009472 formulation Methods 0.000 description 57
- 150000001875 compounds Chemical class 0.000 description 52
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 37
- 239000002562 thickening agent Substances 0.000 description 32
- 208000027418 Wounds and injury Diseases 0.000 description 29
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 28
- 206010052428 Wound Diseases 0.000 description 28
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 28
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 28
- 239000000463 material Substances 0.000 description 28
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 27
- 239000002253 acid Substances 0.000 description 27
- 239000012071 phase Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 239000002674 ointment Substances 0.000 description 25
- 229920001223 polyethylene glycol Polymers 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- 239000003921 oil Substances 0.000 description 23
- 239000000839 emulsion Substances 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- 150000001298 alcohols Chemical class 0.000 description 20
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- 239000003995 emulsifying agent Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 239000000178 monomer Substances 0.000 description 18
- 230000001580 bacterial effect Effects 0.000 description 17
- 235000011187 glycerol Nutrition 0.000 description 17
- 235000019271 petrolatum Nutrition 0.000 description 17
- 235000021317 phosphate Nutrition 0.000 description 17
- 239000004264 Petrolatum Substances 0.000 description 16
- 150000001412 amines Chemical group 0.000 description 16
- 229920001577 copolymer Polymers 0.000 description 16
- 210000001331 nose Anatomy 0.000 description 16
- 229940066842 petrolatum Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 239000011521 glass Substances 0.000 description 14
- 230000007794 irritation Effects 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 13
- 125000000129 anionic group Chemical group 0.000 description 13
- 239000002054 inoculum Substances 0.000 description 13
- 150000007513 acids Chemical class 0.000 description 12
- 125000003710 aryl alkyl group Chemical group 0.000 description 12
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 125000003277 amino group Chemical group 0.000 description 10
- 239000003945 anionic surfactant Substances 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 210000003800 pharynx Anatomy 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 9
- 125000002843 carboxylic acid group Chemical group 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229960001484 edetic acid Drugs 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- HAXVBVDETFUQGV-LNQHITRNSA-L mupirocin calcium (anhydrous) Chemical compound [Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 HAXVBVDETFUQGV-LNQHITRNSA-L 0.000 description 9
- 150000003378 silver Chemical class 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 150000001735 carboxylic acids Chemical class 0.000 description 8
- 229920006317 cationic polymer Polymers 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 150000002334 glycols Chemical class 0.000 description 8
- 150000002433 hydrophilic molecules Chemical class 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 229920001451 polypropylene glycol Polymers 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 7
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 7
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 7
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 150000002170 ethers Chemical class 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 229960003085 meticillin Drugs 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 6
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 6
- 150000003863 ammonium salts Chemical class 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 229960000686 benzalkonium chloride Drugs 0.000 description 6
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 6
- 229920001400 block copolymer Polymers 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 229920001903 high density polyethylene Polymers 0.000 description 6
- 239000004700 high-density polyethylene Substances 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 6
- 229960002510 mandelic acid Drugs 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 229920005615 natural polymer Polymers 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 6
- 235000013824 polyphenols Nutrition 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 125000001453 quaternary ammonium group Chemical group 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 229910001961 silver nitrate Inorganic materials 0.000 description 6
- 150000003512 tertiary amines Chemical class 0.000 description 6
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 5
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 229920000289 Polyquaternium Polymers 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 150000008051 alkyl sulfates Chemical class 0.000 description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 5
- 150000001408 amides Chemical group 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 235000010233 benzoic acid Nutrition 0.000 description 5
- 239000000227 bioadhesive Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 229920001002 functional polymer Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 150000004820 halides Chemical class 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 229920001519 homopolymer Polymers 0.000 description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 229960003128 mupirocin Drugs 0.000 description 5
- 229930187697 mupirocin Natural products 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 206010040882 skin lesion Diseases 0.000 description 5
- 231100000444 skin lesion Toxicity 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 5
- 230000008719 thickening Effects 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical group NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 229920000153 Povidone-iodine Polymers 0.000 description 4
- 241000589516 Pseudomonas Species 0.000 description 4
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 239000002280 amphoteric surfactant Substances 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 229920006037 cross link polymer Polymers 0.000 description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000000883 ear external Anatomy 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000001630 malic acid Substances 0.000 description 4
- 235000011090 malic acid Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical class COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 239000000123 paper Substances 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 238000005191 phase separation Methods 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229960001621 povidone-iodine Drugs 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000003871 sulfonates Chemical class 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 229920001059 synthetic polymer Polymers 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- 239000010457 zeolite Substances 0.000 description 4
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 208000034309 Bacterial disease carrier Diseases 0.000 description 3
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 206010011409 Cross infection Diseases 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 244000303965 Cyamopsis psoralioides Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229920002066 Pluronic® P 65 Polymers 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 229910021536 Zeolite Inorganic materials 0.000 description 3
- 150000003926 acrylamides Chemical class 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003260 anti-sepsis Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 239000000174 gluconic acid Substances 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 239000012052 hydrophilic carrier Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 229940053050 neomycin sulfate Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 3
- 229960005323 phenoxyethanol Drugs 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003207 poly(ethylene-2,6-naphthalate) Polymers 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000011112 polyethylene naphthalate Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000005033 polyvinylidene chloride Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 229920005604 random copolymer Polymers 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 3
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- ZPFAVCIQZKRBGF-UHFFFAOYSA-N 1,3,2-dioxathiolane 2,2-dioxide Chemical compound O=S1(=O)OCCO1 ZPFAVCIQZKRBGF-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 2
- JWYVGKFDLWWQJX-UHFFFAOYSA-N 1-ethenylazepan-2-one Chemical compound C=CN1CCCCCC1=O JWYVGKFDLWWQJX-UHFFFAOYSA-N 0.000 description 2
- BVUXDWXKPROUDO-UHFFFAOYSA-N 2,6-di-tert-butyl-4-ethylphenol Chemical compound CCC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 BVUXDWXKPROUDO-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- KIOWXTOCDZJCBM-UHFFFAOYSA-N 2-docosoxyethyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCOCCOC(=O)C(C)=C KIOWXTOCDZJCBM-UHFFFAOYSA-N 0.000 description 2
- JKRDADVRIYVCCY-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O JKRDADVRIYVCCY-UHFFFAOYSA-N 0.000 description 2
- RJWUMFHQJJBBOD-UHFFFAOYSA-N 2-methylheptadecane Chemical compound CCCCCCCCCCCCCCCC(C)C RJWUMFHQJJBBOD-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- ZSILVJLXKHGNPL-UHFFFAOYSA-L S(=S)(=O)([O-])[O-].[Ag+2] Chemical compound S(=S)(=O)([O-])[O-].[Ag+2] ZSILVJLXKHGNPL-UHFFFAOYSA-L 0.000 description 2
- 239000000589 Siderophore Substances 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229920006318 anionic polymer Polymers 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 229940110830 beheneth-25 methacrylate Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960001716 benzalkonium Drugs 0.000 description 2
- 229960003872 benzethonium Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- ZPOLOEWJWXZUSP-WAYWQWQTSA-N bis(prop-2-enyl) (z)-but-2-enedioate Chemical compound C=CCOC(=O)\C=C/C(=O)OCC=C ZPOLOEWJWXZUSP-WAYWQWQTSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 229940067596 butylparaben Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 208000024035 chronic otitis media Diseases 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000412 dendrimer Substances 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- GQOKIYDTHHZSCJ-UHFFFAOYSA-M dimethyl-bis(prop-2-enyl)azanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC=C GQOKIYDTHHZSCJ-UHFFFAOYSA-M 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019820 disodium diphosphate Nutrition 0.000 description 2
- GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000005308 flint glass Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229960004275 glycolic acid Drugs 0.000 description 2
- 210000004349 growth plate Anatomy 0.000 description 2
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 150000002462 imidazolines Chemical class 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940035535 iodophors Drugs 0.000 description 2
- 229920000831 ionic polymer Polymers 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 125000005394 methallyl group Chemical group 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 229910052814 silicon oxide Inorganic materials 0.000 description 2
- 229940009188 silver Drugs 0.000 description 2
- 229940100890 silver compound Drugs 0.000 description 2
- 150000003379 silver compounds Chemical class 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 229910001923 silver oxide Inorganic materials 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 2
- 229910000367 silver sulfate Inorganic materials 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 125000005208 trialkylammonium group Chemical group 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RRHXZLALVWBDKH-UHFFFAOYSA-M trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CC(=C)C(=O)OCC[N+](C)(C)C RRHXZLALVWBDKH-UHFFFAOYSA-M 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000006702 (C1-C18) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- VUWCWMOCWKCZTA-UHFFFAOYSA-N 1,2-thiazol-4-one Chemical class O=C1CSN=C1 VUWCWMOCWKCZTA-UHFFFAOYSA-N 0.000 description 1
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- LORVPHHKJFSORQ-UHFFFAOYSA-N 1-[1-(1-butoxypropan-2-yloxy)propan-2-yloxy]propan-2-ol Chemical compound CCCCOCC(C)OCC(C)OCC(C)O LORVPHHKJFSORQ-UHFFFAOYSA-N 0.000 description 1
- FKKAGFLIPSSCHT-UHFFFAOYSA-N 1-dodecoxydodecane;sulfuric acid Chemical class OS(O)(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC FKKAGFLIPSSCHT-UHFFFAOYSA-N 0.000 description 1
- OSSNTDFYBPYIEC-UHFFFAOYSA-O 1-ethenylimidazole;hydron Chemical compound C=CN1C=C[NH+]=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-O 0.000 description 1
- WAROVFJVCBYVHY-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;trimethyl-[3-(2-methylprop-2-enoylamino)propyl]azanium;chloride Chemical compound [Cl-].C=CN1CCCC1=O.CC(=C)C(=O)NCCC[N+](C)(C)C WAROVFJVCBYVHY-UHFFFAOYSA-N 0.000 description 1
- VBSTXRUAXCTZBQ-UHFFFAOYSA-N 1-hexyl-4-phenylpiperazine Chemical compound C1CN(CCCCCC)CCN1C1=CC=CC=C1 VBSTXRUAXCTZBQ-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- DSAYAFZWRDYBQY-UHFFFAOYSA-N 2,5-dimethylhexa-1,5-diene Chemical group CC(=C)CCC(C)=C DSAYAFZWRDYBQY-UHFFFAOYSA-N 0.000 description 1
- VPALHPGHKUEVMW-UHFFFAOYSA-N 2,5-ditert-butylphenol;3,5-ditert-butylphenol Chemical compound CC(C)(C)C1=CC=C(C(C)(C)C)C(O)=C1.CC(C)(C)C1=CC(O)=CC(C(C)(C)C)=C1 VPALHPGHKUEVMW-UHFFFAOYSA-N 0.000 description 1
- CQFPDEWFXIBERH-UHFFFAOYSA-N 2,6-ditert-butyl-4-[(2-hydroxyphenyl)methyl]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(CC=2C(=CC=CC=2)O)=C1 CQFPDEWFXIBERH-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- SZSSMFVYZRQGIM-UHFFFAOYSA-N 2-(hydroxymethyl)-2-propylpropane-1,3-diol Chemical compound CCCC(CO)(CO)CO SZSSMFVYZRQGIM-UHFFFAOYSA-N 0.000 description 1
- 229920000536 2-Acrylamido-2-methylpropane sulfonic acid Polymers 0.000 description 1
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 1
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- GWEBWJIKMNJFHE-IFWQJVLJSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OCCN(CCO)CCO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O GWEBWJIKMNJFHE-IFWQJVLJSA-N 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical group ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- OYINQIKIQCNQOX-UHFFFAOYSA-M 2-hydroxybutyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCC(O)C[N+](C)(C)C OYINQIKIQCNQOX-UHFFFAOYSA-M 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 description 1
- BTWOVZZLYFQANR-UHFFFAOYSA-N 2-nonylbenzoic acid Chemical compound CCCCCCCCCC1=CC=CC=C1C(O)=O BTWOVZZLYFQANR-UHFFFAOYSA-N 0.000 description 1
- IXOCGRPBILEGOX-UHFFFAOYSA-N 3-[3-(dodecanoylamino)propyl-dimethylazaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O IXOCGRPBILEGOX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- WUYGEUSUCRMJJG-UHFFFAOYSA-N 3-hydroxy-3,7,11-trimethyldodecanoic acid Chemical compound CC(C)CCCC(C)CCCC(C)(O)CC(O)=O WUYGEUSUCRMJJG-UHFFFAOYSA-N 0.000 description 1
- OFNISBHGPNMTMS-UHFFFAOYSA-N 3-methylideneoxolane-2,5-dione Chemical compound C=C1CC(=O)OC1=O OFNISBHGPNMTMS-UHFFFAOYSA-N 0.000 description 1
- NYUTUWAFOUJLKI-UHFFFAOYSA-N 3-prop-2-enoyloxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCOC(=O)C=C NYUTUWAFOUJLKI-UHFFFAOYSA-N 0.000 description 1
- VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical class C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 description 1
- KJFMXIXXYWHFAN-UHFFFAOYSA-N 4,6-ditert-butylbenzene-1,3-diol Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=C(O)C=C1O KJFMXIXXYWHFAN-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- DXPPIEDUBFUSEZ-UHFFFAOYSA-N 6-methylheptyl prop-2-enoate Chemical compound CC(C)CCCCCOC(=O)C=C DXPPIEDUBFUSEZ-UHFFFAOYSA-N 0.000 description 1
- 229920004439 Aclar® Polymers 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000228193 Aspergillus clavatus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 206010065181 Bacterial rhinitis Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229930185605 Bisphenol Chemical class 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- STUSTWKEFDQFFZ-UHFFFAOYSA-N Chlordimeform Chemical compound CN(C)C=NC1=CC=C(Cl)C=C1C STUSTWKEFDQFFZ-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- VTJBUEPNESMAHX-UHFFFAOYSA-N Citricolic acid Natural products CC(C=CC(C)C1(O)CCC2C3=CC(=O)OC3(O)CCC12C)C(C)(C)O VTJBUEPNESMAHX-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 206010064687 Device related infection Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- PQUCIEFHOVEZAU-UHFFFAOYSA-N Diammonium sulfite Chemical compound [NH4+].[NH4+].[O-]S([O-])=O PQUCIEFHOVEZAU-UHFFFAOYSA-N 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000006782 Fusarium chlamydosporum Species 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- 241000427940 Fusarium solani Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical class SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282372 Panthera onca Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 229920000707 Poly(2-dimethylamino)ethyl methacrylate) methyl chloride Polymers 0.000 description 1
- 229920000688 Poly[(2-ethyldimethylammonioethyl methacrylate ethyl sulfate)-co-(1-vinylpyrrolidone)] Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 229910006067 SO3−M Inorganic materials 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 239000004965 Silica aerogel Substances 0.000 description 1
- 108010082714 Silver Proteins Proteins 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241001147693 Staphylococcus sp. Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- JACRWUWPXAESPB-QMMMGPOBSA-N Tropic acid Natural products OC[C@H](C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-QMMMGPOBSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JNGWKQJZIUZUPR-UHFFFAOYSA-N [3-(dodecanoylamino)propyl](hydroxy)dimethylammonium Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)[O-] JNGWKQJZIUZUPR-UHFFFAOYSA-N 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- YDONNITUKPKTIG-UHFFFAOYSA-N [Nitrilotris(methylene)]trisphosphonic acid Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CP(O)(O)=O YDONNITUKPKTIG-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 208000009736 adult acne Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 125000005376 alkyl siloxane group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- QDHUQRBYCVAWEN-UHFFFAOYSA-N amino prop-2-enoate Chemical class NOC(=O)C=C QDHUQRBYCVAWEN-UHFFFAOYSA-N 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 229940051881 anilide analgesics and antipyretics Drugs 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229920002118 antimicrobial polymer Polymers 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 101150099875 atpE gene Proteins 0.000 description 1
- 101150018639 atpFH gene Proteins 0.000 description 1
- 101150048329 atpH gene Proteins 0.000 description 1
- UKXSKSHDVLQNKG-UHFFFAOYSA-N benzilic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CC=C1 UKXSKSHDVLQNKG-UHFFFAOYSA-N 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- OCBHHZMJRVXXQK-UHFFFAOYSA-M benzyl-dimethyl-tetradecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 OCBHHZMJRVXXQK-UHFFFAOYSA-M 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 229920013641 bioerodible polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 229930188620 butyrolactone Natural products 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical class CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- UUAGAQFQZIEFAH-UHFFFAOYSA-N chlorotrifluoroethylene Chemical group FC(F)=C(F)Cl UUAGAQFQZIEFAH-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical group NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- OVPZVYPVKVHQLZ-UHFFFAOYSA-M diethyl-methyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;bromide Chemical compound [Br-].CC[N+](C)(CC)CCOC(=O)C(C)=C OVPZVYPVKVHQLZ-UHFFFAOYSA-M 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 229940079868 disodium laureth sulfosuccinate Drugs 0.000 description 1
- YGAXLGGEEQLLKV-UHFFFAOYSA-L disodium;4-dodecoxy-4-oxo-2-sulfonatobutanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOC(=O)CC(C([O-])=O)S([O-])(=O)=O YGAXLGGEEQLLKV-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- DUYCTCQXNHFCSJ-UHFFFAOYSA-N dtpmp Chemical compound OP(=O)(O)CN(CP(O)(O)=O)CCN(CP(O)(=O)O)CCN(CP(O)(O)=O)CP(O)(O)=O DUYCTCQXNHFCSJ-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- SYUXAJSOZXEFPP-UHFFFAOYSA-N glutin Natural products COc1c(O)cc2OC(=CC(=O)c2c1O)c3ccccc3OC4OC(CO)C(O)C(O)C4O SYUXAJSOZXEFPP-UHFFFAOYSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- PYGSKMBEVAICCR-UHFFFAOYSA-N hexa-1,5-diene Chemical group C=CCCC=C PYGSKMBEVAICCR-UHFFFAOYSA-N 0.000 description 1
- HCDGVLDPFQMKDK-UHFFFAOYSA-N hexafluoropropylene Chemical group FC(F)=C(F)C(F)(F)F HCDGVLDPFQMKDK-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 229940061515 laureth-4 Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920000092 linear low density polyethylene Polymers 0.000 description 1
- 239000004707 linear low-density polyethylene Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229920001179 medium density polyethylene Polymers 0.000 description 1
- 239000004701 medium-density polyethylene Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- MINDHVHHQZYEEK-HBBNESRFSA-N mupirocin Chemical compound C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-HBBNESRFSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940100657 nasal ointment Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- OTCVAHKKMMUFAY-UHFFFAOYSA-N oxosilver Chemical class [Ag]=O OTCVAHKKMMUFAY-UHFFFAOYSA-N 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920002553 poly(2-methacrylolyloxyethyltrimethylammonium chloride) polymer Polymers 0.000 description 1
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
- 229920000212 poly(isobutyl acrylate) Polymers 0.000 description 1
- 229920000205 poly(isobutyl methacrylate) Polymers 0.000 description 1
- 229920000196 poly(lauryl methacrylate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 description 1
- 229920006294 polydialkylsiloxane Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000197 polyisopropyl acrylate Polymers 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- FJOLTQXXWSRAIX-UHFFFAOYSA-K silver phosphate Chemical compound [Ag+].[Ag+].[Ag+].[O-]P([O-])([O-])=O FJOLTQXXWSRAIX-UHFFFAOYSA-K 0.000 description 1
- 229910000161 silver phosphate Inorganic materials 0.000 description 1
- 229940019931 silver phosphate Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940075560 sodium lauryl sulfoacetate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- KKDONKAYVYTWGY-UHFFFAOYSA-M sodium;2-(methylamino)ethanesulfonate Chemical compound [Na+].CNCCS([O-])(=O)=O KKDONKAYVYTWGY-UHFFFAOYSA-M 0.000 description 1
- GOJYXPWOUJYXJC-UHFFFAOYSA-M sodium;2-[1-(2-hydroxyethyl)-2-undecyl-4,5-dihydroimidazol-1-ium-1-yl]acetate;hydroxide Chemical compound [OH-].[Na+].CCCCCCCCCCCC1=NCC[N+]1(CCO)CC([O-])=O GOJYXPWOUJYXJC-UHFFFAOYSA-M 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- BWYYYTVSBPRQCN-UHFFFAOYSA-M sodium;ethenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C=C BWYYYTVSBPRQCN-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940038774 squalene oil Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229950003914 trethocanic acid Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 229940072029 trilaureth-4 phosphate Drugs 0.000 description 1
- QXJQHYBHAIHNGG-UHFFFAOYSA-N trimethylolethane Chemical compound OCC(C)(CO)CO QXJQHYBHAIHNGG-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
- A01N33/02—Amines; Quaternary ammonium compounds
- A01N33/12—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
- A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
- A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
- A01N47/44—Guanidine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D21/00—Nestable, stackable or joinable containers; Containers of variable capacity
- B65D21/08—Containers of variable capacity
- B65D21/086—Collapsible or telescopic containers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- antimicrobial agents plays an important part in current medical therapy. This is particularly true in the fields of dermatology as well as skin and wound antisepsis, where the most effective course of treatment for skin or mucous membranes, which are afflicted with bacterial, fungal, or viral infections or lesions, frequently includes the use of a topical antimicrobial agent, such as antibiotics. For decades medicine has relied primarily upon antibiotics to fight systemic as well as topical infections.
- Antibiotics are organic molecules produced by microorganisms that have the capacity in dilute solutions (e.g., solutions less than 10 ⁇ g/ml and often less than 1 ⁇ g/ml) to destroy or inhibit the growth of bacteria and other microorganisms.
- Antibiotics are commonly of a narrow spectrum of antimicrobial activity. Furthermore, they often act on very specific sites in cell membranes or on very specific metabolic pathways. This can tend to make it relatively easy for bacteria to develop resistance to the antibiotic(s) (i.e., the genetically acquired ability to tolerate much higher concentrations of antibiotic) either through natural selection, transmission of plasmids encoding resistance, mutation, or by other means. Not only does resistance eliminate the ability of a medication to treat an affliction, but it can also put the patient at further risk, especially if the antibiotic is one that is routinely used systemically.
- SA Staphylococcus aureus
- bacitracin neomycin sulfate, polymyxin B sulfate, gentamicin, framycetin-gramicidin, lysostaphin, methicillin, rifampin, tobramycin, nystatin, mupirocin, and combinations thereof, have been used with varying success for nasal decolonization.
- nasal colonization with SA in presurgical patients has resulted in higher infection rates and higher rates of other nosocomial infections such as catheter infections.
- Nasal colonization with SA in hemodialysis patients has resulted in a much higher incidence of blood stream infections.
- MRSA methicillin resistant staphylococcus aureus
- Mupirocin marketed as the calcium salt in Bactroban Nasal by Glaxo Smith Kline, is the only antibiotic approved by the Food and Drug Administration for nasal decolonization use in the United States. For example, there are multiple reports of resistance to mupirocin when used as a nasal decolonizing agent. Resistance rates have been reported as high as 25% and even as high as 50% (see, for example, E. Perez-Roth et al, Diag. Micro. Infect. Pis., 43:123-128 (2002) and H. Watanabe et al., J. Clin. Micro.. 39(10): 3775-3777 (2001)).
- Antiseptics are synthetic molecules that destroy or inhibit microorganisms and virus by inhibiting metabolic pathways or altering the cell envelope or both. They tend to have broader spectrum of antimicrobial activity and often act by nonspecific means such as disruption of cell membranes, oxidation of cellular components, denaturation of proteins, etc. This nonspecific activity makes it difficult for microorganisms to develop clinical resistance to antiseptics.
- antiseptics such as iodine, lower alcohols (ethanol, propanol, etc.), chlorhexidine, quaternary amine surfactants, chlorinated phenols, and the like.
- Some of these compounds need to be used at concentrations that often result in irritation or tissue damage, especially if applied repeatedly.
- many antiseptics are not active in the presence of high levels of organic compounds.
- formulations containing iodine or quaternary ammonium compounds have been reported to be inactivated by the presence of organic matter such as that in nasal or vaginal secretions, and perhaps even on skin.
- compositions containing iodine and/or chlorhexidine have been reported to cause skin and mucosal tissue irritation. This is particularly true for sensitive mucosal tissues, such as the anterior nares, nasal and esophageal cavities, which can have a high level of microbial colonization in certain otherwise healthy individuals, as well as individuals with infectious diseases such as chronic sinusitis. Additionally, due to the irritating nature many of these compounds maybe unsuitable for application to irritated or infected dermal tissue to treat skin conditions, such as lesions from impetigo and shingles.
- compositions for certain applications, especially in the nose and mouth, it is particularly desirable for the compositions to have little or no color, little or no odor, and an acceptable taste.
- Many antiseptics have undesirable characteristics, such as iodine and iodophors, which have an orange to brown color and a definite odor at concentrations typically employed for antisepsis.
- Chlorhexidine gluconate in combination with neomycin sulfate has been suggested for use in nasal decolonization with limited success.
- Naseptin is an antibiotic emulsified cream comprising neomycin sulphate (3250 units/g) and chlorhexidine gluconate (0.1wt-%) that in combination destroys bacteria.
- the product also contains arachis oil, cetostearyl alcohol/ethylene oxide concentrate, cetostearyl alcohol in a water base. The product must be used 4 times/day over 10 days to eradicate nasal carriage of staphylococci.
- U.S. Patent No. 6,214,866 discloses the use of chlorhexidine in combination with the antibiotic mupirocin.
- Povidone-iodine has also been suggested for use in nasal decolonization (R.L. Hill and M.W. Casewell, Journal of Hospital Infection, 2000, Vol. 45, 198-205).
- Betadine Cream (5wt-% povidone iodine) has been found to kill methicillin resistant staphylococcus aureus in vitro in an enrichment culture technique. Addition of nasal secretions decreased the activity of the povidone-iodine by 80-90% by reaction of the free iodine with the organic load.
- the formulation of components can affect the performance and potential irritation of antimicrobial agents.
- many conventional antimicrobial compositions are too low in viscosity and/or too hydrophilic in nature to maintain sufficient substantivity and persistence to provide sufficient antimicrobial activity on moist tissue, such as the anterior nares or open, exuding, or infected lesions. It has been reported that the presence of solvents can diminish the antimicrobial activity of many antiseptics.
- the present invention provides antimicrobial compositions and methods of using and making the compositions.
- Such compositions are typically useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), although a wide variety of surfaces can be treated. They can provide effective reduction, prevention, or elimination of microbes, particularly bacteria, fungi, and viruses.
- the microbes are of a relatively wide variety such that the compositions of the present invention have a broad spectrum of activity.
- compositions of the present invention provide effective topical antimicrobial activity and are accordingly useful in the local treatment and/or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses, ' bacteria, fungi, mycoplasma, and protozoa) on skin, wounds, and/or mucous membranes.
- microorganisms including viruses, ' bacteria, fungi, mycoplasma, and protozoa
- compositions of the present invention have a very low potential for generating clinical microbial resistance.
- such compositions can be applied multiple times over one or more days to treat topical infections or to eradicate unwanted bacteria (such as nasal colonization of Staphylococcus aureus).
- compositions of the present invention can be used for multiple treatment regimens on the same patient without the fear of generating antimicrobial resistance. This can be particularly important for chronically ill patients who are in need of decolonization of the anterior nares before hemodialysis, for example, or for antiseptic treatment of chronic wounds such as diabetic foot ulcers.
- compositions of the present invention have a generally low irritation level for skin, skin lesions, and mucosal membranes (including the anterior nares, nasal cavities, and nasopharangyl cavity). Also, certain preferred compositions of the present invention are substantive (i.e. resist removal by fluids) for relatively long periods of time to ensure adequate efficacy.
- compositions of the present invention include a cationic antiseptic.
- the cationic antiseptics include biguanides and bisbiguanides such as chlorhexidine and its various salts including but not limited to the digluconate, diacetate, dimethosulfate, and dilactate salts as well as mixtures thereof; polymeric quaternary ammonium compounds such as polyhexamethylenebiguanide; silver and various silver complexes; small molecule quaternary ammonium compounds such as benzalkoium chloride and alkyl substituted derivatives, di-long chain alkyl (C6-C18) quaternary ammonium compounds, cetylpyridinium halides and their derivatives, benzethonium chloride and its alkyl substituted derivatives, and octenidine; and combinations thereof.
- the compositions of the present invention are capable of destroying microorganisms on or in mammalian tissue. Therefore, the concentrations employed are generally greater than those that have been used to simply preserve certain topically applied compositions, i.e., prevent the growth of microorganism in topical compositions for purposes other than antisepsis.
- the concentration may be at least 0.1 wt%, preferably at least 0.2wt% and more preferably at least 0.5wt%.
- the antiseptics may be employed at concentration of at least 1 wt-%, preferably at least 2wt-% and often at least 3% by weight of the composition. All weight percents are based on the total weight of a "ready to use" or "as used" composition.
- compositions of the present invention incorporate a substantial amount of a lipophilic or hydrophobic phase.
- the hydrophobic phase is comprised of one or more water insoluble components. If delivered in a hydrophobic phase, the irritation can be significantly reduced. The incorporation of the hydrophobic phase may significantly reduce the irritation potential of the present compositions.
- Preferred lipophilic phase components have a solubility in water of less than 0.5% by weight and often less than 0.1% by weight at 23°C.
- the antiseptic is preferably present at a concentration approaching or preferably exceeding the solubility limit of the hydrophobic phase.
- compositions also have sufficient viscosity to prevent inhalation into the lungs if used in the nose for applications such as nasal decolonization.
- the relatively high viscosity of the compositions of the present invention also minimizes migration that can be associated with other compositions thus reducing irritation and mess.
- hydrophobic phase many of the antiseptic containing compositions exhibit very effective and rapid antimicrobial activity.
- antimicrobial compositions that include hydrophilic components such as polyols (e.g., glycerin and polyethylene glycols) that themselves have little or no antimicrobial activity can considerably enhance the antimicrobial activity of the compositions.
- the hydrophilic component includes a glycol, a lower alcohol ether, a short chain ester, and combinations thereof, wherein the hydrophilic component is soluble in water in an amount of at least 20 wt-% at 23 0 C.
- compositions of the present invention are preferably free of antibiotics.
- compositions also include a surfactant selected from the group of sulfonate, a sulfate, a phosphonate, a phosphate, amphoteric, a poloxamer, a cationic surfactant, or mixtures thereof.
- a surfactant selected from the group of sulfonate, a sulfate, a phosphonate, a phosphate, amphoteric, a poloxamer, a cationic surfactant, or mixtures thereof.
- compositions also include an enhancer component comprising an alpha-hydroxy acid, a beta-hydroxy acid, a chelating agent, a (Cl-C4)allcyl carboxylic acid, a (C6-C12)aryl carboxylic acid, a (C6-C12)aralkyl carboxylic acid, a (C6-C16)alkaryl carboxylic acid, a phenolic compound, a (Cl- C10)alkyl alcohol, an ether glycol, or combinations thereof.
- an enhancer component comprising an alpha-hydroxy acid, a beta-hydroxy acid, a chelating agent, a (Cl-C4)allcyl carboxylic acid, a (C6-C12)aryl carboxylic acid, a (C6-C12)aralkyl carboxylic acid, a (C6-C16)alkaryl carboxylic acid, a phenolic compound, a (Cl- C10)alkyl alcohol, an ether glycol, or combinations
- the present invention also provides various methods of use of compositions of the present invention.
- the present invention provides a method of preventing and/or treating an affliction caused, or aggravated by, a microorganism on mammalian tissue, such as skin and/or a mucous membrane.
- the method includes contacting the mammalian tissue with an antimicrobial composition of the present invention.
- the present invention provides a method of decolonizing at least a portion of the nasal cavities, anterior nares, and/or nasopharynx of a subject of microorganisms.
- the method includes contacting the nasal cavities, anterior nares, and/or nasopharynx with an antimicrobial composition of the present invention in an amount effective to kill one or more microorganisms in or on tissue.
- the present invention provides a method of decolonizing at least a portion of the throat/esophagus of a subject of microorganisms.
- the method includes contacting the esophageal cavity with an antimicrobial composition of the present invention in an amount effective to kill one or more microorganisms in or on the tissue in the throat.
- the present invention provides a method of decolonizing at least a portion of the throat/esophagus of a subject of microorganisms.
- the method includes contacting the oral cavity and/or nasal with an antimicrobial composition of the present invention in an amount effective to allow a sufficient quantity of the composition to pass down the throat to reduce or eliminate bacterial colonization in or on the tissue in the throat.
- the present invention provides a method of decolonizing at least a portion of the oral cavity of a subject of microorganisms.
- the method includes contacting the oral cavity with an antimicrobial composition of the present invention in an amount effective to kill one or more microorganisms in or on the soft tissue in the oral cavity.
- the present invention provides a method of treating respiratory afflictions (e.g., chronic sinusitis in a subject.
- the method includes contacting at least a portion of the respiratory system (particularly the upper respiratory system including the nasal cavities, anterior nares, and/or nasopharynx) with an antimicrobial composition of the present invention in an amount effective to reduce or eliminate bacterial colonization in or on the soft tissue in the respiratory system.
- the present invention provides a method of treating impetigo on the skin of a subject.
- the method includes contacting the affected area with an antimicrobial composition of the present invention in an amount effective to reduce or eliminate clinical signs of infection.
- the present invention provides methods for killing or inactivating microorganisms.
- to "kill or inactivate” means to render the microorganism ineffective by killing them (e.g., bacteria and fungi) or otherwise rendering them inactive (e.g., viruses).
- the present invention provides methods for killing bacteria such as Staphylococcus spp., Streptococcus spp., Escherichia spp., Enterococcus spp. (including antibiotic resistant strains such as vancomycin resistant
- Staphylococcus aureus including antibiotic resistant strains such as methicillin resistant Staphylococcus aureus
- Staphylococcus epiderrnidis Escherichia coli
- Escherichia coli E. CoIi 7
- Pseudomonas aeruginosa Pseudomonas ae.
- Streptococcus pyogenes which often are on or in the skin or mucosal tissue of a subject.
- the method includes contacting the microorganism with an antimicrobial composition of the present invention in an amount effective to kill one or more microorganisms (e.g., bacteria and fungi) or inactivate one or more microorganisms (e.g., viruses, particularly herpes virus).
- microorganisms e.g., bacteria and fungi
- microorganisms e.g., viruses, particularly herpes virus
- the present invention provides a method of killing or inactivating microorganisms in the nose or nasal cavity of a subject.
- the method includes contacting the affected area with an antimicrobial composition of the present invention in an amount effective to kill one or more microorganisms on or in the tissue in the nose or nasal cavity.
- compositions of the present invention can also be used for providing residual antimicrobial efficacy on a surface that results from leaving a residue or imparting a condition to the surface (e.g., skin, in the anterior nares, mucosal tissue, wound, or medical device that comes in contact with such tissues, but particularly skin, mucosal tissue, and/or wound) that remains effective and provides significant antimicrobial activity.
- a surface e.g., skin, in the anterior nares, mucosal tissue, wound, or medical device that comes in contact with such tissues, but particularly skin, mucosal tissue, and/or wound
- compositions with relatively high concentrations of a hydrophobic component generally greater than 30% by weight, preferably greater than 40% by weight and most preferably greater than 50% by weight
- a composition with a relatively high viscosity e.g., in excess of 1,000 cps and preferably in excess of 10,000 cps when measured by the Viscosity Test.
- the present invention provides a method of providing residual antimicrobial efficacy on the skin, in the anterior nares, mucosal tissue, and/or in a wound of a subject, the method includes contacting the skin, mucosal tissue, and/or wound with an antimicrobial composition of the present invention in an amount effective to kill one or more microorganisms.
- Effective amount means the amount of the one or more antiseptic components when in a composition, as a whole, provides antimicrobial (including, for example, antiviral, antibacterial, or antifungal) activity that when applied in an amount, at a frequency, and for a duration, reduces, prevents, or eliminates one or more species of microbes such that an acceptable level of the microbe results. Typically, this is a level low enough not to cause clinical symptoms, and is desirably a non-detectable level.
- the concentrations or amounts of the components when considered separately, may not kill to an acceptable level, or may not kill as broad a spectrum of undesired microorganisms, or may not kill as fast; however, when used together such components provide an enhanced antimicrobial activity (as compared to the same components used alone under the same conditions).
- the listed concentrations of the components are for "ready to use” or "as used” compositions.
- the compositions can be in a concentrated form. That is, certain embodiments of the compositions can be in the form of concentrates that would be diluted by the user with an appropriate vehicle.
- Hydrophilic or “water-soluble” refers to a material that will disperse or dissolve in deionized water (or other aqueous solution as specified) at a temperature of 23°C in an amount of at least 7% by weight, preferably at least 10% by weight, more preferably at least 20% by weight, even more preferably at least 25% by weight, even more preferably at least 30% by weight, and most preferably at least 40% by weight, based on the total weight of the hydrophilic material and the water.
- the component is considered dissolved if after thoroughly mixing the compound with water at 60°C for at least 4 hours and allowing this to cool to 23-25°C for 24 hours, and mixing the composition thoroughly it appears uniform clear solution without visible cloudiness, phase separation, or precipitate in ajar having a path length of 4 cm.
- the samples typically when placed in 1 x lcm cell, the samples exhibit greater than 70% transmission measured in a suitable spectrophotometer at a wavelength of 655 nm.
- Water dispersible hydrophilic materials disperse in water to form uniform cloudy dispersions after vigorous shaking of a 5% by weight mixture of the hydrophilic component in water.
- Preferred hydrophilic components are water-soluble.
- “Hydrophobic” or “water-insoluble” refers to a material that will not significantly dissolve in deionized water at 23°C. "Not significantly” means that the solubility in water of the material is less than 5% by weight, preferably less than 1% by weight, more preferably less than 0.5% by weight, and even more preferably less than 0.1% by weight, based on the total weight of the hydrophobic material and the water. Solubility can be determined by thoroughly mixing the compound with water at the appropriate concentration at 23°C for at least 24 hours (or at elevated temperature if that is necessary to dissolve the compound), allowing this to sit at 23-25°C for 24 hours, and observing the sample.
- the sample In a glass jar with a 4 cm path length the sample should have evidence of a second phase which can be liquid or solid and may be separated on the top, bottom, or distributed throughout the sample. For crystalline compounds care must be taken to avoid producing a supersaturated solution. The components should be mixed and observed. Cloudiness or presence of a visible precipitate or separate phase indicates that the solubility limit has been exceeded. Typically when placed in 1 x lcm cell the sample has less than 70% transmission measured in a suitable spectrophotometer at a wavelength of 655 nm.
- solubility is determined using radiolabeled compounds as described under "Conventional Solubility Estimations" in Solubility of Long-Chain Fatty Acids in Phosphate Buffer atpH 7.4, Henrik Vorum, et. al., Biochimica et. Bio ⁇ hvsica Acta. 1126 (1992) 135-142.
- “Stable” means physically stable or chemically stable, which are both defined in greater detail below. Preferred compositions are both chemically and physically stable.
- “Antibiotic” means an organic chemical compound produced by microorganisms that has the ability in dilute concentrations to destroy or inhibit microorganisms and is used to treat infectious disease. This may also encompass semi-synthetic compounds that are chemical derivatives of the compound produced by microorganisms or synthetic compounds that act on very specific biochemical pathways necessary for the cell's survival.
- Antiseptic means a chemical agent other than the "enhancers” described herein that kills pathogenic and non-pathogenic microorganisms.
- Preferred antiseptics exhibit at least 4 log reduction of both P. aeruginosa and S. aureus in 60 minutes from an initial inoculum of 1-3 x 10 7 cfu/ml when tested in Mueller Hinton broth at 35 0 C at a concentration of 0.25wt% in a Rate of Kill assay using an appropriate neutralizer as described in The Antimicrobial Activity in vitro of chlorhexidine, a mixture of isothiazolinones (Kathon CG) and cetyl trimethyl ammonium bromide (CTAB), G. Nicoletti, V. Boghossian, F.
- Antiseptics generally interfere more broadly with the cellular metabolism and/or the cell envelope.
- Antiseptics may be small molecule or polymeric. Small molecule antiseptics generally have molecular weights less than about 350 g/mole. Polymeric antiseptics can be much higher in molecular weight.
- Enhancer means a component that enhances the effectiveness of the antiseptic component such that when the composition less the antiseptic component and the composition less the enhancer component are used separately, they do not provide the same level of antimicrobial activity as the composition as a whole.
- an enhancer component in the absence of the antiseptic component may not provide any appreciable antimicrobial activity.
- the enhancing effect can be with respect to the level of kill, the speed of kill, and/or the spectrum of microorganisms killed, and may not be seen for all microorganisms, hi fact, an enhanced level of kill is most often seen in Gram negative bacteria such as Escherichia coli.
- An enhancer may be a synergist such that when combined with the remainder of the composition, the composition as a whole displays an activity that is greater than the sum of the activity of the composition less the enhancer component and the composition less the antiseptic component.
- Mucosal membranes are used interchangeably and refer to the surfaces of the nasal (including anterior nares, nasoparangyl cavity, etc.), oral (e.g., mouth), outer ear, middle ear, vaginal cavities, and other similar tissues. Examples include mucosal membranes such as buccal, gingival, nasal, ocular, tracheal, bronchial, gastrointestinal, rectal, urethral, ureteral vaginal, cervical, and uterine mucosal membranes.
- Preservative refers to antiseptics which are incorporated into a composition to prevent biological contamination and/or deterioration of a composition.
- Affliction means a condition to a body resulting from sickness, disease, injury, bacterial colonization, etc.
- Treatment means to improve the condition of a subject relative to the affliction, typically in terms of clinical symptoms of the condition.
- Decolonization refers to a reduction in the number of microorganisms (e.g., bacteria and fungi) present in or on tissue that do not necessarily cause immediate clinical symptoms. Examples of decolonization include, but are not limited to, decolonization of the nasal cavity and wounds. Ordinarily fewer microorganisms are present in “colonized tissue” than in “infected tissue.” When the tissue is completely decolonized the microorganisms have been “eradicated”. "Subject” and “patient” includes humans, sheep, horses, cattle, pigs, dogs, cats, rats, mice, or other mammal.
- Wound refers to an injury to a subject which involves a break in the normal skin or mucosal tissue barrier exposing tissue below, which is caused.by, for example, lacerations, surgery, burns, damage to underlying tissue such as pressure sores, poor circulation, and the like. Wounds are understood to include both acute and chronic wounds.
- a means one or all of the listed elements (e.g., preventing and/or treating an affliction means preventing, treating, or both treating and preventing further afflications).
- compositions include one or more antiseptics selected from the group consisting of biguanides and bisbiguanides such as chlorhexidine and its various salts including but not limited to the digluconate, diacetate, dimethosulfate, and dilactate salts as well as combinations thereof; polymeric quaternary ammonium compounds such as polyhexamethylenebiguanide; silver and various silver complexes; small molecule quaternary ammonium compounds such as benzalkoium chloride and alkyl substituted derivatives; di-long chain alkyl (C6-C18) quaternary ammonium compounds; cetylpyridinium halides and their derivatives; benzethonium chloride and its alkyl substituted derivatives; and octenidine.
- antiseptics selected from the group consisting of biguanides and bisbiguanides such as chlorhexidine and its various salts including but not limited to the digluconate, diacetate, dimethosulfate, and dilactate salt
- the antiseptics are present in sufficient concentration (at least 0.20wt-% and typically greater than 0.30wt-% and most preferably greater than 0.50% by weight) which when applied to mammalian tissue for an adequate time, for an adequate frequency, and in an adequate dose are capable of decolonizing or eradicating microorganisms from the tissue.
- Certain compositions also include one or more surfactants, one or more hydrophilic compounds, and/or one or more hydrophobic compounds.
- compositions preferably adhere well to bodily tissues (e.g., skin, mucosal tissue, and wounds) and thus are very effective topically.
- bodily tissues e.g., skin, mucosal tissue, and wounds
- the compositions are not bioadhesive and thus will not bond tissue together.
- the present invention provides a wide variety of uses of the compositions.
- Particularly preferred methods involve topical application, particularly to mucosal tissues (i.e., mucous membranes including the anterior nares and other tissues of the upper respiratory tract), as well as skin (e.g., skin lesions) and wounds.
- mucosal tissues i.e., mucous membranes including the anterior nares and other tissues of the upper respiratory tract
- skin e.g., skin lesions
- compositions containing multiple antiseptics can be used.
- compositions containing an antiseptic with limited spectrum may be employed.
- many quaternary ammonium compounds have much higher minimum inhibitory concentrations against Gram- negative organisms compared to gram positive microorganisms and thus may be employed in situations where it is desirable to kill mainly the Gram-positive organisms. This may be useful in nasal decolonization, treatment of impetigo and in other topical infections caused primarily by Gram-positive organisms.
- compositions of the present invention can be used to provide effective topical antimicrobial activity and thereby treat and/or prevent a wide Variety of afflictions.
- they can be used in the treatment and/or prevention of afflictions that are caused, or aggravated by, microorganisms (e.g., Gram positive bacteria, Gram negative bacteria, fungi, protozoa, mycoplasma, yeast, viruses, and even lipid-enveloped viruses) on skin and/or mucous membranes, such as those in the nose (anterior nares, nasopharyngeal cavity, nasal cavities, etc.), outer ear, middle ear, mouth, rectum, vagina, or other similar tissue.
- microorganisms e.g., Gram positive bacteria, Gram negative bacteria, fungi, protozoa, mycoplasma, yeast, viruses, and even lipid-enveloped viruses
- mucous membranes such as those in the nose (anterior nares, nasophary
- Enterococcus spp. and Esherichia spp., bacteria, as well as herpes virus, Aspergillus spp., Fusarium spp., and Candida spp.
- Particularly virulent organisms include Staphylococcus aureus (including resistant strains such as Methicillin Resistant Staphylococcus Aureus (MRSA), Staphylococcus epidermidis, Streptococcus pneumoniae, Enterococcus faecalis, Vancomycin Resistant Enterococcus (VRE),
- MRSA Methicillin Resistant Staphylococcus Aureus
- VRE Vancomycin Resistant Enterococcus
- compositions of the present invention can be used for the prevention and/or treatment of one or more microorganism-caused infections or other afflictions, hi particular, compositions of the present invention can be used for preventing and/or treating one or more of the following: skin lesions, conditions of the skin such as impetigo, eczema, diaper rash in infants as well as incontinent adults, inflammation around ostomy devices, shingles, and bacterial infections in open wounds (e.g., cuts, scrapes, burns, lacerations, chronic wounds); necrotizing faciitis; infections of the outer ear; acute or chronic otitis media (middle ear infection) caused by bacterial, viral, or fungal contamination; fungal and bacterial infections of the vagina or rectum; vaginal yeast infections; bacterial rhinitis; ocular infections; cold sores; genital herpes; colonization by Staphylococcus aureus in the anterior nares (e.g.
- mucositis i.e., inflammation as opposed to infection of a mucous membrane typically induced by non-invasive fungus
- chronic sinusitis e.g., that caused by bacterial or viral contamination
- non-invasive fungus-induced rhinosinusitis chronic colitis; Crohn's disease; burns; napkin rash
- tinea pedis i.e., athlete's foot
- tinea curis i.e., jock itch
- tinea corporis i.e., ringworm
- candidiasis strep throat, strep pharyngitis, and other Group A Streptococci infections
- rosacea often called adult acne
- common cold and respiratory afflictions
- compositions of the present invention can be used for preventing and/or treating a wide variety of topical afflictions caused by microbial infection (e.g., yeast, viral, bacterial infections).
- Compositions of the present invention can be used on a wide variety of surfaces. For example, they can be used on skin, mucosal tissue, chronic wounds, acute wounds, burns and the like. They can also be delivered from swabs, cloth, sponges, foams and non-woven and paper products (e.g., paper towels and wipes), for example where they are used to deliver a significant portion of the antiseptic composition to the tissue.
- compositions of the present invention also provides various methods of use of compositions of the present invention.
- Various embodiments of the present invention include: a method of preventing an affliction caused, or aggravated by, a microorganism on skin and/or a mucous membrane; a method of decolonizing at least a portion of the nasal cavities, anterior nares, and/or nasopharynx of a subject of microorganisms; a method of eradicating microorganisms from at least a portion of the nasal cavities, anterior nares, and/or nasopharynx of a subject; a method of treating a middle ear infection in a subject (by introduction into the middle ear through the Eustachian tube, and/or the tympanic membrane by diffusion or direct injection); a method of treating chronic sinusitis in a subject (by treating at least a portion of the respiratory system, particularly the upper respiratory system, including the nasal cavities, anterior nares, and/
- compositions of the present invention can be used in situations in which there are no clinical indications of an affliction.
- compositions of the present invention can be used in methods of decolonizing at least a portion of the nasal cavities (i.e., space behind the vestibule of the nose), anterior nares (i.e., the opening in the nose to the nasal cavities, also referred to as the external nares), and/or nasopharynx (i.e., the portion of the pharynx, i.e., throat, that lies above the point of food entry into the pharynx) of a subject of microorganisms.
- a suitable in vivo model to test for the effectiveness of compositions to decolonize the anterior nares has been established and is described by K. Kiser et al., Infect and Immunity, 67(10)
- compositions of the present invention can also be used to decolonize microorganisms from wounds. Also disclosed in the example section is an in- vitro model that places microorganisms in contact with a static coating of the antimicrobial composition. This test method is suitable for comparing the potential efficacy of compositions of the present invention for most topical antiseptic applications including nasal decolonization.
- compositions of the present invention are particularly useful in immunocompromised patients (including oncology patients, diabetics, HIV patients, transplant patients an the like), particularly for fungi such as Aspergillus spp. and Fusarium spp.
- compositions of the present invention can be used in chronic wounds to eliminate methicillin-resistant Staphylococcus aureus and vancomycin resistant enterococcus, which may or may not show clinical signs of infection such as inflammation, pus, exudate, etc.
- certain compositions of the present invention can kill lipid-enveloped viruses, which can be very difficult to kill and can cause shingles (Herpes), chronic sinusitis, otitis media, and other local diseases.
- compositions of the present invention provides antimicrobial activity using assay and bacterial screening methods well known in the art.
- One readily performed assay involves exposing selected known or readily available viable microorganism strains, such as Enterococcus spp., Aspergillus spp., Escherichia spp., Staphylococcus spp., Streptococcus spp., Pseudomonas spp., or Salmonella spp., to a test composition at a predetermined bacterial burden level in a culture media at an appropriate temperature. For the preferred compositions of the present invention this is most conveniently done by the Antimicrobial Efficacy Test described in the Examples Section.
- the antimicrobial composition is coated onto a sterile surface and abacterial suspension is distributed directly on the surface of the composition. After a sufficient contact time, the sample containing the exposed bacteria is collected, placed in neutralizing broth, a sample is taken and diluted, and plated out on agar. The plated sample is incubated at an appropriate temperature and humidity for forty-eight hours and the number of viable bacterial colonies growing on the plate is counted. Once colonies have been counted the reduction in the number of bacteria caused by the test composition is readily determined. Bacterial reduction is generally reported as log 10 reduction determined by the difference between the log 10 of the initial inoculum count and the log 10 of the inoculum count after exposure. Preferred compositions of the present invention have an average of at least a 2 log reduction in test bacteria in 10 minutes, and preferably in 2.5 minutes. Many of the preferred compositions were tested as described in the Examples
- compositions of the present invention also exhibit very rapid antimicrobial activity. As shown in the Examples Section, preferred formulations are able to achieve an average log reduction of at least 4 log against at least one of these two organisms after a 10 minute exposure and preferably after a 2.5 minute exposure. More preferred compositions are able to achieve an average log reduction of at least 5 log and even more preferred at least 6 log against at least one of these two organisms after a 10 minute exposure and preferably after a 2.5 minute exposure. For residual antimicrobial efficacy, compositions of the present invention preferably maintain an average log reduction of at least 1 log, more preferably at least.
- compositions were applied to the forearm of a subject as a uniform wet coating in an amount of approximately 4 milligrams per square centimeter (mg/cm ) to the forearm of a healthy subject and allowed to remain on the skin for typically a minimum of 10 minutes over an area of approximately 5 x 5 cm.
- the composition was gently washed with 23 0 C normal saline (0.9% by weight sodium chloride). The saline washed site was exposed to a known quantity of bacteria in an inoculum of about 10 6 bacteria/ml
- compositions retain at least 1 log reduction and preferably at least 2 log reduction of bacteria after a gentle rinse with 500 ml saline poured over the site by placing the saline container as close the the site as possible so as to not have the saline fall onto the site.
- certain embodiments of the present invention have a very low potential for generating microbial resistance.
- preferred compositions of the present invention have an increase in the ratio of final to initial MIC levels (i.e., minimum inhibitory concentration) of less than 16, more preferably less than 8, and even more preferably less than 4.
- Such an emergence of resistance assay should be carried out such that the microorganisms are subjected initially to sub MIC levels (e.g. Vi the MIC) of antiseptic and after 24 hours the microorganisms passed into broth containing twice the concentration of antiseptic. This is repeated for 8 days and each day microorganisms are removed to determine the new MIC.
- sub MIC levels e.g. Vi the MIC
- such low resistance forming compositions can be applied multiple times over one or more days to treat topical infections or to eradicate unwanted bacteria (such as nasal colonization of Staphylococcus aureus).
- compositions of the present invention contain an effective amount of cationic antiseptic to rapidly kill or inactivate microorganisms on skin, skin lesions, and mucosal membranes.
- essentially all the microorganisms are eradicated or inactivated within five days, preferably within three days, more preferably two days, and most preferably within 24 hours using one or more doses.
- compositions of the present invention have a generally low irritation level for skin, skin lesions, and mucosal membranes (including the anterior nares, nasal cavities, nasopharyngeal cavity and other portions of the upper respiratory tract).
- certain preferred compositions of the present invention are no more irritating than BACTROBAN ointment (on skin) or BACTROBAN NASAL (in the anterior nares) products available from Glaxo Smith Kline.
- compositions of the present invention are substantive for relatively long periods of time to ensure adequate efficacy. For example, certain compositions of the present invention remain at the site of application with antimicrobial activity for at least 1 hour, preferably at least 4 hours, and more preferably at least 8 hours. This can be easily determined by swabbing the site after a predetermined, time and testing for the antimicrobial active by a suitable analytical technique such as gas chromatography (GC) or high performance liquid chromatography (HPLC).
- GC gas chromatography
- HPLC high performance liquid chromatography
- Preferred compositions of the present invention are physically stable. As defined herein "physically stable" compositions are those that do not significantly change due to substantial precipitation, crystallization, phase separation, and the like, from their original condition during storage at 23° C for at least 3 months, and preferably for at least 6 months.
- compositions are completely physically stable if a 10-milliliter (10-ml) sample of the composition when placed in a 15-ml conical- shaped graduated plastic centrifuge tube (Corning) and centrifuged at about 2275 x g (e.g. 3,000 revolutions per minute (rpm) for 10 minutes using a Labofuge B, model 2650 manufactured by Heraeus Sepatech GmbH, Osterode, West Germany) or similar centrifuge at a centrifugal force of 2275 x g has no visible phase separation in the bottom or top of the tube. Phase separation of less than 0.5ml is also considered stable as long as there is no other sign of physical separation in the sample.
- a 10-milliliter (10-ml) sample of the composition when placed in a 15-ml conical- shaped graduated plastic centrifuge tube (Corning) and centrifuged at about 2275 x g (e.g. 3,000 revolutions per minute (rpm) for 10 minutes using a Labofuge B, model 2650 manufactured
- compositions of the present invention exhibit good chemical stability. This can be especially a concern with compounds that may hydrolyze or undergo heat and/or light degradation such as chlorhexidine.
- the most preferred compositions retain an average of at least 97% of the antiseptic component after aging for 4 weeks at 4O 0 C in a sealed container beyond the initial 5-day equilibration period at 23 0 C.
- the percent retention is understood to mean the weight percent of antiseptic component retained. This is determined by comparing the amount remaining in a sample aged (i.e., aged beyond the initial 5-day equilibration period) in a sealed container that does not cause degradation, to the actual measured level in an identically prepared sample (preferably from the same batch) and allowed to sit at 23°C for five days.
- the level of antiseptic component is preferably determined using gas chromatography or high performance liquid chromatography.
- compositions of this invention may be in one of the following forms:
- a hydrophobic ointment The compositions are formulated with a. hydrophobic base (e.g., petrolatum, thickened or gelled water insoluble oils and the like) and optionally having a minor amount of a water-soluble phase.
- a. hydrophobic base e.g., petrolatum, thickened or gelled water insoluble oils and the like
- compositions may be formulations in which the antiseptic is emulsified into an emulsion comprising a discrete phase of a hydrophobic component and a continuous aqueous phase comprising water and optionally one or more polar hydrophilic carrier as well as salts, surfactants, emulsifiers, or other components.
- emulsions may comprise water-soluble or water swellable polymers as well as one or more emulsifiers that help to stabilize the emulsion.
- These emulsions generally have higher conductivity values as described in U.S. Serial No. 09/966,511.
- compositions may be formulations in which the antiseptic is incorporated into an emulsion comprising a continuous phase of a hydrophobic component and an aqueous phase comprising water, and optionally one or more polar hydrophilic carrier as well as salts or other components.
- emulsions may comprise oil soluble or oil swellable polymers as well as one or more emulsifiers that help to stabilize the emulsion.
- Thickened aqueous gels These systems are comprised of an aqueous phase that- has been thickened to achieve a viscosity in excess of 500 cps and preferably greater than 5000 cps. Most preferred systems have a viscosity in excess of 10,000 cps, more preferably greater than 25,000 cps and most preferably greater than 50,000 cps. The viscosity is determined using the Viscosity Test described herein.
- These systems comprise the antiseptics described here in and are thickened by suitable natural, modified natural, or synthetic polymers as described below.
- the thickened aqueous gels can also be thickened using suitable emulsifiers such as alkyl alcohols and polyethoxylated alkyl chain surfactants that effectively thicken the composition.
- Examples include the Polawax, Behenyl TMS, Crodaphos CES, Cosmowax, and Crothix systems from Croda Inc.
- Hydrophilic gels These are systems in which the continuous phase is comprised of at least one water soluble hydrophilic component other than water.
- the formulations may optionally also contain water up to about 20% by weight. Higher concentrations may be suitable in some compositions.
- Suitable hydrophilic components include one or more glycols (such as glycerin, propylene glycol, butylenes glycol, etc.), polyethylene glycols (PEG), random or block copolymers of ethylene oxide, propylene oxide, and/or butylenes oxide, polyalkoxylated surfactants having one or more hydrophobic moieties per molecule, silicone copolyols, as well as combinations thereof.
- the level of ethoxylation must be sufficient to render the hydrophilic component water-soluble or water dispersible at 23°C.
- the water content is less than 10wt-% and more preferably less than about 5% by weight of the composition.
- the compositions have a viscosity of at least 20 cps, preferably greater than 100 cps, more preferably greater than 1000 cps, even more preferably greater than 10,000 cps and most preferably greater than 25,000 cps when measured by the Viscosity Test described herein. Higher viscosities are preferred to reduce migration as well as to provide substantivity (resistance to removal by fluids) to ensure long-term antimicrobial activity. Most preferred compositions have viscosities in excess of 50,000 cps and most preferably in excess of 100,000 cps at 23-25°C when measured by the Viscosity Test. Most preferred compositions meet these viscosity values even after heating to 32 0 C, 35 0 C or as high as 37 0 C to ensure when in contact with mammalian tissue the compositions remain substantive.
- the antiseptic component is that component of the composition that provides at least part of the antimicrobial activity. That is, the antiseptic component has at least some antimicrobial activity for at least one microorganism. It is generally considered the main active component of the compositions of the present invention.
- the antiseptic component includes an effective amount of one or more antiseptics selected from the group consisting of biguanides and bisbiguanides such as chlorhexidine and its various salts including but not limited to the digluconate, diacetate, dimethosulfate, and dilactate salts, as well as combinations thereof; polymeric quaternary ammonium compounds such as polyhexamethylenebiguanide; silver and various silver complexes; small molecule quaternary ammonium compounds such as benzalkoium chloride and alkyl substituted derivatives'; di-long chain alkyl (C6-C18) quaternary ammonium compounds; cetylpyridinium halides and their derivatives; benzethonium chloride and its alkyl substituted derivatives; octenidine and compatible combinations thereof.
- biguanides and bisbiguanides such as chlorhexidine and its various salts including but not limited to the digluconate, diacetate, dimethosulfate, and dilactate
- This class of antiseptics is represented by the formula:
- n 3-10, preferably 4-8, and most preferably 6
- R C4-C18 branched or straight chain all ⁇ yl optionally substituted in available positions by halogen or C6-C12 aryl or alkaryl optionally substituted in available positions by halogen.
- the preferred compound of this class is chlorhexidine. This may be present as the free base but is preferably present as a disalt of acetate, gluconate, lactate, methosulfate
- CH 3 OSO 3 " a halide or combinations thereof.
- the diacetate, digluconate, dilactate, and dimethosulfate salts since these salts all have solubility limits in excess of lg/lOOml.
- the solubility limit of the digluconate salt is 20g/100ml and that of the diacetate is 1.9g/100ml.
- the most preferred compound is chlorhexidine digluconate (CHG).
- CHG chlorhexidine digluconate
- Other anions may be useful. It is particularly important, however, with this class as well as other cationic antiseptics to use a counter ion that ensures solubility in aqueous fluid above the minimum inhibitory concentration (MIC) of the treatment organism.
- antiseptics of this class are particularly preferred in formulations that are non ⁇ aqueous and protected from light. This is believed to reduce the degradation of the compound.
- antiseptics of this class are preferably formulated with a hydrophilic carrier that solublizes the antiseptic.
- suitable solvents for chlorhexidine gluconate include glycols (compounds having at least two hydroxylgroups per molecule) such as
- PEGs having a molecular weight below 2000 and preferably less than 1000 and most preferably less than about 800 daltons; glycerin and polyglycerols, propylene glycol, dipropylene glycol, tripropyelne glycol, polypropylene glycol, ethylene oxide/propylene oxide random or block copolymers, trimethylolpropane, pentraerithiritol, sorbitol, panetothenol, glucurono lactone, gluconic acid, and the like as well as other polar solvents such as N-methyl pyrrolidone, propylene carbonate, butyrolactone and the like.
- glycerin and polyglycerols propylene glycol, dipropylene glycol, tripropyelne glycol, polypropylene glycol, ethylene oxide/propylene oxide random or block copolymers, trimethylolpropane, pentraerithiritol, sorbitol
- Preferred formulations are hydrophilic ointments;- aqueous solutions thickened with polymeric thickeners that are either surfactant free or contain surfactants that do not reduce the activity of the CHG, such as poloxamers; and ointments comprising a major amount of a hydrophobic component and preferably further comprising a hydrophilic component.
- Bis(biguanide)s such as chlorhexidine are very basic and capable of forming multiple ionic bonds with anionic materials.
- biguanide-containing compositions are preferably free of anioinic compounds that can result in precipitation of the antiseptic.
- thickener systems if present, are preferably based on non-ionic and/or cationic polymers or emulsifiers.
- Anionic surfactants useful, for example, as wetting agents, may also need to be avoided.
- Certain zwitterionic, very water soluble, or non-precipitating anionic emulsifiers and surfactants may also be useful.
- Halide salts may need to be avoided. For example, chlorhexidine digluconate
- CHG halide salts
- a system includes CHG or other antiseptic of this class, and needs to comprise salts for stability or other purposes, preferably gluconate salts such
- composition as triethanolamine gluconate or sodium gluconate, are used.
- an additional antiseptic is incorporated into the composition it is preferably non-ionic or cationic.
- Antimicrobial polymers comprising quaternary amine groups may also be used as the antiseptic of the present invention. These are typically polymers having quaternary amine groups with at least one alkyl or aralkyl chain of at least 6 carbon atoms and preferably as least 8 carbon atoms. The polymers may be linear, branched, hyperbranched or dendrimers. Preferred antimicrobial polymeric quaternary amine polymers include those described in U.S. Patent Nos. 6,440,405; 5,408,022; and 5,084,096; PCT Publication No. WO/02102244; and Disinfection, Sterilization and
- a particularly preferred class of polymeric quaternary ammonium antiseptic compounds are polybiguanides.
- Compounds of this class are represented by the formula: X-R 1 -NH-C(NH)-NH-C(NH)-NH-R 2 -NHC(] ⁇ ffl)-NH-C(NH)-NH-R 3 -X
- R 1 , R 2 , and R 3 are bridging groups such as polymethylene groups preferably having 2 to 10 methylene groups, more preferably 4 to 8 methylene groups and most preferably 6 methylene groups.
- the methylene groups can be optionally substituted in available positions with halogen, hydroxyl, or phenyl groups.
- X is a terminal group and is typically an amine, amine salt, or a dicyandiamide group.
- the preferred compound of this class is polyhexamethylene biguanide (PHMB) commercially available as Cosmocil CQ from Aveci, Wilmington, DE.
- Compounds of this class are typically used at levels of at least 0.05% by weight, preferably at least 0.1 % by weight and most preferably at least 0.25% by weight and most preferably at least 0.5% by weight. Compounds of this class are preferably used at levels less than about 8%, more preferably less than about 6%, and most preferably less than about 4% by weight of the composition.
- Poly(biguanide) antiseptics such as PHMB are very basic and are capable of forming multiple ionic bonds with anionic materials. For this reason, biguanide-containing compositions are preferably free of anionic compounds that can result in precipitation and/or inactivation of the antiseptic.
- thickener systems are preferably based on non-ionic and/or cationic polymers or emulsifiers.
- Anionic surfactants useful for example, as wetting agents, may also need to be avoided.
- Certain zwitterionic, very water soluble, or non- precipitating anionic emulsifiers and surfactants may also be useful.
- Halide salts also may need to be avoided.
- Silver is also known to be an effective antiseptic and has been used in creams to treat wounds and other topical infections. Silver may also be useful for nasal decolonization.
- the active form of silver is the ion Ag+ which may be delivered from a variety of well known silver salts and complexes including silver zeolites; inorganic silver salts such as silver nitrate, silver chloride, silver sulfate, silver thiosulfate; silver alkyl, aryl, and aralkyl carboxylates (preferred carboxylate anions have less than about
- silver oxide such as the acetate, lactate, salicylate, and gluconate salts
- silver oxide colloidal silver, nanocrysta ⁇ line silver, silver coated microspheres, silver complexed with various polymers as well as silver delivered from dendrimers as described in U.S. Patent Nos. 6,579,906 and 6,224,898
- silver antimicrobial complexes such as silver sufadiazine.
- the silver may optionally complexed with primary, secondary, tertiary, and quaternary amines as well as polymeric forms thereofs, and silver protein complexes. Where sldn discoloration is undesireable, certain silver complexes can be used, such as those disclosed, for example, in U.S. Patent Nos.
- silver compounds and ions can be delivered from the hydrophobic vehicle compositions of the present invention.
- Particularly preferred compositions have a hydrophilic component incorporated into the composition.
- Silver antiseptics may also be delivered from compositions comprising hydrophobic component(s) as the vehicle.
- Silver containing compositions must be protected from light and precipitating excipients.
- preferred wetting agents, penentration enhancers, and/or emulsifiers are non-ionic, cationic or zwitterionic.
- the anions of the cationic surfactants also should be chosen to prevent inactivation of the silver.
- Preferred surfactants are non- ionic and amine funcitonal surfactants (including primary, secondary, tertiary and quaternary amine-group-containing surfactants).
- concentration of silver ion in the antiseptic compositions is at least
- the silver concentration is less than 10wt%, more preferably less than 8wt%, and most preferably less than 6% by weight based on the total weight of the composition.
- Silver salts and complexes should be adjusted accordingly based on molecular weight to achieve the silver ion concentration in the ranges described, as one skilled in the art understands.
- Silver compounds when used in the present compositions are capable of producing silver ion when in contact with microorganisms.
- Examples are silver salts and silver oxides.
- Preferred compounds are silver nitrate, silver thiosulfate, silver chloride, silver phosphate, silver sulfate, and silver halide salts.
- This class of compounds typically comprise one or more quaternary ammonium groups wherein attached to the quaternary ammonium group is at least one C6-C18 linear or branched alkyl or aralkyl chain.
- Suitable compounds include those disclosed in Disinfection, Sterilization and Preservation, S. Block, 4 th ed., 1991, Chapter 13, Lea & Febiger.
- Particularly preferred compounds of this class have one or two C8-C18 alkyl or aralkyl chains and may be represented by the following formula: R 1 R 2 NR 3 R 4 + X "
- R and R are Cl-Cl 8 linear or branched alkyl, alkaryl, or aralkyl chains that may be substituted in available positions by N, O, or S provided at least one R 1 or R 2 is a C8-C18 linear or branched alkyl, alkaryl, or aralkyl chains that may be substituted in available positions by N, O, or S.
- R 3 and R 4 are C1-C6 alkyl, phenyl, benzyl, or C8-
- R 3 and R 4 may also form a ring such as a pyridine ring with the nitrogen of the quaternary ammonium group.
- X is an anion, preferably a halide, and most preferably Cl- or Br-.
- Other anions may include methosulfate, ethosulfate, phosphates and the like.
- Preferred compounds of this class include mnoalyltrimethylammonium salts, monalkyldimethylbenzyl ammonium salts, dialkyldimethyl ammonium salts, benzethonium chloride, and octenidine.
- quaternary ammonium antiseptics include benzalkonium halides having an alkyl chain length of C8-C18, more preferably C12-C16, and most preferably a mixture of chain lengths.
- a typical benzalkonium chloride sample may be comprise of 40% C12 alkyl chains, 50% C14 alkyl chains, and 10%
- C16 alkyl chains These are commercially available from numerous sources including Lonza (Barquat MB-50); Benzalkonium halides substituted with alkyl groups on the phenyl ring.
- Lonza Barquat MB-50
- Benzalkonium halides substituted with alkyl groups on the phenyl ring A commercially avaible example is Barquat 4250 available from Lonza; dimethyldialkylammonium halides where the alkyl groups have chain lengths of C8- C 18.
- a mixture of chain lengths such as mixture of dioctyl, dilauryl, and dioctadecyl may be particularly useful.
- Exemplary compounds are commercially available from Lonza as Bardac 2050, 205M and 2250 from Lonza; Cetylpyridinium halides such as cetylpyridinium chloride available from Merrell labs as Cep ' acol Chloride; Benzethonium halides and alkyl substituted benzethonium halides such as Hyamine 1622 and Hyamine 1OX available from Rohm and Haas; octenidine and the like.
- the antiseptics are typically added to the compositions at a concentration of at least 0.50wt%, more preferably at least 0.75wt% and most preferably at least 1.0% by weight based on the total weight of the composition.
- concentration is less than 6wt%, more preferably less than 4wt%, and most preferably less than 3% by weight based on the total weight of the composition.
- compositions of the present invention include one or more antiseptics at a suitable level to produce the desired result.
- Such compositions preferably include a total amount of antiseptic of at least 0.2 percent by weight (wt-%), more preferably at least 0.25 wt-%, even more preferably at least 0.35 wt-%, even more preferably at least 0.5 wt-%, and even more preferably at least 1, at least two 2, or even at least 3 wt-%, based on the total weight of the "ready to use" or "as used" composition.
- the antiseptic(s) are present in a total amount of no greater than 20 wt-%, more preferably no greater than 15 wt-%, even more preferably no greater than 10 wt- %, and even more preferably no greater than 6 wt-%, based on the "ready to use" or "as used" composition. Certain compositions may be higher in concentration if they are intended to be diluted prior to use.
- the antiseptics of this invention may be used alone or in combination in order to effectively kill microorganisms on tissue. Certain combinations of antiseptics may be particularly useful while others may result in unstable formulations or inactivation of the antimicrobial activity. For example, combination of cationic antiseptics such as biguanides and bisbiguanides, polymeric quaternary ammonium compounds, quaternary ammonium compounds, and silver could be incompatible with alkyl carboxylic acids. On the other hand, other antiseptic combinations may produce an enhancement or synergistic effect.
- the antiseptics of this invention may be used alone, in combination, or with other antiseptics in order to effectively kill microorganisms on tissue.
- antiseptics for use with those described herein include peroxides, C6-C14 alkyl carboxylic acids and alkyl ester carboxylic acids, antimicrobial natural oils, and compatible combinations thereof as provided in Applicants' copending application entitled “Antiseptic Compositions and Methods of Use,” U.S. Serial No. 10/936,133, filed
- the antiseptics of this invention may optionally be combined with an effective amount of an antimicrobial lipid antiseptic comprising a (C7-C 14)saturated fatty acid ester of a polyhydric alcohol, a (C8-C22)unsaturated fatty acid ester of a polyhydric alcohol, a (C7-C14)saturated fatty ether of a polyhydric alcohol, a (C8-C22)unsaturated fatty ether of a polyhydric alcohol, an alkoxylated derivative thereof, or combinations thereof, wherein the alkoxylated derivative has less than 5 moles of alkoxide per mole of polyhydric alcohol; with the proviso that for polyhydric alcohols other than sucrose, the esters comprise monoesters and the ethers comprise monoethers, and for sucrose the esters comprise monoesters, diesters, or combinations thereof, and the ethers comprise monoethers, diethers, or combinations thereof.
- an antimicrobial lipid antiseptic
- fatty refers to alkyl and alkylene hydrocarbon chains of odd or even number of carbon atoms from C6-C18.
- the antimicrobial lipid can be a (C8-C12)fatty alcohol ester of a (C2-C8)hydroxycarboxylic acid (also often referred to as a (C2-C8)hydroxycarboxylic acid ester of a (C8-C12)fatty alcohol), a (C8-C22)mono- or poly-unsaturated fatty alcohol ester of a (C2-C8)hydroxycarboxylic acid (also often referred to as a (C2-C8)hydroxycarboxylic acid (also often referred to as a (C2-C8)
- the alkoxylated derivatives have less than 5 moles of alkoxide per mole of polyhydric alcohol or hydroxyl acid.
- the hydroxycarboxylic acid moiety can include aliphatic and/or aromatic groups. For example, fatty alcohol esters of salicylic acid are possible.
- Useful antiseptics of this class are further described in applicants' copending application "Antimicrobial Compositions and Methods" U.S. Serial No. 60/660,594, filed on March 10, 2005.
- a "fatty alcohol” is an alkyl or alkylene monofunctional alcohol having an even or odd number of carbon atoms and a "fatty acid” is a alkyl or alkylene monofunctional carboxylic acid having an even or odd number of carbon atoms.
- formulations may incorporate one or more antiseptics in the composition approaching or preferably exceeding the solubility limit in the hydrophobic phase. While not intended to be bound by theory we believe that antiseptics that preferably partition into the hydrophobic component are not readily available to kill microorganisms which are almost always in or associated with an aqueous phase.
- the antiseptic is preferably incorporated in at least 60%, preferably, 75%, more preferably 100% and most preferably 120% of the solubility limit of the hydrophobic component at 23 0 C. This in conveniently determined by making the formulation without the antiseptic, separating the phases (e.g.
- Enhancer Component Compositions of the present invention may include an enhancer to enhance the antimicrobial activity.
- the activity enhancement may be especially useful against Gram negative bacteria, such as E. coli and Psuedomonas sp.
- the enhancer chosen preferably affects the cell envelope of the bacteria. While not bound by theory, it is presently believed that the enhancer functions by allowing the antiseptic to more easily enter the cell cytoplasm and/or by facilitating disruption of the cell envelope.
- the enhancer component may include an alpha-hydroxy acid, a beta-hydroxy acid, other carboxylic acids, a (Cl-C4)alkyl carboxylic acid, a (C6-C12)aryl carboxylic acid, a (C6-C12)aralkyl carboxylic acid, a (C6-C16)alkaryl carboxylic acid, a chelator, a phenolic compound (such as certain antioxidants and parabens), a (Cl- C10)monohydroxy alcohol, or a glycol ether (i.e., ether glycol).
- a glycol ether i.e., ether glycol
- alpha-hydroxy acid, beta-hydroxy acid, and other carboxylic acid enhancers are preferably present in their protonated, free acid form. It is not necessary for all of the acidic enhancers to be present in the free acid form, however, the preferred concentrations listed below refer to the amount present in the free acid form.
- the chelator enhancers that include carboxylic acid groups are preferably present with at least one, and more preferably at least two, carboxylic acid groups in their free acid form.
- concentrations given below assume this to be the case.
- Chelator enhancers may also comprise phosphate or phosphonic acid groups. If precipitation occurs due to interaction with other composition components alternative enahncers should be considered. While the non-ionic enhancers may be useful for all of the antiseptic classes of this invention the anionic enhancers such as the carboxylic acids and chelators may not be compatible with the cationic antiseptics. If precipitation occurs, alternative enhancers should be employed.
- enhancers may be useful, such as the siderophores and iron-bonding proteins described in U.S. Serial No. 10/936,949, filed September 8; 2004 entitled “Antimicrobial Compositions and Methods”; and the sugar and/or alcohols as described in U.S. Serial No. 60/660,830, filed March 10, 2005 entitled
- One or more enhancers maybe used in the compositions of the present invention at a suitable level to produce the desired result.
- they are present in a total amount greater than 0.01 wt-%, preferably in an amount greater than 0.1 wt%, more preferably in an amount greater than 0.2 wt%, even more preferably in an amount greater than 0.25 wt% and most preferably in an amount greater than about 0.4 wt% based on the total weight of the ready to use composition.
- they are present in a total amount of no greater than 20 wt-%, based on the total weight of the ready to use composition.
- concentrations typically apply to alpha-hydroxy acids, beta-hydroxy acids, other carboxylic acids, chelating agents, phenolics, ether glycols, and (C5-C10)monohydroxy alcohols. Generally, higher concentrations are needed for (Cl-C4)monohydroxy alcohols, as described in greater detail below.
- alpha-hydroxy acid, beta-hydroxy acid, and other carboxylic acid enhancers, as well as chelators that include carboxylic acid groups are preferably present in a concentration of no greater than 100 milliMoles per 100 grams of formulated composition.
- alpha-hydroxy acid, beta-hydroxy acid, and other carboxylic acid enhancers, as well as chelators that include carboxylic acid groups are preferably present in a concentration of no greater than 75 milliMoles per 100 grams, more preferably no greater than 50 milliMoles per 100 grams, and most preferably no greater than 25 milliMoles per 100 grams of formulated composition.
- the total concentration of the enhancer component relative to the total concentration of the antiseptic component is preferably within a range of 10:1 to 1 :300, and more preferably 5 : 1 to 1 : 10, on a weight basis.
- an enhancer is insoluble in preferred hydrophobic components such as mineral oil and petrolatum. It has been found that the addition of a minor amount (typically less than 30 wt-%, preferably less than 20 wt-%, and more preferably less than 12 wt-%) of a hydrophilic component not only helps dissolve and physically stabilize the composition but improves the antimicrobial activity as well.
- the enhancer may be present in excess of the solubility limit provided that the composition is physically stable. This may be achieved by utilizing a sufficiently viscous composition that stratification (e.g. settling or creaming) of the antiseptic does not appreciably occur.
- Alpha-hvdroxy Acids An alpha-hydroxy acid is typically a compound represented by the formula:
- alpha-hydroxy acids include, but are not limited to, lactic acid, malic acid, citric acid, 2-hydroxybutanoic acid, mandelic acid, gluconic acid, glycolic acid (i.e., alpha-hydroxyethanoic acid), tartaric acid, ascorbic acid, alpha-hydroxyoctanoic acid, and alpha hydroxycaprylic acid, as well as derivatives thereof (e.g., compounds substituted with hydroxyls, phenyl groups, hydroxyphenyl groups, alkyl groups, halogens, as well as combinations thereof).
- Preferred alpha-hydroxy acids include lactic acid, malic acid, and mandelic acid. These acids may be in D, L, or DL form and may be present as free acid, lactone, or partial salts thereof. AU such forms are encompassed by the term "acid.” Preferably, the acids are present in the free acid form.
- the alpha-hydroxy acids useful in the compositions of the present invention are selected from the group consisting of lactic acid, mandelic acid, and malic acid, and mixtures thereof.
- Other suitable alpha-hydroxy acids are described in U.S. Pat. No. 5,665,776 (Yu).
- One or more alpha-hydroxy acids may be used in the compositions of the present invention at a suitable level to produce the desired result. In a preferred embodiment, they are present in a total amount of at least 0.25 wt-%, more preferably, at least 0.5 wt-
- % and even more preferably, at least 1 wt-%, based on the total weight of the ready to use composition. In a preferred embodiment, they are present in a total amount of no greater than 10 wt-%, more preferably, no greater than 5 wt-%, and even more preferably, no greater than 3 wt-%, based on the total weight of the ready to use composition. Higher concentrations may become irritating.
- the ratio of alpha-hydroxy acid enhancer to total antiseptic component is preferably at most 10:1, more preferably at most 5:1, and even more preferably at most 1:1.-
- the ratio of alpha-hydroxy acid enhancer to total antiseptic component is preferably at least 1 :20, more preferably at least 1:12, and even more preferably at least 1:5.
- Preferably the ratio of alpha-hydroxy acid enhancer to total antiseptic component is within a range of 1 : 12 to 1:1.
- Beta-hydroxy Acids A beta-hydroxy acid is typically a compound represented by the formula:
- beta-hydroxy acids include, but are not limited to, beta- hydroxybutanoic acid, 3-hydroxybutanoic acid, tropic acid, and trethocanic acid.
- the beta-hydroxy acids useful in the compositions of the present invention are selected from the group consisting of salicylic acid, beta- hydroxybutanoic acid, and mixtures thereof.
- Other suitable beta-hydroxy acids are described in U.S. Pat. No. 5,665,776 (Yu).
- One or more beta-hydroxy acids may be used in the compositions of the present invention at a suitable level to produce the desired result. In a preferred embodiment, they are present in a total amount of at least 0.1 wt-%, more preferably at least 0.25 wt-
- % and even more preferably at least 0.5 wt-%, based on the total weight of the ready to use composition. In a preferred embodiment, they are present in a total amount of no greater than 10 wt-%, more preferably no greater than 5 wt-%, and even more preferably no greater than 3 wt-%, based on the total weight of the ready to use composition. Higher concentrations may become irritating.
- the ratio of beta-hydroxy acid enhancer to total antiseptic component is preferably at most 10:1, more preferably at most 5:1, and even more preferably at most 1:1.
- the ratio of beta-hydroxy acid enhancer to total antiseptic component is preferably at least 1 :20, more preferably at least 1:15, and even more preferably at least 1:10.
- Preferably the ratio of beta-hydroxy acid enhancer to total antiseptic component is within a range of 1:15 to 1:1.
- esterification may be the principle route of loss of the enhancer by reaction with, for example, the antiseptic or a hydroxyl functional hydrophilic component.
- AHA alpha-hydroxy acids
- BHA beta-hydroxy acids
- salicylic acid may be particularly preferred in certain formulations since the phenolic hydroxyl group is much moire acidic than an aliphatic hydroxyl group and thus much less likely to react.
- anhydrous or low-water content formulations include lactic, mandelic, malic, citric, tartaric, and glycolic acid.
- Benzoic acid and substituted benzoic acids which do not comprise a hydroxyl group while not an hydroxyl acid is also preferred due to a reduced tendency to form ester groups.
- Carboxylic acids other than alpha- and beta-carboxylic acids are suitable for use in the enhancer component. These include alkyl, aryl, aralkyl, or alkaryl carboxylic acids typically having 16 carbon atoms, preferably equal to or less than 12 carbon atoms and even more preferably less than about 8 carbon atoms. A preferred class of these can be represented by the following formula:
- the carboxylic acid is a (Cl-C4)alkyl carboxylic acid, a (C6-C12)aralkyl carboxylic acid, or a (C6- C16)alkaryl carboxylic acid.
- Exemplary acids include, but are not limited to, acetic acid, propionic acid, benzoic acid, benzylic acid, nonylbenzoic acid, and the like. Particularly preferred is benzoic acid.
- One or more carboxylic acids may be used in the compositions of the present invention at a suitable level to produce the desired result.
- they are present in a total amount of at least 0.1 wt-%, more preferably at least 0.25 wt-%, even more preferably at least 0.5 wt-%, and most preferably at least 1 wt-%, based on the ready to use concentration composition.
- they are present in a total amount of no greater than 10 wt-%, more preferably no greater than 5 wt-%, and even more preferably no greater than 3 wt-%, based on the ready to use composition.
- the ratio of the total concentration of carboxylic acids (other than alpha- or beta- hydroxy acids) to the total concentration of the antiseptic component is preferably within a r range of 10: 1 to 1 : 100, and more preferably 2 : 1 to 1 : 10, on a weight basis.
- a chelating agent i.e., chelator
- chelator is typically an organic compound capable of multiple coordination sites with a metal ion in solution.
- these chelating agents are polyanionic compounds and coordinate best with polyvalent metal ions.
- Exemplary chelating agents include, but are not limited to, ethylene diamine tetraacetic acid (EDTA) and salts thereof (e.g., EDTA(Na) 2 , EDTA(Na) 4 , EDTA(Ca),
- EDTA(K) 2 sodium acid pyrophosphate, acidic sodium hexametaphosphate, adipic acid, succinic acid, polyphosphoric acid, sodium acid pyrophosphate, sodium hexametaphosphate, acidified sodium hexametaphosphate, nitrilotris(methylenephosphonic acid), diethylenetriaminepentaacetic acid, 1- hydroxyethylene, 1,1-diphosphonic acid, and diethylenetriaminepenta- (methylenephosphonic acid).
- Certain carboxylic acids, particularly the alpha-hydroxy acids and beta-hydroxy acids can also function as chelators, e.g., malic acid and tartaric acid.
- chelators are compounds highly specific toward ferrous or ferric ions such as siderophores and iron-bonding proteins such as lactoferrin and transferrin.
- the chelating agents useful in the compositions of the present invention include those selected from the group consisting of ethylenediaminetetraacetic acid and salts thereof, succinic acid, and mixtures thereof.
- either the free acid or the mono- or di-salt form of EDTA is used.
- One or more chelating agents may be used in the compositions of the present invention at a suitable level to produce the desired result. In a preferred embodiment, they are present in a total amount of at least 0.01 wt-%, more preferably at least 0.05 wt-%, even more preferably at least 0.1 wt-%, and even more preferably at least 0.25 wt-%, based on the weight of the ready to use composition.
- the chelators are present in a total amount of at least 30OuM (micromolar), preferably at least 50OuM, more preferably at least lOOOuM and most preferably at least 200OuM based on the total weight/volume of composition even if it may comprise multiple phases, hi a preferred embodiment, they are present in a total amount of no greater than 10 wt-%, more preferably no greater than 5 wt-%, and even more preferably no greater than 1 wt-%, based on the weight of the ready to use composition.
- the ratio of the total concentration of chelating agents (other than alpha- or beta- hydroxy acids) to the total concentration of the antiseptic component is preferably within a range of 10:1 to 1:100, and more preferably 1 :1 to 1 :10, on a weight basis.
- a phenolic compound enhancer is typically a compound having the following general structure (including at least one group bonded to the ring thorugh an oxygen:
- each R 12 independently is alkyl or alkenyl of up to 12 carbon atoms (especially up to 8 carbon atoms) optionally substituted with O in or on the chain (e.g., as a carbonyl group) or OH on the chain
- each R 13 independently is H or alkyl or alkenyl of up to 8 carbon atoms (especially up to 6 carbon atoms) optionally substituted with O in or on the chain
- n preferably is 1 or 2.
- phenolic derivative enhancers include, but are not limited to, butylated hydroxy anisole, e.g., 3(2)-tert-butyl-4-methoxyphenol (BHA), 2,6-di-tert- butyl-4-methylphenol (BHT), 3,5-di-tert-butyl-4-hydroxybenzylphenol, 2,6-di-tert-4- hexylphenol, 2,6-di-tert-4-octylphenol, 2,6-di-tert-4-decylphenol, 2,6-di-tert-butyl-4- ethylphenol, 2,6-di-tert-4-butylphenol, 2,5-di-tert-butylphenoL 3,5-di-tert-butylphenol, 4,6-di-tert-butyl-resorcinol, methyl paraben (4-hydroxybenzoic acid methyl ester), ethyl paraben, propyl paraben,
- Some of the preferred phenolic derivative enhancers are BHA, BHT, methyl paraben, ethyl paraben, propyl paraben, and butyl paraben as well as combinations of these.
- One or more phenolic derivative compounds may be used in the compositions of the present invention at a suitable level to produce the desired result.
- concentrations of the phenolic compounds in medical-grade ' compositions may vary widely, but as little as 0.001 wt-%, based on the total weight of the composition, can be effective when the above-described esters are present within the above-noted ranges.
- they are present in a total amount of at least 0.01 wt-%, more preferably at least 0.10 wt-%, and even more preferably at least 0.25 wt-%, based on the ready to use composition. In a preferred embodiment, they are present in a total amount of no greater than 8 wt-%, more preferably no greater than 4 wt-%, and even more preferably no greater than 2 wt-%, based on the ready to use composition.
- the ratio of the total phenolic concentration to the total concentration of the antiseptic component be within a range of 10: 1 to 1 :300, and more preferably within a range of 1 : 1 to 1 : 10, on a weight basis.
- concentrations of the phenolic derivative enhancers are normally observed unless concentrated formulations for subsequent dilution are intended.
- the minimum concentration of the phenolics and the antiseptic to provide an antimicrobial effect will vary with the particular application.
- An additional enhancer class includes monohydroxy alcohols having 1-10 carbon atoms. This includes the lower (i.e., C1-C4) monohydroxy alcohols (e.g., methanol, ethanol, isopropanol, and butanol) as well as longer chain (i.e., C5-C10) monohydroxy alcohols (e.g., isobutanol, t-butanol, octanol, and decanol).
- the alcohols useful in the compositions of the present invention are selected from the group consisting of methanol, ethanol, isopropyl alcohol, and mixtures thereof.
- One or more alcohols may be used in the compositions of the present invention at a suitable level to produce the desired result.
- the short chain (i.e., C1-C4) alcohols are present in a total amount of at least 5 wt-%, even more preferably at least 10 wt-%, even more preferably at least 15 wt-%, and even more preferably at least 20 wt-%, based on the total weight of the ready to use composition.
- the (Cl-C4)alcohols are present in a total amount of no greater than 50 wt-%, more preferably no greater than 40 wt-%, and even more preferably no greater than 30 wt-%, based on the total weight of the ready to use composition.
- the concentration of (Cl- C4)alcohols is preferably less than 20%, more preferably less than about 15%.
- longer chain (i.e., C5-C10) alcohols are present in a total amount of at least 0.1 wt-%, more preferably at least 0.25 wt-%, and even more preferably at least 0.5 wt-%, and most preferably at least 1.0%, based on the ready to use composition.
- the (C5-C10)alcohols are present in a total amount of no greater than 10 wt-%, more preferably no greater than 5 wt-%, and even more preferably no greater than 2 wt-%, based on the total weight of the ready to use composition.
- An additional enhancer class includes ether glycol. Exemplary ether glycols include those of the formula:
- R 1 H, a (Cl-C8)alkyl, a (C6-C12) aryl or a (C6-C12)aralkyl or (C6-C12) alkaryl
- n 0-5, preferably 1-
- Examples include 2 phenoxyethanol, dipropylene glycol, triethylene glycol, the line of products available under the trade designation DOWANOL DB (di(ethylene glycol) butyl ether), DOWANOL DPM (di(propylene glycol)monomethyl ether), and DOWANOL TPnB (tri(propylene glycol) monobutyl ether), as well as many others available from Dow Chemical, Midland MI.
- DOWANOL DB di(ethylene glycol) butyl ether
- DOWANOL DPM di(propylene glycol)monomethyl ether
- DOWANOL TPnB tri(propylene glycol) monobutyl ether
- One or more ether glycols may be used in the compositions of the present invention at a suitable level to produce the desired result. In a preferred embodiment, they are present in a total amount of at least 0.01 wt-%, based on the total weight of the ready to use composition. In a preferred embodiment, they are present in a total amount of no greater than 20 wt-%, based on the total weight of the ready to use composition.
- compositions of the present invention can include one or more surfactants to emulsify the composition and to help the composition wet the surface and/or to aid in contacting the microorganisms.
- surfactant means an amphiphile (a molecule possessing both polar and nonpolar regions which are covalently bound) capable of reducing the surface tension of water and/or the interfacial tension between water and an immiscible liquid.
- the term is meant to include soaps, detergents, emulsifiers, surface active agents and the like.
- the surfactant can be cationic, anionic, nonionic, or amphoteric. This includes a wide variety of conventional surfactants. Combinations of surfactants can be used if desired.
- ethoxylated surfactants may reduce or eliminate the antimicrobial efficacy of the antiseptic component.
- the exact mechanism of this is not known and not all ethoxylated surfactants display this negative effect.
- poloxamer may reduce or eliminate the antimicrobial efficacy of the antiseptic component.
- poloxamer may reduce or eliminate the antimicrobial efficacy of the antiseptic component. The exact mechanism of this is not known and not all ethoxylated surfactants display this negative effect. For example, poloxamer
- polyethylene oxide/polypropylene oxide surfactants have been shown to be compatible with some antiseptic components, but ethoxylated sorbitan fatty acid esters such as those sold under the trade name TWEEN by ICI have not been compatible and may even be useful in neutralizing the antiseptic in microbiological assays.
- anionic surfactants may not be compatible with the cationic antiseptics of this invention. It should be noted that these are broad generalizations and the activity could be formulation dependent. One skilled in the art can easily determine compatibility of a surfactant by making the formulation and testing for antimicrobial activity as described in the Examples Section.
- certain antiseptics are amphiphiles and may be surface active.
- the small molecule quaternary ammonium compound antiseptics described herein may be surface active.
- the surfactant is a component separate from the amphiphilic antiseptic.
- Preferred surfactants are those that have an HLB (i.e., hydrophile to lipophile balance) of at least 4 and more preferably at least 8. Even more preferred surfactants have an HLB of at least 12. Most preferred surfactants have an HLB of at least 15.
- HLB hydrophile to lipophile balance
- the surfactants useful in the compositions of the present invention are selected from the group consisting of sulfonates, sulfates, phosphonates, phosphates, poloxamer (polyethylene oxide/polypropylene oxide block copolymers), cationic surfactants, and mixtures thereof.
- Cationic, amphoteric, and non-ionic surfactants and in particular the ethylene oxide/propylene oxide surfactants such as poloxamers are particularly preferred for use with cationic antiseptics.
- One or more surfactants may be used in the compositions of the present invention at a suitable level to produce the desired result.
- they are present in a total amount of at least 0.01 wt-%, preferably 0.1 wt%, more preferably at least 0.5 wt-%, and even more preferably at least 1.0 wt-%, based on the total weight of the ready to use composition.
- Ih a preferred embodiment where, for example, irritation may be a concern, they are present in a total amount of no greater than 10 wt-%, more preferably no greater than 5 wt-%, and even more preferably no greater than 2 wt-%, based on the total weight of the ready to use composition.
- the ratio of the total concentration of surfactant to the total concentration of the antiseptic is preferably within a range of 5 : 1 to 1 : 100, more preferably 3 : 1 to 1 : 10, and most preferably 2 : 1 to 1 : 3, on a weight basis.
- Cationic Surfactants are preferably within a range of 5 : 1 to 1 : 100, more preferably 3 : 1 to 1 : 10, and most preferably 2 : 1 to 1 : 3, on a weight basis.
- Exemplary cationic surfactants include, but are not limited to, salts of optionally polyoxyalkylenated primary, secondary, or tertiary fatty amines; quaternary ammonium salts such as tetraalkylammonium, alkylamidoallcyltrialkylammonium, trialkylbenzylammonium, trialkylhydroxyalkylammonium, or alkylpyridinium having compatible anionic counterions such as halides (preferably chlorides or bromides) or alkyl sulfates such as methosulfate or ethosulfate as well as other anionic counterions; imidazoline derivatives; amine oxides of a cationic nature (e.g., at an acidic pH), and mixtures thereof.
- anionic counterions such as halides (preferably chlorides or bromides) or alkyl sulfates such as methosulfate or ethosulfate as well as other anionic counterions
- the cationic surfactants useful in the compositions of the present invention are selected from the group consisting of tetralkyl ammonium, trialkylbenzylammonium, and alkylpyridinium halides, and mixtures thereof.
- amine oxide surfactants including alkyl and alkylamidoalkyldialkylamine oxides of the following formula: wherein R 14 is a (Cl-C30)alkyl group (preferably a (Cl-C14)alkyl group) or a (C6- C18)aralklyl or alkaryl group, wherein any of these groups can be optionally substituted in or on the chain by N-, O-, or S-containing groups such as amide, ester, hydroxyl, and the like.
- Each R 14 may be the same or different provided at least one R 14 group includes at least eight carbons.
- the R 14 groups can be joined to form a heterocyclic ring with the nitrogen to form surfactants such as amine oxides of alkyl morpholine, alkyl piperazine, and the like.
- surfactants such as amine oxides of alkyl morpholine, alkyl piperazine, and the like.
- two R 14 groups are methyl and one R 14 group is a (C12-C16)alkyl or alkylamidopropyl group.
- amine oxide surfactants include those commercially available under the trade designations AMMONYX LO, LMDO, and CO, which are lauryldimethylamine oxide, laurylamidopropyldimethylamine oxide, and cetyl amine oxide, all from Stepan Company of Northfield, IL.
- anionic surfactants include, but are not limited to, sarcosinates, glutamates, alkyl sulfates, sodium or potassium alkyleth sulfates, ammonium alkyleth sulfates, ammonium laureth-n-sulfates, laureth-n-sulfates, isethionates, alkyl and aralkyl glycerylether sulfonates, alkyl and aralkyl sulfosuccinates, alkylglyceryl ether sulfonates, alkyl phosphates, aralkyl phosphates, alkylphosphonates, and aralkylphosphonates.
- anionic surfactants may have a metal or organic ammonium counterion.
- the anionic surfactants useful in the compositions of the present invention are selected from the group consisting of:
- Suitable anionic surfactants include sulfonates and sulfates such as alkyl sulfates, alkylether sulfates, alkyl sulfonates, alkylether sulfonates, alkylbenzene sufonates, alkylbenzene ether sulfates, alkylsulfoacetates, secondary alkane sulfonates, secondary alkylsulfates, and the like. Many of these can be represented by the formulas:
- R 14 is defined as above provided at least one R 14 or R 15 is at least C8;
- R 15 is a (Cl- C12)alkyl group (saturated straight, branched, or cyclic group) that may be optionally substituted by N, O, or S atoms or hydroxyl, carboxyl, amide, or amine groups;
- Ph phenyl;
- M is a cationic counterion such as H, Na, K, Li, ammonium, or a protonated tertiary amine such as triethanolamine or a quaternary ammonium group.
- R 1 includes an alkylamide group such as R 16 -C(O)N(CH 3 )CH 2 CH 2 - as well as ester groups such as - OC(O)-CH 2 - wherein R 16 is a (C8-C22)alkyl group (branched, straight, or cyclic group).
- (C14-C17)secondary alkane sulfonates (alpha-olefin sulfonates) available from Clariant Corp., Charlotte, NC; methyl-2-sulfoalkyl esters such as sodium methyl-2-sulfo(C12- 16)ester and disodium 2-sulfo(C12-C16)fatty acid available from Stepan Company under the trade designation ALPHASTEP PC-48; alkylsulfoacetates and alkylsulfosuccinates available as sodium laurylsulfoacetate (under the trade designation LANTHANOL LAL) and disodiumlaurethsulfosuccinate (STEPANMILD SL3), both from Stepan Company; alkylsulfates such as ammoniumlauryl sulfate commercially available under the trade designation STEPANOL AM from Stepan Company; dialkylsulfosuccinates such as dioctylsodiumsulfosuccinate
- Suitable anionic surfactants also include phosphates such as alkyl phosphates, alkylether phosphates, aralkylphosphates, and aralkylether phosphates. Many may be represented by the formula:
- Examples include a mixture of mono-, di- and tri-(alkyltetraglycolether)- o-phosphoric acid esters generally referred to as trilaureth-4-phosphate commercially available under the trade designation HOSTAPHAT 340KX from Clariant Corp., as well as PPG-5 ceteth 10 phosphate available under the trade designation CRODAPHOS SG from Croda Inc., Parsipanny, NJ, and mixtures thereof.
- trilaureth-4-phosphate commercially available under the trade designation HOSTAPHAT 340KX from Clariant Corp.
- PPG-5 ceteth 10 phosphate available under the trade designation CRODAPHOS SG from Croda Inc., Parsipanny, NJ, and mixtures thereof.
- Surfactants of the amphoteric type include surfactants having tertiary amine groups, which may be protonated, as well as quaternary amine containing zwitterionic surfactants. Those that have been particularly useful include: 1. Ammonium Carboxylate Amphoterics. This class of surfactants can be represented by the following formula:
- R 19 is H it is understood that the surfactant at higher pH values could exist as a tertiary amine with a cationic counterion such as Na, K, Li, or a quaternary amine group.
- amphoteric surfactants include, but are not limited to: certain betaines such as cocobetaine and cocamidopropyl betaine (commercially available under the trade designations MACKAM CB-35 and MACE-AM L from Mclntyre Group Ltd., University Park, IL); monoacetates such as sodium lauroamphoacetate; diacetates such as disodium lauroamphoacetate; amino- and alkylamino-propionates such as lauraniinopropionic acid (commercially available under the trade designations
- MACKAM IL MACKAM 2L, and MACKAM 15 IL, respectively, from Mclntyre Group Ltd.
- amphoterics This class of amphoteric surfactants are often referred to as "sultaines” or “sulfobetaines” and can be represented by the following formula
- Examples include cocamidopropylhydroxysultaine (commercially available as ' MACKAM 50-SB from Mclntyre Group Ltd.).
- the sulfoamphoterics may be preferred over the carboxylate amphoterics since the sulfonate group will remain ionized at much lower pH values.
- Nonionic Surfactants include, but are not limited to, alkyl glucosides, alkyl polyglucosides, polyhydroxy fatty acid amides, sucrose esters, esters of fatty acids and polyhydric alcohols, fatty acid alkanolamides, ethoxylated fatty acids, ethoxylated aliphatic acids, ethoxylated fatty alcohols (e.g., octyl phenoxy polyethoxyethanol available under the trade name TRITON X-IOO and nonyl phenoxy poly(ethyleneoxy) ethanol available under the trade name NONIDET P- 40, both from Sigma, St.
- alkyl glucosides alkyl polyglucosides
- polyhydroxy fatty acid amides sucrose esters, esters of fatty acids and polyhydric alcohols
- fatty acid alkanolamides ethoxylated fatty acids
- ethoxylated aliphatic acids ethoxylated fatty alcohol
- ethoxylated and/or propoxylated aliphatic alcohols e.g., that available under the trade name Brij from ICI
- ethoxylated glycerides ethoxylated/propoxylated block copolymers such as the Pluronic and Tetronic surfactants available from BASF
- ethoxylated cyclic ether adducts ethoxylated amide and imidazoline adducts
- ethoxylated amine adducts ethoxylated mercaptan adducts
- ethoxylated condensates with alkyl phenols ethoxylated nitrogen- based hydrophobes
- ethoxylated polyoxypropylenes polymeric silicones
- fluorinated surfactants e.g., those available under the trade names FLUORAD-FS 300 from 3M Conpany, St.
- nonionic surfactants useful in the compositions of the present invention are selected from the group consisting of Poloxamers such as PLURONIC from BASF, sorbitan fatty acid esters, and mixtures thereof.
- compositions of the present invention can include a hydrophilic or water-soluble component to help solubilize and/or physically stabilize the antiseptic and/or enhancer component in the composition and/or to enhance the antimicrobial efficacy and/or the speed of antimicrobial efficacy.
- a hydrophilic or water-soluble component to help solubilize and/or physically stabilize the antiseptic and/or enhancer component in the composition and/or to enhance the antimicrobial efficacy and/or the speed of antimicrobial efficacy.
- compositions may be solutions, emulsions (one liquid/gel/paste dispersed in another liquid/gel/paste), or dispersions (solid in liquid/paste/gel).
- the ratio of total hydrophilic component to total hydrophobic component (water insoluble ingredients) should be at least 5:95 wt/wt, preferably at least 10:90 wt/wt, more preferably at least 15:85 wt/wt and most preferably at least 20:80 wt/wt.
- Levels as high as 30:70, 40:60, 50:50 wt/wt of total hydrophilic component to total hydrophobic component (water insoluble ingredients) or higher may be appropriate for certain compositions.
- a hydrophilic material is typically a compound that has a solubility in water of at least 7 wt-%, preferably at least 10 wt-%, more preferably at least 20 wt-%, even more preferably at least 25 wt-%, and even more preferably at least 40 wt-%, at 23°C. Most preferably, a hydrophilic component is infinitely miscible with water at 23 0 C.
- hydrophilic components include, but are not limited to, water, polyhydric alcohols, lower alkyl ethers (i.e., having a sufficiently small number of carbon atoms to meet the solubility limit above), N-methylpyrrolidone, alkyl esters (i.e., having a sufficiently small number of carbon atoms to meet the solubility limit above), and the lower monohydroxy alcohols discussed above as enhancers, as well as combinations thereof.
- a lower monohydroxy alcohol can function as both a hydrophilic compound and an enhancer.
- the hydrophilic components include polyhydric alcohols, lower alkyl ethers, and short chain esters. More preferably, the hydrophilic components include polyhydric alcohols.
- Suitable polyhydric alcohols have a molecular weight of less than 500, preferably less than 400, and more preferably less than 200.
- polyhydric alcohols include, but are not limited to, glycerol, propylene glycol, dipropylene glycol, tripropylene glycol, polypropylene glycol, polyethylene glycol, diethylene glycol, pentaerythritol, trimethylolpropane, trimethylolethane, trimethylolbutane, sorbitol, mannitol, xylitol, pantothenol, ethylene glycol adducts of polyhydric alcohol, propylene oxide adducts of polyhydric alcohol, 1,3-butanediol, dipropylene glycol, diglycerine, polyglycerine, erythritol, sorbitan, sugars (e.g., sucrose, glucose, fructos), sorbitan, sugars (e.g., sucrose
- Certain preferred polyhydric alcohols include glycols (i.e., those containing two hydroxyl groups) including glycerin and propylene glycol. Certain other preferred polyhydric alcohols include xylitol, mannitol, sorbitol, sucrose and polyglycerin.
- Ethers include materials such as dimethylisosorbide, polyethylene glycol and methoxypolyethylene glycols, block and random copolymers of ethylene oxide and propylene oxide, and laureth-4.
- Alkyl esters include triacetin, methyl acetate, esters of polyethoxylated glycols, and combinations thereof.
- the hydrophilic components useful in the • compositions of the present invention include those selected from the group consisting of glycols, and in particular glycerin and propylene glycol, and mixtures thereof.
- compositions of the present invention may esterify with hydroxylfunctional hydrophilic components conditions are selected to minimize this occurrence. For example, the components are not heated together for extended periods of time, the pH is maintained close to neutral if possible, and the like.
- hydrophilic materials may be used in the compositions of the present invention at a suitable level to produce the desired result.
- the hydrophilic component is present in a total amount of at least 0.1%, preferably at least 1 wt-%, more preferably at least 4 wt-%, and even more preferably at least 8 wt-%, based on the weight of the ready to use composition In certain embodiments, for example when faster rate of kill is desired, higher levels of hydrophilic component may be employed. In these cases the hydrophilic component is present in a total amount of at least 10% by weight, more preferably at least 20% by weight and most preferably at least 25% by weight.
- the hydrophilic component is present in a total amount of no greater than 70 wt-%, more preferably no greater than 60 wt-%, and even more preferably no greater than 50 wt-%, based on the ready to use composition.
- the hydrophilic component is present in the greatest amount it is referred to as a "vehicle.”
- the hydrophilic component is present in an amount no greater than about 30% by weight.
- compositions comprising a hydrophilic component vehicle that is thickened with soluble, swellable or insoluble (e.g. insoluble) organic polymeric thickeners or inorganic thickeners such as silica, fumed silica, precipitated silica, silica aerogel and carbon black, and the like; other particle fillers such as calcium carbonate, magnesium carbonate, kaolin, talc, titanium dioxide, aluminum silicate, diatomaceous earth, ferric oxide and zinc oxide, clays, and the like; ceramic microspheres or glass microbubbles; ceramic microspheres sue as those available under the tradenames "ZEOSPHERES” or "Z-LIGHT” from 3M.
- the above fillers can be used alone or in combination.
- water is used in certain embodiments, it is present in an amount of less than 20 wt %, preferably less than 10 wt-%, more preferably less than 5 wt-%, and even more preferably less than 2 wt-%, based on the ready to use composition. This helps the chemical stability of the compositions and may reduce irritation. For certain other embodiments, water can be used in a much greater amount, and can even be the primary component, as long as the composition is highly viscous.
- such highly viscous compositions have a viscosity of at least 500 centipoise (cps), more preferably at least 1,000 cps, even more preferably at least 10,000 cps, even more preferably at least 20,000 cps, even more preferably at least 50,000 cps, even more preferably at least 75,000 cps, even more preferably at least 100,000 cps, and even more preferably at least 250,000 cps (and even as high as about 500,000 cps, 1,000,000 cps, or more).
- the viscosity can be measured as described below in the Viscosity Test. Most preferred compositions meet these viscosity values even after heating to 32C or even 35C or as high as 37C to ensure when in contact with mammalian tissue the compositions remain substantive.
- compositions of the present invention also include one or more hydrophobic materials.
- a hydrophobic material is typically an organic compound, which at 23 0 C is a liquid, gelatinous, semisolid or solid and has a solubility in water of less than 5% by weight, preferably less than 1 % by weight, more preferably less than 0.5% by weight, and even more preferably less than 0.1% by weight.
- These materials include compounds typically considered emollients in the cosmetic art.
- Examples of general emollients include, but are not limited to, short chain (i.e, C1-C6) alkyl or (C6-C12)aryl esters of long (i.e., C8-C36) straight or branched chain alkyl or alkenyl alcohols or acids and polyethoxylated derivatives of the alcohols; short chain (i.e., C1-C6) alkyl or (C6-C12)aryl esters of (C4-C12)diacids or (C4-C12)diols optionally substituted in available positions by -OH; (C2-C 18)alkyl or (C6-C 12)aryl esters of glycerol, pentaerythritol, ethylene glycol, propylene glycol, as well as polyethoxylated derivatives of these; (C 12-C22) alkyl esters or (C12-C22)ethers of polypropylene glycol; (C12-C22
- hydrophobic components include cyclic dimethicones including volatile cyclic silicones such as D3 and D4, polydialkylsiloxanes, polyaryl/alkylsiloxanes, silicone copolyols, long chain (i.e., C8-C36) alkyl and alkenyl esters of long (i.e., C8-C18) straight or branched chain alkyl or alkenyl alcohols or acids, long chain (i.e., C8-C36) allcyl and alkenyl amides of long straight or branched chain (i.e., C8-C36) alkyl or alkenyl amines or acids; hydrocarbons including straight and branched chain alkanes and alkenes such as isoparafms (e.g.
- the hydrophobic components useful in the compositions of the present invention include those selected from the group consisting of petrolatum USP and short chain (i.e., C1-C6) alkyl or (C6-C12)aryl esters of long (i.e., C8-C36) straight or branched chain alkyl or alkenyl alcohols or acids and polyethoxylated derivatives of the alcohols; short chain (i.e., C1-C6) allcyl or (C6- C12)aryl esters of (C4-C12)diacids or (C4-C12)diols optionally substituted in available positions by -OH (such as diisopropyladipate, diisopropylsebacate); (Cl-C9)alkyl or (C6-C12)aryl esters of glycerol, pentaerythritol, ethylene glycol, propylene glycol (such as glyceryl tri
- the hydrophobic component is petrolatum.
- One or more hydrophobic materials may be used in the compositions of the present invention at a suitable level to produce the desired result.
- the hydrophobic component is present in a total amount of at least 30 wt-%, preferably at least 50 wt%, more preferably at least 60 wt-%, and even more preferably at least 70 wt-%, based on the ready to use composition.
- the hydrophobic component is present in a total amount of no greater than 99 wt-%, more preferably no greater than 95 wt-%, and even more preferably no greater than 92 wt-%, based on the ready to use composition.
- the hydrophobic component is present in the greatest amount it is referred to as a "vehicle.” If the hydrophobic component(s) and the hydrophilic component(s) are present at the same concentrations the continuous phase is consider the "vehicle”. If the hydrophobic component(s) and the hydrophilic component(s) are present at the same concentrations the continuous phase is consider the "vehicle".
- compositions of the present invention may additionally employ adjunct components conventionally found in pharmaceutical compositions in their art- established fashion and at their art-established levels.
- the compositions may contain additional compatible pharmaceutically active materials for combination therapy (such as supplementary antimicrobials, anti-parasitic agents, antipruritics, astringents, local anaesthetics, steroids, non-steorodial antinflammatory agents, or other anti-inflammatory agents), or may contain materials useful in physically formulating various dosage forms of the present invention, such as excipients, dyes, perfumes, fragrances, lubricants, thickening agents, stabilizers, skin penetration enhancers, preservatives, or antioxidants.
- an emulsifier may be used.
- an "emulsifier” means a small molecule or polymeric amphophilic compound capable of helping to stabilize an emulsion.
- Emulsifiers used herein include many of the surfactants disclosed but may also include many other amphiphilic molecules. The emulsions are detectably more stable with the emulsifier present than without as determined by centrifugation and/or freeze thaw studies.
- antiseptics disinfectants, or antibiotics
- antibiotics include, for example, addition of metals such as silver, copper, zinc; iodine and iodophors: "azole" antifungal agents including clortrimazole, miconazole, econazole, ketoconazole, and salts thereof; and the like.
- Antibiotics such as neomycin sulfate, bacitracin, mupirociri, tetracycline, polymixin, and the like, also may be included.
- Preferred compositions are free of antibiotics due to the chance of resistance formation.
- compositions of the present invention demonstrate a broad spectrum of antimicrobial activity and thus are generally not terminally sterilized but if necessary may be sterilized by a variety of industry standard techniques. For example, it may be preferred to sterilize the compositions in their final packaged form using electron beam.
- compositions of the present invention preferably adhere well to mammalian tissue (e.g., skin, mucosal tissue, and wounds), in order to deliver the antimicrobial to the intended site over a prolonged period even in the presence of perspiration
- compositions are typically non-aqueous, although high viscosity compositions can include a large amount of water.
- the component in the greatest amount (i.e., the vehicle) in the formulations of the invention may be any conventional vehicle commonly used for topical treatment of human or animal skin.
- the formulations are typically selected from one of the following five types: (1) formulations with a hydrophobic vehicle (i.e., the hydrophobic component, which can include one or more hydrophobic compounds, present in the greatest amount) which may be anhydrous, nearly anhydrous or further comprise a aqueous phase; (2) formulations based on water in oil emulsions in which the water insoluble continuous "oil" phase is comprised of one or more hydrophobic components; (3) formulations with a hydrophilic vehicle (i.e., the hydrophilic component, which can include one or more hydrophilic compounds, is present in the greatest amount) which may be anhydrous, nearly anhydrous or further comprise a aqueous phase; (4) highly viscous water-based formulations which may be solutions or oil in water emulsions; and (5) neat compositions which are essentially free of a hydrophobic or hydrophilic vehicle component comprising antiseptic, optionally an enhancer, and further optionally a surfactant. In this latter case the compositions may optional
- compositions include an antiseptic component in a hydrophobic vehicle optionally in combination with surfactant(s), an enhancer component, and a small amount of a hydrophilic component.
- the enhancers are not soluble in the hydrophobic component at room temperature although they may be at elevated temperatures.
- the hydrophilic component is generally present in a sufficient amount to stabilize (and perhaps to solubilize) the enhancer(s) in the composition.
- these formulations produce an emulsion in which the enhancer and/or surfactant is dissolved, emulsified, or dispersed in the hydrophilic component which is emulsified into the hydrophobic component(s). These compositions are stable upon cooling and centrifuging.
- the hydrophilic component also helps to stabilize many of the surfactants used in preferred formulations.
- DOSS dioctylsulfosuccinate sodium salt
- the hydrophilic component improves the antimicrobial activity. The mechanism for this is unknown; however, it may speed the release of the enhancer component and/or the antiseptic component.
- the water content of these formulations is preferably less than 20 wt-%, more preferably less than 10 wt-%, and even more preferably less than 5 wt-%, and most preferably less than 2 wt-%, in order to minimize chemical degradation of antiseptics present as well as to reduce concerns with microbial contamination in the composition during storage, and to reduce irritation of the tissue to which it is applied.
- These formulations can be manufactured with relative ease. The following description assumes all components are present in order to describe their manufacture. It is understood, however, that certain compositions may not contain one or more of these components.
- the compositions are manufactured by first heating the hydrophobic component to 85°C, adding in the surfactant, hydrophilic component, and optional enhancer component, cooling to 65°C, and adding the antiseptic component which may be above its melting point.
- the enhancer component if used, can be predissolved in the hydrophilic component (optionally along with the surfactant) and added to the hydrophobic component either before or after addition of the antiseptic component. If either the antiseptic component or the hydrophobic component is solid at room temperature, this is done at the minimum temperature necessary to ensure dissolution and uniformity of the composition.
- ester-containing antiseptics or excipients to enhancers or other components comprising either acid or hydroxyl groups at elevated temperatures for extended periods of time should be avoided to prevent transesterification reactions. There are exceptions, for example, when heating lower purity fatty acid esters in combination with glycol hydrophilic components to produce the monoesters of higher purity.
- the present invention provides methods of manufacture.
- One method involves: combining the hydrophobic vehicle and the hydrophilic component with mixing to form a mixture; optionally heating the hydrophobic vehicle to a temperature sufficient to form a pourable liquid (which for many hydrophobic vehicles this is above its melting point) before or after combining it with the hydrophilic component; adding the antiseptic component to the mixture; and cooling the mixture before or after adding the antiseptic component.
- One preferred method involves: dissolving at least a portion of the enhancer component in the hydrophilic component; combining the hydrophobic vehicle and the hydrophilic component with the enhancer component dissolved therein with mixing to form a mixture; optionally heating the hydrophobic vehicle to a temperature sufficient to form a pourable liquid (which for many hydrophobic vehicles this is above its melting point) before or after combining it with the hydrophilic component and enhancer component; adding the antiseptic component to the mixture; and cooling the mixture before or after adding the antiseptic component.
- the hydrophilic component may or may not be present in the formulations that include a hydrophobic vehicle.
- another preferred method of manufacture involves: optionally heating the hydrophobic vehicle to a temperature sufficient to form a pourable liquid (which for many hydrophobic vehicles is above its melting point) before or after combining it with the optional enhancer component; adding the antiseptic component to the mixture with mixing; and cooling the mixture before or after adding the antiseptic component.
- compositions are significantly less irritating than formulations using hydrophilic vehicles
- hydrophobic components e.g., petrolatum
- AHA enhancer an AHA enhancer
- surfactant an AHA enhancer
- lOwt-% hydrophilic component e.g., glycerin
- hydrophilic components e.g., PEG 400
- the viscosity of these formulations intended for use on skin or in the anterior nares is preferably relatively high to prevent excessive drainage off the treatment site.
- the formulations intended for use on skin, anterior nares, or where drainage would be a concern are essentially gelatinous at room temperature, having a significant yield point such that they do not flow readily at temperatures below 35°C.
- the viscosity is measured using the viscosity test described herein.
- Certain gelatinous vehicles may also have a characteristic temperature at which they "melt" or begin to dramatically lose viscosity. Preferably this is higher than body temperature also to ensure that excess drainage of the composition of the treatment site does not occur.
- the melting point of the composition is preferably greater than 32°C, more preferably greater than 35°C, and even more preferably greater than about 37°C.
- the melting point is taken as the lowest temperature at which the viscosity becomes dramatically less or is equal to or less than 100,000 cps.
- aqueous compositions based on Pluronic F127 e.g., greater than about 17% by weight
- Pluronic F127 e.g., greater than about 17% by weight
- Poloxamers of similar structure are relatively low viscosity at 4°C but when warmed to body temperature become very viscous. In these applications, the viscosity should be measured at 35°C.
- the viscosity and/or melt temperature can be enhanced by either incorporating a crystalline or semicrystalline emulsifier and/or hydrophobic carrier such as a higher melting petrolatum, addition of an insoluble filler/thixotrope, or by addition of a polymeric thickener (e.g., a polyethylene wax in a petrolatum vehicle).
- a polymeric thickener e.g., a polyethylene wax in a petrolatum vehicle.
- Polymeric thickeners may be linear, branched, or slightly crosslinked. It is important for comfort that the formulations are relatively soft and that they spread easily to allow easy application, especially over a wound, rash, or infected area or in the anterior nares.
- a particularly preferred vehicle for use on skin, in the anterior nares, or in other areas where high viscosity is desirable is white petrolatum USP having a melting point greater than 40°C.
- Antiseptic components of this invention can be formulated into water-in-oil emulsions in combination with enhancer(s) and surfactant(s).
- Particularly preferred compositions comprise at least 35wt-%, preferably at least 40wt ⁇ %, more preferably at least 45wt-% and most preferably at least 50% by weight oil phase.
- the oil phase is comprised of all components which are either insoluble in water or preferentially soluble in the oil(s) present at 23°C.
- One method of preparing these emulsions is described in applicant's copending U.S. Serial No. 09/966,571.
- the hydrophobic component (oil) is mixed in a first container along with any emulsifier(s) optionally including polymeric emulsifiers and heated to a temperature sufficient to ensure a homogenous composition and subsequent stable emulsion.
- the temperature is typically raised to at least 6O 0 C, preferably to at least 80 0 C and more preferably to 100 0 C or more.
- the hydrophilic ingredients are mixed, including one or more of the following: water, hydrophilic component, enhancer(s), surfactant(s), and acids ⁇ ases to adjust the pH of the final composition.
- the contents of the second container are heated to a temperature sufficient to ensure a stable final emulsion composition without significantly degrading any of the components, typically greater than 40 0 C, preferably greater than 50 0 C and more preferably to greater than 6O 0 C. While hot, the second container is added to the first container using a high shear mixer. The composition may be continuously mixed until cool (T ⁇ 40°C) or it can be allowed to sit as long as the contents remain uniformly mixed. If the antiseptic is heat sensitive, it is added with mixing during the cooling down period. If it is not heat sensitive, it may be added to either container.
- compositions may be adjusted by altering the levels of emulsifier; changing the ratio of water to oil phase; selection of the oil phase (e.g., select an oil (hydrophobic component) which is more or less viscous); incorporation of a polymeric or particulate thickener, etc.
- Antiseptic components of this invention can be formulated into a hydrophilic component such as that based on the hydrophilic compounds discussed above optionally in combination with the enhancer(s) and surfactant(s). Particularly preferred are polyethylene glycols (PEGs), glycols, and combinations thereof, including blends of different molecular weight PEGs optionally containing one or more glycols.
- a hydrophilic component i.e., the component used in the greatest amount, which can include one or more hydrophilic compounds
- the viscosity can be enhanced by either incorporating a crystalline or semicrystalline hydrophilic compound such as a PEG of sufficient molecular weight, addition of an insoluble filler/thixotrope, or by addition of a polymeric thickener.
- Polymeric thickeners may be linear, branched, or slightly crosslinked. It is important for comfort that the formulations are relatively soft and that they spread easily to allow easy application, especially in the anterior nares or over a wound, rash, or infected area. For this reason, a particularly preferred vehicle is based on a blend of a liquid or semi ⁇ solid PEG (PEG 400-1000) with a more crystalline PEG (PEG 1000-2000).
- compositions are in the form of an ointment or cream. That is, the compositions are in the form of a relatively viscous state such that they are suitable for application to nasal passageways.
- Aqueous compositions of the present invention are those in which water is present in the greatest amount, thereby forming the "vehicle.”
- a relatively high viscosity be imparted to the composition to ensure that the antimicrobial composition is not rapidly dispersed off the treated area.
- These formulations also adhere well to tissue and thus deliver the antiseptic " to the intended site over a prolonged period even in the presence of perspiration, drainage (e.g., mucosal secretions), or mild lavage.
- Such a high viscosity can be imparted by a thickener system.
- the thickener system of the invention is compatible with the antiseptic composition described above in order to provide suitable antimicrobial efficacy, chemical and physical stability, acceptable cosmetic properties, and appropriate viscosity for retention in the afflicted area.
- Preferred thickener systems used in the compositions of the present invention are capable of producing viscoelastic compositions that are very stable.
- the degree of elasticity can be adjusted from almost a purely viscous composition to a highly elastic and even gel-like composition. If emollients are added, increasing the elasticity and/or yield stress of the system imparts added stability to prevent separation of immiscible emollients. Excessive elasticity, however, is not preferred because an excessively elastic composition usually does not provide a cosmetically appealing product.
- thickener systems used in the present invention are capable of achieving high viscosities at relatively low total concentrations.
- the total concentration of the thickener system is preferably less than 8 wt-%, more preferably less than 5 wt- %, and most preferably less than 3 wt-%, based on the total weight of the ready to use composition.
- the total concentration of the thickener system can be as little as 0.5 wt-%, based on the total weight of the composition.
- the total concentration of thickener system is greater than 1 wt-%, based on the total weight of the ready to use composition.
- the thickener system can include organic polymers or inorganic thixotropes such as silica gel, clays (such as betonite, laponite, hectorite, montmorrillonite and the like), as well as organically modified inorganic particulates materials, and the like.
- organic polymers or inorganic thixotropes such as silica gel, clays (such as betonite, laponite, hectorite, montmorrillonite and the like), as well as organically modified inorganic particulates materials, and the like.
- organic polymers or inorganic thixotropes such as silica gel, clays (such as betonite, laponite, hectorite, montmorrillonite and the like), as well as organically modified inorganic particulates materials, and the like.
- an organic polymer is considered part of the thickener system if its presence in the composition results in an increase in the viscosity of the composition.
- certain nonionic polymers such as lower molecular weight polyethylene glycols (e.g., those having a molecular weight of less than 20,000) do not increase the viscosity of the composition significantly. These are considered part of the hydrophilic component, for example, rather than part of the thickener system.
- the thickener system can be prepared from one or more nonionic, cationic, anionic, zwitterionic, or associative polymers as long as they are compatible with the antiseptic and enhancer components of the composition.
- certain acidic enhancers such as those that include carboxylic acid groups are most effective in their protonated form. This requires that the composition has an acidic pH. For this reason, many anionic thickeners based on neutralized carboxylic acid groups would not be suitable.
- Carbopol-type thickeners based on polyacrylic acid salts do not typically thicken well at pH values of less than 5 and certainly less than a pH of 4.5.
- the polymers are preferably based on sulfonic acid, sulfate, phosphonic acid, or phosphate groups. These polymers are able to thicken at much lower p ' H values due to the lower pKa of these acid groups.
- Preferred polymers of this class include ARISTOFLEX HMB (ammonium acryloyldimethyltaurate/beheneth-25 methacrylate crosspolymer) and ARISTOFLEX ASV (ammonium acryloyldimethyltaurate/NVP copolymer) from Clariant Corporation.
- Other preferred sulfonic acid polymers are those described in U.S. Pat. No. 5,318,955.
- the compositions that include an acidic enhancer component are thickened using cationic or nonionic thickeners since these perform well at low pH.
- many of the nonionic and cationic polymers can tolerate higher levels of salts and other additives and still maintain high viscosity.
- nonionic polymeric thickeners include modified celluloses, guar, xanthan gum, and other natural polymers such as polysaccharides and proteins, associative polymers based on nonionic ethylenically unsaturated monomers wherein at least one comonomer has at least 16 carbon atoms, and polymers based on ethylenically unsaturated monomers selected from the group consisting of acrylates, acrylamides, vinyl lactams, vinyl acetate and its hydrolyzed derivatives, methyl vinyl ethers, styrene, and acrylonitrile.
- a preferred group of cationic polymeric thickeners include cationically modified celluloses, quaternized natural amino-functional polymers, and polymers based on ethylenically unsaturated monomers selected from the group consisting of acrylates, acrylamides, vinyl lactams, vinyl acetates, methyl vinyl ethers, styrene, and acrylonitrile.
- Cationic polymers for use in the compositions of this invention can be selected from both permanently charged quaternary polymers (those polymers with quaternary amines such as Polyquaternium 4, 10, 24, 32, and 37, described below) as well as protonated primary, secondary, and tertiary amine functional polymers that have been protonated with a suitable protonic acid.
- Preferred protonated cationic polymers are based on tertiary amines.
- the protonated catiom ' c polymers are preferably protonated with suitable acids that will not result in undue. skin irritation.
- (Cl-ClO)alkylcarboxylic acids optionally substituted by oxygen e.g., acetic acid, alpha-hydroxy acids such as lactic acid, gluconic acid, benzoic acid, mandelic acid, and the like
- (Cl-ClO)alkylsulfonic acids e.g., methylsulfonic acid and ethylsulfonic acid
- (Cl-ClO)alkylhydrogensulfates e.g., methylhydrogensulfate
- mineral acids e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and the like.
- the charge on protonated cationic polymers is pH dependent. For this reason, in order to ensure the polymer is sufficiently protonated, the pH is adjusted appropriately and should be in the range of preferably 2-9.5, more preferably 2-8, and most preferably 2.5-7.5.
- the pH of preferred compositions that include acidic enhancers should be lower and is typically 2-5, and preferably 2-4. It should be noted that it is not necessary to have all of the amines on a particular polymer protonated. The level of protonation will to a certain extent be pH dependent. With certain polymers in order to obtain optimum thickening with low skin irritation it may be beneficial to only protonate a small percentage of the available amine groups while with other polymers it may be beneficial to protonate substantially all of the amine groups. This can be easily determined by one skilled in the art.
- the quaternary, tertiary, secondary, and primary amine functional polymers may be chosen from natural polymers, modified natural polymers, as well as synthetic polymers. These polymers may be soluble or swellable in the aqueous solvent. Furthermore, these polymers may also possess hydrophobic side chains and thus be associative polymers.
- Polymers can be classified as soluble, swellable, or associative in the aqueous compositions. Some polymers may fall into one or more of these classes. For example, certain associative polymers can be soluble in the aqueous system. Whether they are considered soluble, swellable, or associative in the aqueous system, suitable polymers for use in the compositions of the present invention may be film forming or not. Film forming polymers may retain the active antimicrobial component at the afflicted site for longer periods of time. This may be desirable for certain applications. For example, some film forming polymers may produce compositions that could not be easily washed off with water after being applied and dried.
- a soluble polymer is one that in dilute solution (i.e., 0.01-0.1 wt- % in the desired aqueous solvent system defined as containing water and any other hydrophilic compounds), after heating for a sufficient time to ensure solubilization of any potentially soluble components, has no significant observable particles of greater than 1 micron in particle size, as determined by light scattering measurements using, for example, Malvern Masterisizer E Laser Particle Size Analyzer available from Malvern Co., Boston, MA.
- a swellable polymer is one that in dilute solution (i.e., 0.01-0.1 wt-% in the desired aqueous solvent system), after heating for a sufficient time to ensure solubilization of any potentially soluble components, has a significant (i.e., detectable) number of observable particles of greater than 1 micron in particle size, as determined by light scattering measurements using, for example, Malvern Masterisizer E Laser Particle Size Analyzer.
- an associative polymer is one that has greater than 2 hydrophobic chains per polymer molecule of greater than 12 and preferably greater than 16 carbon atoms. Examples of such polymers are described below.
- Soluble Polymers Cationic Natural Polymer Derivatives.
- Cationic modified cellulosic polymers are reported in the literature to be soluble in water. Such polymers have been found to be useful in the present invention.
- the most preferred modified cellulose products are sold under the trade names CELQUAT (National Starch and Chemicals Corp., Bridgewater, NJ) and UCARE (Amerchol Corporation, Edison, NJ).
- CELQUAT is a copolymer of a polyethoxylated cellulose and dimethyldiallyl ammonium chloride and has the Cosmetic, Toiletry and Fragrance Association (CTFA) designation Polyquaternium-4.
- CTFA Cosmetic, Toiletry and Fragrance Association
- alkyl modified quaternary ammonium salt of hydroxy ethyl cellulose and a trimethyl ammonium chloride substituted epoxide can also be used.
- the polymer conforms to the CTFA designation Polyquaternium 24 and is commercially available as
- QUATRISOFT LM-200 from Amerchol Corp., Edison, NJ.
- a particularly suitable type of cationic polysaccharide polymer that can be used is a cationic guar gum derivative, such as guar hydroxypropyltrimonium chloride (Commercially available from Rhone-Poulenc under the trade designation JAGUAR).
- Soluble Polymers Cationic Synthetic Polymers.
- Synthetic cationic linear polymers useful in the present invention are preferably quite high in cationic charge density— generally having greater than 10 wt-% cationic monomer, preferably greater than 25 wt-%, and more preferably greater than 50 wt-%. This ensures a good cosmetic feel and may actually improve water solubility.
- the polymers useful in the present invention have sufficient molecular weight to achieve thickening at generally less than 5 wt-% polymer, but not too high that the.lotion/cream/ointment feels slimy and stringy.
- the polymers preferably have a molecular weight of at least 250,000 daltons, and more preferably at least 500,000 daltons.
- the polymers preferably have a molecular weight of no greater than
- the homopolymers are preferably prepared from methacryloyloxyalkyl trialkyl ammonium salt, acryloyloxyalkyl trialkyl ammonium salt, and/or quaternized dialkylaminoalkylacrylamidine salt.
- the polymers are copolymers of at least two monomers selected from the group consisting of trialkylaminoalkyl acrylate and methacrylate salts, dialkyldiallyl ammonium salts, acrylamidoalkyltrialkyl salts, methacrylamidoalkyltrialkyl salts, and alkyl imidazolinium salts, N-vinyl pyrrolidinone, N-vinyl caprolactam, methyl vinyl ether, acrylates, methacrylates, styrene, acrylonitrile, and combinations thereof.
- a variety of quaternary copolymers of varying quaternization can be synthesized based on homo or copolymers of amino acrylates with methyl, ethyl, or propyl side chains. These monomers could also be copolymerized with other nonionic monomers including quaternary acrylic homopolymers, such as homopolymers of 2- methacryloxyethyl trimethylammonium chloride and 2-methacryloxyethyl methyl diethyl ammonium bromide; and copolymers of quaternary acrylate monomers with a water-soluble monomers, such as Petrolite Product No. Q-0043, a proprietary copolymer of a linear quaternary acrylate and acrylamide at high molecular weight (4-5 million MW).
- quaternary acrylic homopolymers such as homopolymers of 2- methacryloxyethyl trimethylammonium chloride and 2-methacryloxyethyl methyl diethyl ammonium bromid
- polystyrene resin polystyrene resin
- Hypan poly(N,N-dimethylaminopropyl-N- acrylamidine) (which is quaternized with diethylsulfate) bound to a block of polyacrylonitrile.
- This block copolymer is available under the trade designation Hypan
- Suitable cationic polymers include, for example, copolymers of l-vinyl-2- pyrrolidine and l-vinyl-3-methyl-imidazolium salt (e.g., chloride salt), referred to in the industry by the Cosmetic, Toiletry, and Fragrance Association, (CTFA) as Polyquaternium-16. This material is commercially available from BASF Wyandotte
- cationic diallyl quaternary ammonium-containing polymers including, for example, dimethyldiallyammonium chloride homopolymer and copolymers of acrylamide and dimethyldiallylammonium chloride, referred to in the industry (CTFA) as Polyquaternium 6 and Polyquaternium 7, respectively.
- Soluble Polvmers-Nonionic A variety of cellulosic ethers are reported in the literature to be soluble in water. Materials in this class that are nonionic and have been shown to be useful include: methylhydroxypropylcellulose, available as BENECEL MP 943 from Aqualon, Wilmington, DE; hydroxypropylcellulose, available as KLUCEL (LF, GF, MF, HF) from Aqualon; hydroxybutylmethylcellulose (3.5wt-% hydroxybutyl and 30wt-% methoxyl) from Scientific Polymer Products, Ontario, NY; and hydroxyethylcelluloses, available under the trade designation ,NATROSOL from Aqualon.
- BENECEL MP 943 from Aqualon
- KLUCEL LF, GF, MF, HF
- hydroxybutylmethylcellulose 3.5wt-% hydroxybutyl and 30wt-% methoxyl
- hydroxyethylcelluloses available under the trade designation ,NATROS
- Xanthan gum, guar, locust bean gum, and other polysaccharides may also be suitable. These polymers may be produced from plant sources or can be produced through microbial cell culture. Polyvinyl alcohol (PVA) also may be suitable. For example, PVA made from polyvinyl acetate, which has been hydrolyzed to about 87%, is highly water soluble at room temperature. Those with higher percent hydrolysis become progressively more crystalline and may need to be heated to get into solution. Protein thickeners such as gelatin and pectin may also be useful.
- Soluble Polymers Amine oxide polymers such as those described in U.S. Pat. No. 6,123,933 and those commercially available under the trade designation DIAFORMER Z-711, Z-712, Z-731, and Z-751 from Clariant Corp. are useful. Additionally, zwitterionic polymers, such as methacryloyl ethyl betaine/acrylate copolymer that are commercially available under the trade designation DIAFORMER Z-400 from Clariant Corp. can also be used. Zwitterionic polymers described in U.S. Pat. No. 6,590,051 may also be useful.
- Carboxylic acid functional polymers including naturally occurring carboxylic acid functional polymers such as hyaluronic acid and derivatives of natural polymers such as carboxymethylcelMose, alginic acid and other alginate polymers, Fucogel (a polysaccharide consisting of three mono-saccharides, fucose, galactose, and galacturonic acid), hyaluronic acid, and the like, also may be useful.
- carboxylic acid functional polymers such as hyaluronic acid and derivatives of natural polymers such as carboxymethylcelMose, alginic acid and other alginate polymers, Fucogel (a polysaccharide consisting of three mono-saccharides, fucose, galactose, and galacturonic acid), hyaluronic acid, and the like, also may be useful.
- Synthetic polymers may also be useful, such as those based on carboxylic acid, phosphonic acid, or sulfonic acid functional monomers, including but not limited to, polymers derived from acrylic acid, methacrylic acid, maleic anhydride, itaconic anhydride, sodium AMPS (the sodium salt of 2-acrylamido-2-methylpropane sulfonic acid), sulfopropyl acrylate or methacrylate, sulphomethylated acrylamide, allyl sulphonate, sodium vinyl sulphonate, combinations thereof, or other water-soluble forms of these or other polymerizable carboxylic or sulphonic acids.
- swellable polymers which are slightly crosslinked, function as viscosifiers in aqueous solvent systems. In general, these swellable polymers are preferred because they tend to be far less “slimy” going on and once the hands perspire and are exposed to water after treatment. Excessive crosslinking will result in polymers that do not swell sufficiently to increase the viscosity of the composition. In order to ensure adequate swelling, if a chemical crosslinker is used, the concentration of crosslinker is quite low, e.g., less than about 1000 parts per million (ppm), and preferably less than 500 ppm, based on the weight of the dry polymer.
- ppm parts per million
- a class of crosslinked polymers suitable for use in the compositions of the present invention include acrylamide and at least one other quaternary monomer selected from the group consisting of trialkylaminoalkylacrylate and methacrylate salts, dialkyldiallyl ammonium salts, acrylamidoalkyltrialkyl ammonium salts, methaciylamidoalkyltrialkyl ammonium salts, and monomers that include imidazolinium salts.
- comonomers may also be added including N- vinyl pyrrolidone, N-vinyl caprolactam, methyl vinyl ether, acrylates, methacrylates, styre ⁇ e, and the like.
- a particularly preferred polymer is a poly(2-methacryloxyethyl trimethyl ammonium chloride) polydimethylaminoethyl methacrylate, which conforms to the CTFA designation Polyquaternium 37.
- Another preferred polymer includes acrylamide and methacryloyloxyethyl trimethyl ammonium chloride, which conforms to the CTFA designation Polyquaternium 32. These are commercially available from Allied Colloids Inc. of Suffolk, VA as SALCARE SC95,
- swellable polymers i.e., slightly crosslinked polymers
- polymers of N-vinyl lactams such as N-vinyl pyrrolidone
- N-vinyl pyrrolidone when exposed to gamma radiation increase in molecular weight and may actually crosslink. This crosslinking allows for more efficient thickening (less polymer required to achieve a certain viscosity) and an improved cosmetic feel.
- polymers that when exposed to gamma radiation result in crosslinking, include polymers such as LUVIQUAT HM 552 (copolymers of vinylimidazolium methochloride and vinylpyrrolidone, which conforms to the CTFA designation Polyquaternium-16), and GAFQUAT HS-100
- Suitable crosslinkers are multi-ethylenically unsaturated compounds wherein the ethylenic groups are vinyl groups (including substituted vinyl groups, such as isopropenyl groups), allyl groups, and/or methallyl groups, which groups are bonded to nitrogen or oxygen atoms.
- Vinyl, allyl, and methallyl groups, as used herein, include substituted derivatives.
- Exemplary compounds include divinyl, diallyl, or dimethallyl esters, ethers, amides, or ureas. Specific examples are disclosed in U.S. Pat. No. 5,225,473 (Duan) and U.S. Pat. No. 4,931,282 (Asmus et al.).
- PVP polyvinylpyrrolidone
- Anionic swellable polymeric thickeners may also be useful.
- preferred anionic polymers for use with antimicrobial compositions which include carboxylic acid functional enhancers are polymers having sulfonic acid, sulfonate, phosphonic acid, or phosphate groups.
- Associative Polymers can be used to thicken the compositions of the present invention as well. Such polymers thicken as a result of hydrophobic or Van de Waals association of hydrophobic side chains. Such associative polymers can form viscous to gelled aqueous solutions despite their relatively low molecular weights. Polymers that are alcoholic soluble can be modified by the addition of a long chain hydrophobic group.
- a preferred class of such associative polymers is based on nonionic ethylenically unsaturated monomers wherein at least one comonomer has at least 12 and preferably at least 16 carbon atoms.
- cetyl hydroxyethylcellulose available as NATROSOL PLUS from Aqualon, which utilizes an associative mechanism to enhance the viscosity it produces. Grafted side chains of cetyl alkyl groups can associate with neighboring alkyl hydrophobes. These interpolymer associations can dramatically increase the viscosification efficiency of the polymer. Longer chain alklyl, alkenyl, and aralkyl groups may also be suitable.
- Arsitoflex HMB is ammonium acryloyldimethyltaurate/beheneth-25 methacrylate crosspolymer and is available from Clariant Corp.
- the antiseptic compositions of the present invention also may be delivered to the treatment site in a neat form or in a volatile solvent that rapidly evaporates to leave behind a neat composition.
- Such compositions may be solid, semi ⁇ solid or liquid.
- the antiseptic and/or the enhancer and/or the surfactant may optionally be microencapsulated to either sustain the delivery or facilitate manufacturing a powder that is easily delivered.
- the composition can be micronized into a fine powder without the addition of other components or it may optionally contain fillers and other ingredients that facilitate powder manufacture.
- Suitable powders include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
- a method for micronizing a hydrophobic agent may be used wherein the hydrophobic agent is dissolved in an effective amount of a first solvent that is free of polymer such as the method described in U.S. Patent No.
- the hydrophobic agent and the solvent form a mixture having a continuous phase.
- a second solvent and then an aqueous solution are introduced into the mixture.
- the introduction of the aqueous solution causes precipitation of the hydrophobic agent and produces a composition of micronized hydrophobic agent having an average particle size of 1 micron or less.
- the particle size for use in delivery to the nose or other tissue may be significantly larger to direct delivery to the proper site. For example, to deliver the antiseptic powder to the nose, nasal cavities, and/or throat without passing into the lungs, larger particles may be required.
- Bioadhesive polymers optionally may be added to the neat compositions as well as the other physical forms. Numerous suitable bioadhesive polymers are discussed in
- bioadhesive polymers of particular interest include bioerodible hydrogels described by H. S. Sawhney, C. P. Pathak and J. A. Hubell in Macromolecules, 1993, 26:581-587, polyhyaluronic acids, casein, gelatin, glutin, polyanhydrides, polyacrylic acid, alginate, chitosan, poly(methyl methacrylates), poly(ethyl methacrylates), poly butylmethacrylate), poly(isobutylmethacrylate), poly(hexlmethacrylate), poly(isodecl methacrylate), poly(lauryl methacrylate), poly ⁇ henyl methacrylate), ⁇ oly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecl acrylate).
- bioerodible hydrogels described by H. S. Sawhney, C. P. Pathak and J. A. Hubell
- Preferred polymers are polyacrylic acid (e.g. Carbomer) and is poly(fumaric-co-sebacic)acid.
- Other bioadhesive and bioerodible polymers are described in U.S. Patent No. 6,746,635.
- Particularly preferred are slightly crosslinked polyacrylic acids such as those sold under the CARBOPOL brand by BF Goodrich.
- the antimicrobial compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
- the neat antiseptic compositions according to the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- Inhaled medications are preferred in some embodiments because of the direct delivery to the lung.
- metered dose inhalers are regularly used for administration by inhalation. These types of devices include metered dose inhalers (MDI), breath- actuated MDI, dry powder inhaler (DPI), spacer/holding chambers in combination with MDI, and nebulizers.
- MDI metered dose inhalers
- DPI dry powder inhaler
- spacer/holding chambers in combination with MDI spacer/holding chambers in combination with MDI
- nebulizers spacer/holding chambers in combination with MDI
- Techniques for preparing aerosol delivery systems are well known to those of skill in, the art. Generally, such systems should utilize components that will not significantly impair the biological properties of the agent (see, for example, Sciarra and Cutie, "Aerosols," in Remington's Pharmaceutical Sciences, 18th edition, 1990, pp. 1694-1712).
- the compounds may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- compositions of the present invention have a viscosity of at least 500 Centipoise (cps) for ease of application topically. More preferably, compositions of the present invention have a viscosity of at least 1,000 cps,. even more preferably at least 10,000 cps, even more preferably at least 20,000 cps, even more preferably at least 50,000 cps, even more preferably at least 75,000 cps, even more preferably at least 100,000 ops, and even more preferably at least 250,000 cps (and even as high as about 500,000 cps, 1,000,000 cps, or more).
- the viscosity can be measured as described below in the Viscosity Test.
- Preferred formulations have high viscosity even after application to mammalian tissue at 32-37°C. Because certain optional ingredients, such as enhancers, hydrophilio compounds, hydrophobic compounds, and the like, may affect the viscosity (either positively or negatively), the measured viscosity is that of the final composition.
- Lower viscosity compositions can be used, however, in certain applications, such as for the treatment of middle ear infection and chronic sinusitis.
- afflictions of the middle ear e.g., otitis media or infection of the middle ear
- compositions of the present invention having a viscosity lower than 1000 cps more readily by administration through the outer ear or through the nose and into the Eustachian tubes.
- the viscosity is measured by the Viscosity Test described herein.
- Preferred compositions meet the above viscosity limitations even when warmed to 32 0 C. Most preferred compositions meet the above viscosity limitations even when warmed to 35°C.
- Antimicrobial compositions of the present invention can be provided to a medical professional in a single composite formulation or in multiple parts.
- a composition can be provided in two parts (e.g., in two separate containers or two separate compartments of the same container), one part containing the antiseptic component and one part containing the enhancer.
- Other components of the composition can be combined with either one of the two parts.
- the other components can be included in a third part.
- Topical antimicrobial treatment regimens include applying a safe and effective amount of the compositions described herein directly to the infected or at-risk skin, wound, or mucous membrane; particularly, the nasal nares and passages that are particularly susceptible to microbial contamination.
- the dose and frequency of application will depend on many factors including the condition to be treated, the concentration of antiseptic and optional enhancer, the microbe to be killed, etc.
- the compositions will be delivered in dosages of at least 10 mg per cm ⁇ of tissue, preferably 20 mg per cm ⁇ of tissue, more preferably at least 30 mg per cm ⁇ of tissue, and most preferably at least 50 mg per cm ⁇ of tissue for most applications.
- Application can be made once, or several (e.g., 2-4) times daily for one or more days.
- the composition is applied 1 or 2 times/day for 1-7 days.
- decolonization of the anterior nares may require a dose of 0.25 gram (g) per nares applied 1-3 times per day for 1-5 days.
- Treatment of impetigo may require about 0.5 g/15 cm ⁇ (33mg/cm 2 ) applied 1-3 times/day for 3-10 days.
- compositions of the present invention can be delivered using a variety of techniques. Typically, the compositions are delivered to the skin and/or mucosal tissue in a manner that allows them to penetrate into the skin and/or mucosal tissue, as opposed to through the tissue into the blood stream. This concentrates the compositions locally at the site in need of treatment. This delivery can be accomplished by spraying, dipping, wiping, dropping, pouring, toweling, inhaling, or the like, onto the area to be treated.
- the antiseptic compositions may be provided as a formulation suitable for delivery to mammalian tissue (e.g., skin and/or mucosal surfaces).
- Suitable formulations can include, but are not limited to, creams, gels, foams, ointments, lotions, balms, waxes, salves, solutions, suspensions, dispersions, water in oil or oil in water emulsions, microemulsions, pastes, powders, oils, lozenges, boluses, and sprays, and the like.
- compositions may be sprayed from a pressurized container.
- the pressure may be supplied by an external means such as squeezing the container, through the use of a mechanical pump, or with the use of a propellant.
- propellants include chlorofluorocarbons (CFCs), hydrochlorofluorocarbons (HCFCs), hydrofluorocarbons (HFCs), hydrofluoroethers (HFEs), perfluorinated alkanes, and (C1-C5) alkanes as well as nitrous oxide and dimethyl ether.
- the composition maybe dispensed from an aerating dispenser such as the F2 Finger Pump Foamer available from Air Spray International Pompano Beach, FL.
- the foam may be generated using a suitable propellant such as those described above.
- the composition may be delivered in essentially a solid dosage form by placing the composition in or on the tissue to be treated.
- a small suppository type delivery could be placed into the anterior nares for eradication of staphylococcus sp.
- afflictions of the middle ear e.g., otitis media or infection of the middle ear
- compositions of the present invention by administration through the nose and into the Eustachian tubes or they can be instilled directly into the middle ear through the tympanic membrane.
- the formulations may traverse the tympanic membrane with the aid of a syringe or do so by diffusion.
- Penetration enhancers may be used to enhance diffusion across the tympanic membrane.
- the compositions may be applied directly to the tissue from a collapsible container such as a flexible tube, blow/fill/seal container, pouch, capsule, etc.
- the primary container itself is used to dispense the composition directly onto the tissue or it can be used to dispense the composition onto a separate applicator.
- the composition could be dispensed directly from a tube and spread by a number of means including squeezing the outside of the nose together repeatedly, wiping with the tip of the tube or with a separate device such as a spatula, cotton, rayon, or other natural or synthetic based fiber swab.
- applicator devices may also be suitable including applicators with foam tips, brushes, and the like.
- the applicator must be able to deliver the requisite amount of composition to the tissue. Therefore, in most instances applicator devices such as webs and swabs are coated on the applicator web at greater than 50% by weight of the dry web and preferably in excess of 100% by weight of the dry web
- the collapsible containers may be made in a number of single layer, laminate, or coextruded constructions.
- Materials of construction may include polyolefins such as low, medium or high density polyethylene including low and linear low density polyethylene, polypropylene, as well as copolymers of ethylene and/or propylene with other polar or non-polar comonomers; polyamides such as nylons, polyesters such as polyethylene terephalate, polybutyleneterephalate, polyethylenenaphthalate; polyurethanes, polyacrylates, and the like.
- a barrier material to prevent evaporation of one or more components of the formulation.
- Suitable barrier materials include polyesters (e.g., polyethylene terephthalate, polyethylene naphthalate and polybutylene terephalate and the like), fluorinated layers such as polytetrafluoroethylene (PTFE, e.g., TEFLON), polyamides ( e -g- 5 nylon), chlorotriflouroethylene (ACLAR), polyvinylidene fluoride, as well as copolymers of perflourinated monomers with partially fluorinated monomers such as copolymers of tetraflouroethylene/hexafluoropropylene/vinylidene fluoride (THV Fluorothermoplastic from Dyneon Company), polyvinylchloride, polyvinylidene chloride (PVDC, e.g., SARAN HB), ethylene vinyl alcohol (EVOH), polyolefms (e.g., polyethylene, high density polyethylene, polypropylene, and combinations thereof).
- Oriented and biaxially oriented polymers may be particularly preferred.
- metallic foil barriers such as aluminum foil laminates, HDPE, PET, PETG, PEN laminates of polyester and polyolefm (in particular PET/HDPE or HDPE/PET/HDPE), laminates of PET and EVOH, biaxially oriented nylon, PVDC 5 Nylon/EVOH/Nylon (OXYSHIELD OUB-R), chlorotrifluoroethylene and laminate
- compositions of the present invention can also be incorporated in (e.g., delivered from) cloth, sponges, paper products (e.g., paper towels, towelettes, and wipes), tampons, undercast padding, and dental floss, for example.
- an applicator may be used to place the device and/or antimicrobial composition in the proper location, for example, on the mucosal surface of a vagina, nasal cavity, rectum, or the like.
- compositions of the present invention can be delivered from various substrates for delivery to the tissue.
- the compositions can be delivered from a wipe or pad which when contacted to tissue will deliver at least a portion of the composition to the tissue.
- the compositions may be provided by a non-woven swab such as a "Q-tip" brand cotton swab, into a foam tip applicator, and the like.
- the substrate may be used to deliver the composition essentially instantaneously or may be left in contact with the tissue.
- a substrate in a tubular form could be delivered to the anterior nares using a suitable applicator and left in the anterior nares.
- the annular nature of the device is designed to allow delivery of the active while allowing the patient to freely breath through the nose.
- compositions of the present invention can be coated onto medical devices that contact skin, mucous membranes, wounds, etc.
- medical devices include catheters such as urinary tract catheters and vascular access catheters.
- Obj ects and advantages of this invention are further illustrated by the following examples, but the particular materials and amounts thereof recited in these examples, as well as other conditions and details, should not be construed to unduly limit this invention.
- compositions of the present invention are intended to kill microorganisms on mammalian tissue such as skin and mucosal tissue.
- the extent of kill can be determined in the following manner.
- Subjects are identified who are naturally colonized with the microorganism of interest. This is preferred over methods where the tissue is artificially colonized with non-resident flora.
- subjects may be identified whom are colonized with staphylococcus aureus (SA) in the anterior nares by swabbing the anterior nares and culturing the swab. This is normally repeated at least one additional time to ensure the subject is a "chronic carrier", i.e. one who carries the organism all or most of the time.
- SA staphylococcus aureus
- a swab may also be taken several days prior to treatment to increase the probability that the subject is, in fact, a carrier.
- the subject is then treated with the indicated composition in a dose and at a frequency stated.
- the anterior nares once again are swabbed to determine if the bacteria has been reduced or eradicated (decolonized).
- Preferred formulations eradicate the SA in less than 72 hours, more preferably in less than 48 hours, and most preferably in 24 hours or less.
- On skin the procedure is similar except that a control site distinct from the treatment site may be selected on the treatment day. In this case, a log reduction may be determined.
- the procedure on skin is described in Federal Register, 21 CFR Parts 333 and 369, Tentative Final Monograph for Healthcare Antiseptic Drug Products; Proposed Rule, 1994 (scrub cup method).
- the antiseptic compositions are generally allowed to remain in contact with the skin for at least 6 hours under a suitable dressing such as Tegaderm (3M Company) to check for antimicrobial activity.
- Preferred formulations show at least 1 log reduction and preferably at least 1.5 log reduction in 6 hours on a dry skin site (e.g., the abdomen).
- This method tries to mimic the actual use conditions for many topical antiseptics.
- a topical antiseptic is applied to the area, optionally with some rubbing, and allowed to remain in contact and kill any microorganisms present in an essentially static state.
- a composition is spread onto a film to form a uniform coating 10 mil (250 ⁇ m) thick, a suspension of bacteria are directly inoculated onto the surface of the composition, after a defined period of time, the inoculated disk is placed in a neutralizing broth, and at least a portion of this is diluted and plated to enumerate the surviving bacterial. It should be noted that just as in the in-vivo condition, this in- vitro method takes into account wetting.
- the bacterial suspension will wet the composition very well and spread. With other compositions the bacterial suspension may remain as discrete droplets. This is expected to simulate in-vivo performance in wetting tissue and bacterial biofilms. Since preferred compositions of the present invention are ointments this works very well.
- a compatible thickening agent should be incorporated to achieve a viscosity of at least 20,000 cps and preferably at least 50,000 cps.
- Toxicity Control was also run by adding 100 ⁇ L of inoculum to 20 mL neutralizer broth to yield an organism concentration of 10-100 CFU/mL.
- Neutralizer Effectiveness If the loglO CFU/mL of the test sample is not more than 0.3 log less than the corresponding Numbers Control, the neutralization will be considered effective.
- Toxicity Control If the Toxicity Control (TC) is not more than 0.3 log less than the corresponding Numbers Control sample, the sampling solution will be considered non-toxic.
- test organisms for this assay were methicillin resistant Staphylococcus aureus, MRSA (ATCC 33953), Staphylococcus epidermidis (ATCC 35984) and E. coli (ATCC 11229).
- the initial suspension was prepared by suspending bacterial colonies from overnight growth plates in phosphate-buffered water (PBW).
- PBW phosphate-buffered water
- a 0.5 McFarland turbidity standard was used to obtain a cell density of approximately 1.0 x 108 CFU/mL.
- the samples for this assay spread at room temperature to a uniform thickness of 10 mil (250 ⁇ m) using a laboratory knife coater onto a 100 ⁇ m thick biaxially oriented clean and 70% isopropanol sanitized polyesterterephthalate (PET) film. These coated samples were placed in sterile petridishes and sealed with Paraf ⁇ lm to prevent evaporation and preserve cleanliness. Spread samples containing any volatile solvents such as water were used within 24 hrs of spreading. Test samples were cut from the same PET coated films using a 70% isopropyl alcohol (IPA) disinfected 23 mm die, as described in the next section. The sample disks were stored in sterile Petri dishes until testing.
- IPA isopropyl alcohol
- the inoculum was serially diluted with phosphate buffered water (PBW) 10,000 fold (10 "4 ) to achieve a concentration of 1-5 x 10 4 CFU/mL.
- PBW phosphate buffered water
- the inoculum suspension was enumerated at the beginning and end of the test period. The final count was within 0.1 log/mL of the initial count.
- Each disk was inoculated with between 10 6'5 and IO 7 5 bacteria.
- the DE broth was Dey Engle broth purchased as a solid and reconstituted according to directions from Difco Laboratoris, Detroit Michigan.
- the DE broth was used for all the antiseptics of this invention: chlorhexidine gluconate (CHG), polyhexamethylenebiguanide (PHMB), benzethonium chloride, benzalkonium chloride, Healthshield silver zeolite, silver nitrate, phospholipid CDM
- samples were tested for antimicrobial activity using an in vitro model that attempts to simulate in- ⁇ se conditions.
- 23 mm disks of each formulation were cut using a 70% IPA-disinfected 23 mm die.
- Three bacteria were tested: Staphylococcus aureus MRSA (ATCC 33953), Staphylococcus epidermidis (ATCC 35984) and E. coli (ATCC 11229).
- Each inoculum was prepared by suspending bacterial colonies from overnight growth plates in phosphate-buffered water (PBW).
- PBW phosphate-buffered water
- a 0.5 McFarland turbidity standard was used to obtain a cell density of approximately 1.0 x 10 8 CFU/mL. 50 ⁇ L of the inoculum was rapidly spotted on the surface of the test ointment (in 8-12 tiny droplets). After the last drop was applied the bacteria were allowed to remain in contact with the ointment for the specified period of time (e.g. 2.5 and 10 minutes). At the end of the exposure time (time bacteria are in contact with the composition) the inoculated disk was dropped into warm (36 0 C) Neutralizer Broth (20 mL for DE) and mixed vigorously (vortexed using a VWR Vortex Genie 2 for 2 minutes).
- CFUs Colony Forming Units
- the CFUs for each plates were multiplied by the dilution factor to arrive at CFU/mL, and converted to loglO CFU/sample.
- LoglO CFU/sample of duplicate tests were averaged and the loglO reduction was calculated.
- Log reductions were calculated by subtracting the loglO bacterial recovery of the test materials from the loglO bacterial recovery of the control (100 ⁇ L of inoculum in 20 mL warm D/E neutralizing).
- compositions of the present invention were analyzed for their ability to kill MRSA and E.coli at 2.5 and 10 minutes. Select compositions were analyzed for their ability to kill Staph Epi at 10 minutes. By comparison Bactroban Nasal ointment in this assay showed essentially no kill of this strain of MRSA at 2.5 minutes. (The log reduction values were 0.030 and -0.040.) In fact, Bactroban Nasal showed essentially no kill after contact for 2 hours. It is a significant advantage that the compositions of the present invention are able to kill microorganisms rapidly. Preferred compositions achieve a at least a 1.5 log reduction in 10 minutes, more preferably at least a 2 log reduction in 10 minutes, and most preferably at least a 3 log reduction in 10 minutes. Particularly preferred compositions of the present invention achieve at least a 1.5 log reduction in 2.5 minutes, more preferably at least a 2 log reduction in 2.5 minutes, and most preferably at least a 3 log reduction in 2.5 minutes.
- Viscosity was measured at approximately 22°C at ambient pressure using a Brookfield LVDV-I + viscometer equipped with a model D Brookfield heliopath and LV spindles. The spindle and speed was chosen for each particular sample such that the viscometer was operating in the middle of its range. All samples were allowed to equilibrate at approximately 22°C for 24 hours prior to measurement. Preferably the viscosity is taken at the lowest speed possible while staying within 20-
- Emulsifying polymer GG was prepared in the following manner. A mixture of isooctyl acrylate (IO A, 21.6 parts), and MPEG (5.4 parts) [80/20 IO A/MPEG, respectively, weight ratio] was dissolved in ethyl acetate (33 parts) that contained VAZO 67 radical initiator (0.081 part). The solution was contained in a flint glass bottle that was closed with a Teflon-lined metal cap and maintained at 65 0 C for 50 hours. Monomer conversion (determined by percent solids measured by loss on drying at 105 0 C) was essentially complete at 50 hours. Solvent exchange was accomplished by adding isopropyl palmitate (IPP) to the ethyl acetate solution and. stripping the lower boiling ethyl acetate on a ROTOVAP evaporator to obtain a 25 weight percent solution of polymer in IPP.
- IPP isopropyl palmitate
- Polymer QQ was prepared in the following manner. A mixture of SMA (10.8 parts), IOA (10.8 parts), and M90G (5.4 parts) [80/20, respectively, weight ratio] was dissolved in ethyl acetate (33 parts) that contained VAZO 67 radical initiator (0.081 part). The solution was contained in a flint glass bottle that was closed with a Teflon- lined metal cap and maintained at 65 0 C for 50 hours. Monomer conversion (determined by percent solids measured by loss on drying at 105 0 C) was essentially complete at 50 hours.
- Solvent exchange was accomplished by adding isopropyl palmitate (IPP) to the ethyl acetate solution and stripping the lower boiling ethyl acetate on a ROTOVAP evaporator to obtain a 25 weight percent solution of polymer in IPP.
- IPP isopropyl palmitate
- Example compositions were prepared according to the procedures listed below. The examples were tested according to the Antimicrobial Efficacy test against both MRSA and E.coli at 2.5 minutes and 10 minutes or Staph Epi at 10 minutes. Control Examples C 1 -C2
- Carbowax 1450 PEG was heated in an oven until melted in a first glass container.
- Glycerin In a second glass container Glycerin, Carbowax 400 and Aerosol OT-75 DOSS were also heated to
- Antimicrobial compositions of 125 grams were prepared using the components shown in Tables 2a —2b.
- the antiseptic component Silver Zeolite, phospholipid CDM, Irgasan DP300, benzethonium chloride, or benzalkonium chloride was combined with Pluronic P-65 and glycerin in a first glass container and heated to 70°C in an oven.
- Carbowax 1450 was heated to melting in a separate container then added to the first container along with the remaining components, swirled by hand to mix and then reheated to 70°C in the oven.
- the composition was removed from the oven allowed to cool to approximately 40°C, while mixing on rollers, then transferred into jars and sealed.
- Examples 7-8, which contained PHMB, and example 9, which contained CHG were prepared as described above with the exception that there was no initial heating required and these antiseptics were added after all other components were combined.
- Examples 1-9 comprised hydrophilic vehicles containing a mixture of PEG compounds and glycerin.
- Example 1 and 2 incorporated Phospholipid CDM, an antimicrobial quaternary ammonium compound. The antimicrobial efficacy against both MRSA and E. coli was greater than 3 log at 2.5 minutes for Example 1.
- Example 2 further incorporated EDTA as an enhancer. Despite the anionic nature of this enhancer, it increased the antimicrobial efficacy of this quaternary ammonium compound.
- Example 2 killed 3.9 log MRSA and 7.1 log (complete kill) against E. coli at 2.5 minutes.
- Examples 3 and 6 contained the antimicrobial quaternary ammonium compounds benzethonium chloride and benzalkonium chloride respectively.
- Example 5 used a combination of a quaternary ammonium compound (benzalkonium chloride) and a phenolic antiseptic (triclosan), both at relatively low concentration, and exhibited 3.9 log kill against MRSA and 5.2 log kill against E. coli after 2.5 minutes exposure.
- Example 4 used a silver/zeolite complex. The composition did not achieve 2 log kill against either MRSA or E. coli after a 2.5 minutes, exposure possibly because the silver is not released rapidly enough.
- Example 10 (below), which used silver nitrate, achieved 6.3 log kill against MRSA and 4.8 log kill against E. coli after a 2.5 min. exposure.
- Examples 7 and 8 used PHMB at 0.2 and 5% respectively. These compositions achieved complete kill (6.8 log) against MRSA and at least 4.8 log kill against E. coli after a 10 min. exposure.
- An antimicrobial composition of 250 grams was prepared using the components shown in Table 2b.
- Carbowax 1450 was preheated to melting (approximately 65 0 C), in an oven, in a glass container. All other components, except silver nitrate, were combined with the Carbowax 1450 and swirled by hand to mix.
- the composition was • allowed to cool to approximately 50°C and then the silver nitrate was added.
- the solution was allowed to further cool to approximately 40 0 C, then transferred to storage jars protected from light.
- Antimicrobial compositions of 120 grams each were prepared using the components shown in Table 2c for each example. Petrolatum was added to a first glass container and heated in an oven to approximately 70°C. All other components were added to a second glass container and also heated in an oven at approximately 70°C.
- Example 11 were formulated in a hydrophobic vehicle.
- Example 11 incorporated CHG as the antiseptic and glycerin as a hydrophilic component and achieved 4.4 and 7.1 log kill against MRSA and E. coli respectively after a 2.5 min. exposure.
- Examples 12 and 13 had Phospholipid CDM as the antiseptic and glycerin ' as a hydrophilic component.
- Example 12 further incorporated a surfactant, Pluronic P-65.
- Example 12 The antimicrobial efficacy of Example 12 was 4.2 log and 2.9 log kill against MRSA and E. coli respectively.
- the antimicrobial efficacy of Example 13 was 5.7 log and 6.3 log against MRSA and E. coli respectively.
- Examples 15-16 also shown in Table 2c, were prepared in the same manner as Examples 11-14, above, except the benzalkonium chloride was added to the Petrolatum prior to heating.
- Examples 11-16 use petrolatum as the hydrophobic vehicle.
- Example 15 which incorporated glycerin as a hydrophilic component achieved complete kill against both MRSA and E. coli after a 2.5 min. exposure.
- Example 16 which did not incorporate a hydrophilic component did not achieve 2 log kill for either MRSA nor E. coli after a 2.5 min exposure.
- Petrolatum was used as a hydrophobic vehicle and added to a first glass container and heated in an oven to approximately 7O 0 C.
- AU other components were added to a second glass container and also heated in an oven at approximately 70 0 C.
- the mixture of components in the second container was then added to the first container and then further mixed using a high shear rotor/stator Silverson homogenizer on high speed for 1 minute. Mixing was continued at low speed using a Gast overhead air mixer with radial flow impeller until just before the composition congealed at approximately 40°C.
- the compositions were removed from the mixer, poured into jars, and sealed.
- Examples 17 and 18 used CHG as the antiseptic component. Note that the CHG was incorporated as a solution in water. Examples C3 and C4 were the vehicle controls. Example 17 had 2.5 log kill and 4.8 log kill against MRSA and E. coli respectively after 2.5 minutes exposure.
- Antimicrobial compositions 120 grams each were prepared using the components shown in Table 2d. Petrolatum was added to a first glass container and heated in an oven to approximately 70°C. AU other components except CHG were added to a second glass container and heated in an oven at approximately 50°C. The contents of the second container were added to the first container while hand swirling the container to mix. CHG was then added and the mixture was swirled by hand to mix.
- CHG the antiseptic component
- Several enhancers were evaluated including lactic acid/propyl paraben and a Dowanol ether.
- Control example C5 containing no antiseptic and examples of antimicrobial compositions of 120 grams each were prepared using the components shown in Table 2e.
- Water, glycerin and Lurol ASY were added to a glass container and heated in an oven to approximately 70 °C.
- Examples 22, 25-26 were pH adjusted with sodium hydroxide to approximately 4.5. All the remaining components were added to a second glass container, which was swirled by hand and heated in an oven to approximately 110 0 C.
- the contents of the first container were then added to the second container and then mixed using a high shear rotor/stator Silverson homogenizer on high speed for approximately 1-2 minutes.
- Each composition was placed in a steam bath and mixed at low speed using a Gast overhead air mixer with radial flow impeller.
- CHG was then added, followed by high-speed shear mixing for approximately 1-2 minutes, again using the Silverson homogenizer. Mixing continued until the composition was less than 40°C, using the Gast overhead air mixer.
- Examples 24-26 which incorporated an anionic phosphate surfactant (Lurol ASY), all achieved at least 3 log kill against one of the test organisms.
- Examples 25 and 26 further incorporated lactic acid and achieved greater than 6 log kill against Staphylococcus epidermidis.
- Examples 27-32 Antimicrobial compositions of 250 grams were prepared using the components shown in Table 2f.
- a mixture of Polawax, mineral oil, Incroquat Belienyl TMS and Centroflex F were added to a first container and heated to 70 0 C in an oven. Water was heated in to 7O 0 C in a separate container. The water was added to the first container and finally CHG or Cosmocil CQ was also added.
- Each composition was mixed using a high shear rotor/stator Silverson homogenizer on high speed for 1 minute.
- Example 27 which did not incorporate lecithin achieved 6.7 and 7 log kill against MRSA and E.coli at 2.5 min.
- Example 28 (2% total CHG) incorporated lecithin. The lecithin partially inactivated the CHG decreasing the efficacy against both MRSA and E. coli significantly.
- Example 30 (only 0.1 % total CHG), despite the low level of CHG was able to kill 2.5 log E.coli after a 10 min. exposure.
- Example 31 was very similar to Example 30 except that it contained lecithin. The CHG was clearly neutralized by the lecithin as indicated by essentially no antimicrobial efficacy and further due to the observation of heavy bacterial growth in the sample after standing. The sample was not intentionally inoculated.
- Example 32 had an elevated level of
- Example 33 were prepared in quantities of 250 grams, using the components shown in Table 2g. Benzethonium chloride (Example 33, only) was combined with Ceraphyl 494 in a container and heated in an oven to approximately 80 0 C. Pluronic P-65 and AC 540 were added to the container, which was briefly swirled by hand and then further heated in an oven to approximately 110 0 C. The composition was removed from the oven, swirled by hand and allowed to cool without stirring. Example 33 used Ceraphyl 494 as the hydrophobic vehicle and achieved complete kill against MRSA at 2.5 and lOmin. and 4.4 log kill against E. coli after 10 min. exposure.
- Tables 2a-2g show the weight/weight % concentration of each component in each example composition as well as the antimicrobial efficacy results. A test result of "NT" indicates "not tested.”
- a dose was 0.5 mL of Composition W or X applied using a preloaded 1 mL plastic syringe.
- the volunteers applied the first dose after viewing a demonstration of the technique.
- the volunteers applied a second and third dose during Day 1.
- One-half of the volunteers (5) were dosed with Composition W and one-half of the volunteers were dosed with Composition X on Day 1 and given a Rhinoscopic Examination of Nares before and after application on Day 1 and after 24 hours on Day 2.
- those volunteers dosed with Composition W on Day 1 received Composition X and those dosed with Composition X on Day 1 received Composition W. They were given a Rhinoscopic Examination of Nares before and after application on Day 8 and after 24 hours on Day 9.
- Composition W was preferred by 10/10 of the volunteers. Five often volunteers could not complete all three application of Composition X. They cited stinging, burning and runny noses as primary reasons. Composition X caused more rhinorrhea than Composition W. Volunteers using Composition X felt they could use the ointment for a shorter period of time than with Composition W. Composition W could be felt to remain in the nasal vestibule longer (mean 218 minutes) than Composition X (mean 145 minutes).
- a second panel evaluation was done to determine acceptability of essentially anhydrous ointments based hydrophobic vehicles containing lactic acid or mandelic acid.
- the criteria for the panel were the same as for the first panel.
- the compositions evaluated are given in Table 4.
- test procedure was the same as that used for the first panel except a cotton swab was used to apply the composition rather than a tube.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Mechanical Engineering (AREA)
- Toxicology (AREA)
- Dispersion Chemistry (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17186934.0A EP3275437A1 (fr) | 2004-09-07 | 2005-09-07 | Compositions antiseptiques cationiques et leurs procédés d'utilisation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/936,135 US9028852B2 (en) | 2004-09-07 | 2004-09-07 | Cationic antiseptic compositions and methods of use |
PCT/US2005/031956 WO2006029255A2 (fr) | 2004-09-07 | 2005-09-07 | Compositions antiseptiques cationiques et leurs procedes d'utilisation |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17186934.0A Division-Into EP3275437A1 (fr) | 2004-09-07 | 2005-09-07 | Compositions antiseptiques cationiques et leurs procédés d'utilisation |
EP17186934.0A Division EP3275437A1 (fr) | 2004-09-07 | 2005-09-07 | Compositions antiseptiques cationiques et leurs procédés d'utilisation |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1786264A2 true EP1786264A2 (fr) | 2007-05-23 |
EP1786264A4 EP1786264A4 (fr) | 2012-10-17 |
EP1786264B1 EP1786264B1 (fr) | 2017-11-22 |
Family
ID=35996518
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05793861.5A Active EP1786264B1 (fr) | 2004-09-07 | 2005-09-07 | Composition antiseptiques cationiques et leur utilisation |
EP17186934.0A Withdrawn EP3275437A1 (fr) | 2004-09-07 | 2005-09-07 | Compositions antiseptiques cationiques et leurs procédés d'utilisation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17186934.0A Withdrawn EP3275437A1 (fr) | 2004-09-07 | 2005-09-07 | Compositions antiseptiques cationiques et leurs procédés d'utilisation |
Country Status (11)
Country | Link |
---|---|
US (3) | US9028852B2 (fr) |
EP (2) | EP1786264B1 (fr) |
JP (4) | JP5154933B2 (fr) |
KR (1) | KR20070102479A (fr) |
CN (1) | CN101437394B (fr) |
AU (1) | AU2005282377B2 (fr) |
BR (1) | BRPI0514939A (fr) |
CA (2) | CA2969582A1 (fr) |
MX (2) | MX343725B (fr) |
TW (1) | TW200616609A (fr) |
WO (1) | WO2006029255A2 (fr) |
Families Citing this family (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2484761C (fr) * | 2002-05-24 | 2010-11-09 | Angiotech International Ag | Compositions et procedes d'enrobage d'implants medicaux |
US8313760B2 (en) * | 2002-05-24 | 2012-11-20 | Angiotech International Ag | Compositions and methods for coating medical implants |
US20050032896A1 (en) * | 2002-06-21 | 2005-02-10 | Liisa Neumann | Use of synthetic retinoic acid in form of 13-cis vitamin A for treatment of autism |
AU2004270266B2 (en) * | 2003-09-09 | 2011-02-10 | 3M Innovative Properties Company | Concentrated antimicrobial compositions and methods |
US20050058673A1 (en) * | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
US7745509B2 (en) * | 2003-12-05 | 2010-06-29 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US20060051384A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Antiseptic compositions and methods of use |
US9028852B2 (en) | 2004-09-07 | 2015-05-12 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
US8198326B2 (en) * | 2004-09-07 | 2012-06-12 | 3M Innovative Properties Company | Phenolic antiseptic compositions and methods of use |
GB0426308D0 (en) * | 2004-12-01 | 2004-12-29 | Byotrol Llc | Preservative and embalming fluids |
MX2007010908A (es) * | 2005-03-10 | 2007-12-05 | 3M Innovative Properties Co | Composiciones antimicrobianas que comprenden esteres de acidos hidroxicarboxilicos. |
US8476319B2 (en) * | 2005-03-10 | 2013-07-02 | 3M Innovative Properties Company | Methods of treating ear infections |
CA2598985A1 (fr) * | 2005-03-10 | 2006-09-21 | 3M Innovative Properties Company | Lingette antimicrobienne pour animaux domestiques et procedes associes |
US20060229364A1 (en) * | 2005-03-10 | 2006-10-12 | 3M Innovative Properties Company | Antiviral compositions and methods of use |
CA2599653A1 (fr) * | 2005-03-10 | 2006-09-21 | 3M Innovative Properties Company | Methodes de reduction d'une contamination microbienne |
US20060246383A1 (en) * | 2005-04-29 | 2006-11-02 | Kai-Kong Iu | Amphoteric stilbene composition |
KR101439555B1 (ko) * | 2005-06-27 | 2014-09-11 | 스미쓰 앤드 네퓨 피엘씨 | 항균 물질 |
ES2619630T3 (es) * | 2005-06-27 | 2017-06-26 | Smith & Nephew, Plc | Complejos metálicos antimicrobianos de biguanida |
US8343523B2 (en) * | 2005-08-22 | 2013-01-01 | Quick-Med Technologies, Inc. | Disinfectant with durable activity based on alcohol-soluble quaternary ammonium polymers and copolymers |
CA2620175C (fr) * | 2005-08-22 | 2013-04-30 | Quick-Med Technologies, Inc. | Desinfectant a activite durable a base de polymeres et de copolymeres d'ammonium quaternaire solubles dans l'alcool |
US20070110788A1 (en) * | 2005-11-14 | 2007-05-17 | Hissong James B | Injectable formulation capable of forming a drug-releasing device |
GB0525504D0 (en) * | 2005-12-14 | 2006-01-25 | Bristol Myers Squibb Co | Antimicrobial composition |
GB0601687D0 (en) * | 2006-01-27 | 2006-03-08 | Smith & Nephew | Antimicrobial materials |
US8119115B2 (en) | 2006-02-09 | 2012-02-21 | Gojo Industries, Inc. | Antiviral method |
US9629361B2 (en) | 2006-02-09 | 2017-04-25 | Gojo Industries, Inc. | Composition and method for pre-surgical skin disinfection |
CA2646289C (fr) * | 2006-04-11 | 2014-08-19 | Tyco Healthcare Group Lp | Pansements dotes d'agents antimicrobien et contenant du zinc |
US20080108674A1 (en) * | 2006-05-01 | 2008-05-08 | Enturia, Inc. | Cationic antiseptic and dye formulation |
US20070253909A1 (en) * | 2006-05-01 | 2007-11-01 | Medi-Flex, Inc. | Aqueous Antiseptic Solution and Compatible Cationic Dye for Staining Skin |
US20070254854A1 (en) * | 2006-05-01 | 2007-11-01 | Medi-Flex, Inc. | Aqueous Antiseptic Solution and Compatible Anionic Dye for Staining Skin |
US7993675B2 (en) * | 2006-05-10 | 2011-08-09 | Medtronic Xomed, Inc. | Solvating system and sealant for medical use in the sinuses and nasal passages |
US20070264296A1 (en) * | 2006-05-10 | 2007-11-15 | Myntti Matthew F | Biofilm extracellular polysachharide solvating system |
US7959943B2 (en) * | 2006-05-10 | 2011-06-14 | Medtronics Xomed, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
US7976873B2 (en) * | 2006-05-10 | 2011-07-12 | Medtronic Xomed, Inc. | Extracellular polysaccharide solvating system for treatment of bacterial ear conditions |
KR101457712B1 (ko) | 2006-06-08 | 2014-11-03 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 중합체 비드 및 중합체 비드의 제조 방법 |
US20080075793A1 (en) * | 2006-09-21 | 2008-03-27 | Dunshee Wayne K | Antiviral compositions and methods of use |
KR20090075701A (ko) | 2006-10-27 | 2009-07-08 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 항미생물성 조성물 |
DE102006051891A1 (de) | 2006-10-31 | 2008-05-08 | Schülke & Mayr GmbH | Antimikrobiell wirksame Zusammensetzung mit einem Gehalt an Bispyridiniumalkan |
JP4884180B2 (ja) * | 2006-11-21 | 2012-02-29 | 東京エレクトロン株式会社 | 基板処理装置および基板処理方法 |
US20110097372A1 (en) * | 2009-10-26 | 2011-04-28 | Rucinski Paul J | Devices, methods, and compositions for controlling infections |
BRPI0721211A2 (pt) * | 2007-02-08 | 2013-01-15 | Medtronic Xomed Inc | uso de um tensoativo e um selante mÉdico, mÉtodo para tratar as condiÇÕes de ouvido, nariz e garganta, e, composiÇço |
US8088095B2 (en) * | 2007-02-08 | 2012-01-03 | Medtronic Xomed, Inc. | Polymeric sealant for medical use |
US7939578B2 (en) * | 2007-02-23 | 2011-05-10 | 3M Innovative Properties Company | Polymeric fibers and methods of making |
ES2343208T3 (es) * | 2007-04-19 | 2010-07-26 | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL | Gel para el tratamiento de heridas. |
US8747872B2 (en) * | 2007-05-02 | 2014-06-10 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US8513322B2 (en) * | 2007-05-31 | 2013-08-20 | 3M Innovative Properties Company | Polymeric beads and methods of making polymeric beads |
JP5432175B2 (ja) | 2007-12-12 | 2014-03-05 | スリーエム イノベイティブ プロパティズ カンパニー | 物品の製造方法及び物品 |
US8696975B2 (en) * | 2007-12-12 | 2014-04-15 | 3M Innovative Properties Company | Methods of making shaped polymeric materials |
EP2625957A1 (fr) * | 2007-12-31 | 2013-08-14 | 3M Innovative Properties Company | Compositions antimicrobiennes |
US8372051B2 (en) * | 2007-12-31 | 2013-02-12 | 3M Innovative Properties Company | Medical dressing with edge port and methods of use |
JP2011511103A (ja) * | 2008-01-08 | 2011-04-07 | クイック−メッド テクノロジーズ、インク. | 殺菌性アルコール可溶性第四級アンモニウムポリマー |
CN102046121A (zh) | 2008-04-04 | 2011-05-04 | 3M创新有限公司 | 具有微型泵的伤口敷料 |
US8784790B2 (en) | 2008-06-12 | 2014-07-22 | Medtronic Xomed, Inc. | Method for treating chronic wounds with an extracellular polymeric substance solvating system |
CN102088964B (zh) * | 2008-07-07 | 2014-06-25 | 博磊科技股份有限公司 | 带静电荷的多功能鼻应用产品 |
US8846595B2 (en) * | 2008-07-14 | 2014-09-30 | 3M Innovative Properties Company | Method of making a cleaning solution from hydrogel cleaning concentrate and packaged cleaning concentrate |
WO2010036938A2 (fr) * | 2008-09-26 | 2010-04-01 | Nanobio Corporation | Compositions thérapeutiques de nanoémulsion et procédés d'utilisation de celles-ci |
WO2010042427A2 (fr) * | 2008-10-06 | 2010-04-15 | Microbial Defense Systems, Llc | Composition antimicrobienne et ses procédés de fabrication et d'utilisation |
PE20110680A1 (es) | 2008-11-20 | 2011-10-04 | Water Visions International Inc | Dispositivo antimicrobiano y materiales para el tratamiento de fluidos |
US20100135949A1 (en) * | 2008-12-01 | 2010-06-03 | Becton, Dickinson And Company | Antimicrobial compositions |
US10314935B2 (en) | 2009-01-07 | 2019-06-11 | Entrotech Life Sciences, Inc. | Chlorhexidine-containing antimicrobial laminates |
US8637489B2 (en) * | 2009-02-09 | 2014-01-28 | L'oreal | Clear carrier compositions for lipophilic compounds, and method of treating keratinous substrates using such compositions |
US20100202988A1 (en) * | 2009-02-09 | 2010-08-12 | L'oreal | Clear carrier compositions containing an alkoxylated monoacid and an alkyl monoamine and method of treating keratinous substrates using such compositions |
US20100202995A1 (en) * | 2009-02-09 | 2010-08-12 | L'oreal | Clear carrier compositions for lipophilic compounds, and method of treating keratinous substrates using such compositions |
US8597668B2 (en) * | 2009-02-09 | 2013-12-03 | L'oreal | Clear carrier compositions for lipophilic compounds, and method of treating keratinous substrates using such compositions |
US8968793B2 (en) * | 2009-02-11 | 2015-03-03 | Ramot At Tel-Aviv University Ltd. | Antiseptic compositions and uses thereof |
MX2011011855A (es) * | 2009-05-08 | 2011-12-06 | 3M Innovative Properties Co | Metodo y kit para el cuidado oral. |
WO2010134942A1 (fr) * | 2009-05-16 | 2010-11-25 | Trutek Corp. | Application nasale multi-actions chargée électrostatiquement, produit et procédé |
JP6001449B2 (ja) | 2009-06-16 | 2016-10-05 | スリーエム イノベイティブ プロパティズ カンパニー | 自己支持基材を備える柔軟性のある接着性医療用物品 |
BR112012006107A2 (pt) * | 2009-09-17 | 2016-06-07 | Eugene B Guthery | formulações nasais, de ferida e de pele e métodos para controle de staphylococci e outras bactérias gram-positivas resistentes a antibiótico |
US20110086078A1 (en) * | 2009-10-14 | 2011-04-14 | Water Visions International, Inc. | Fibrous antimicrobial materials, structures, and barrier applications |
EP2493442A4 (fr) * | 2009-10-26 | 2013-05-15 | Innovation Technologies Inc | Dispositifs, méthodes et composition permettant de lutter contre les infections |
DE102010010174A1 (de) * | 2010-03-03 | 2011-09-08 | Bode Chemie Gmbh | Antimikrobielle Öl-in-Wasser-Emulsion enthaltend quaternäre Ammoniumverbindungen |
DE102010013081A1 (de) * | 2010-03-26 | 2011-09-29 | B. Braun Melsungen Ag | Antimikrobielle Öl in Wasser Emulsion |
DE102010013274A1 (de) * | 2010-03-29 | 2011-11-17 | Beiersdorf Ag | Mikrobiologisch stabile anwendungsfreundliche Zubereitungen |
CN101812383B (zh) * | 2010-05-20 | 2012-02-22 | 北京绿伞化学股份有限公司 | 一种消毒洗涤剂及其制备方法 |
CN101869537B (zh) * | 2010-06-29 | 2012-02-08 | 大连欧派科技有限公司 | 一种女士洁阴湿巾 |
EP2588117B1 (fr) | 2010-06-29 | 2018-04-25 | 3M Innovative Properties Company | Compositions antiseptiques stables et procédés |
US20130165880A1 (en) | 2010-09-17 | 2013-06-27 | David T. Amos | Antimicrobial disposable absorbent articles |
US20130211310A1 (en) | 2010-10-28 | 2013-08-15 | 3M Innovative Properties Company | Engineered surfaces for reducing bacterial adhesion |
GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
EP3456200B1 (fr) | 2011-05-10 | 2023-05-03 | Next Science IP Holdings Pty Ltd | Article ayant un solide antimicrobien et son utilisation |
WO2013003373A1 (fr) | 2011-06-27 | 2013-01-03 | 3M Innovative Properties Company | Surfaces microstructurées permettant de réduire l'adhérence de bactéries |
FR2978664B1 (fr) | 2011-08-04 | 2014-01-10 | Petcare Innovation | Composition antiseptique |
WO2013043608A1 (fr) * | 2011-09-20 | 2013-03-28 | Bio-Rad Laboratories, Inc. | Élimination d'agents virucides de préparations biomoléculaires |
US9717798B2 (en) | 2011-11-16 | 2017-08-01 | 3M Innovative Properties Company | Polymeric colorant compositions and methods of use |
LT2782584T (lt) | 2011-11-23 | 2021-09-10 | Therapeuticsmd, Inc. | Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas |
US8829053B2 (en) | 2011-12-07 | 2014-09-09 | Rochal Industries Llp | Biocidal compositions and methods of using the same |
WO2013101884A1 (fr) | 2011-12-29 | 2013-07-04 | 3M Innovative Properties Company | Champ opératoire |
US20130255061A1 (en) * | 2012-04-03 | 2013-10-03 | Becton, Dickinson And Company | Systems and methods for applying a novel antimicrobial coating material to a medical device |
US9352119B2 (en) | 2012-05-15 | 2016-05-31 | Becton, Dickinson And Company | Blood control IV catheter with antimicrobial properties |
US9579486B2 (en) | 2012-08-22 | 2017-02-28 | Becton, Dickinson And Company | Blood control IV catheter with antimicrobial properties |
WO2014035981A1 (fr) | 2012-08-28 | 2014-03-06 | 3M Innovative Properties Company | Compositions de gluconate de chlorhexidine, systèmes de résine et articles |
DE102012215511A1 (de) | 2012-08-31 | 2014-06-12 | Schülke & Mayr GmbH | Verfahren zur Herstellung einer Bispyridiniumalkan enthaltenden halbfesten Zubereitung |
JP5872430B2 (ja) * | 2012-09-20 | 2016-03-01 | 日本電子照射サービス株式会社 | グルコン酸クロルヘキシジン製剤、消毒用キット及び滅菌方法 |
EP2897548A4 (fr) | 2012-09-21 | 2016-05-25 | 3M Innovative Properties Co | Protection d'incision |
US20150354096A1 (en) | 2012-12-20 | 2015-12-10 | Convatec Technologies Inc. | Processing of chemically modified cellulosic fibres |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
CN103081940B (zh) * | 2013-02-05 | 2014-06-18 | 河南科技学院 | 一种复方醋酸氯己定微乳消毒剂及其制备方法 |
US9695323B2 (en) | 2013-02-13 | 2017-07-04 | Becton, Dickinson And Company | UV curable solventless antimicrobial compositions |
US9750928B2 (en) | 2013-02-13 | 2017-09-05 | Becton, Dickinson And Company | Blood control IV catheter with stationary septum activator |
CN105051123A (zh) * | 2013-02-21 | 2015-11-11 | 科林斯波特公司 | 对经常触摸的表面的处理用于改善卫生 |
EP2999794B1 (fr) | 2013-05-21 | 2018-03-28 | 3M Innovative Properties Company | Nanostructuré vehicule porteur de spores |
WO2014197344A1 (fr) | 2013-06-06 | 2014-12-11 | 3M Innovative Properties Company | Film polymère co-extrudé successivement pelable à couche(s) antimicrobienne(s) intégrée(s) |
WO2014209798A1 (fr) * | 2013-06-28 | 2014-12-31 | 3M Innovative Properties Company | Lingette avec un polymère contenant du guanidinyle |
WO2015013093A1 (fr) | 2013-07-23 | 2015-01-29 | 3M Innovative Properties Company | Pansement ajustable |
MX361642B (es) | 2013-09-13 | 2018-12-13 | 3M Innovative Properties Co | Composiciones antisépticas catiónicas. |
GB201405660D0 (en) * | 2014-03-28 | 2014-05-14 | Gama Healthcare Ltd | A liquid disinfecting composition |
EP3131540B1 (fr) | 2014-04-18 | 2023-11-22 | Entrotech, Inc. | Procédés de traitement de compositions polymérisables contenant de la chlorhexidine et articles antimicrobiens ainsi formés |
US9675793B2 (en) | 2014-04-23 | 2017-06-13 | Becton, Dickinson And Company | Catheter tubing with extraluminal antimicrobial coating |
US10376686B2 (en) | 2014-04-23 | 2019-08-13 | Becton, Dickinson And Company | Antimicrobial caps for medical connectors |
US9789279B2 (en) | 2014-04-23 | 2017-10-17 | Becton, Dickinson And Company | Antimicrobial obturator for use with vascular access devices |
US9970303B2 (en) | 2014-05-13 | 2018-05-15 | Entrotech, Inc. | Erosion protection sleeve |
US20160354307A1 (en) * | 2014-05-19 | 2016-12-08 | Carl Hilliard | Antimicrobial composition and methods of use |
US10232088B2 (en) | 2014-07-08 | 2019-03-19 | Becton, Dickinson And Company | Antimicrobial coating forming kink resistant feature on a vascular access device |
US9848604B2 (en) * | 2014-07-11 | 2017-12-26 | Medtronic Xomed, Inc. | Antimicrobial wash |
WO2016048304A1 (fr) * | 2014-09-24 | 2016-03-31 | Colgate-Palmolive Company | Biodisponibilité d'ions métalliques |
EP3233036B1 (fr) | 2014-12-15 | 2023-01-25 | 3M Innovative Properties Company | Trousses pour l'élimination du tartre |
EP3253370A4 (fr) * | 2015-02-05 | 2018-08-01 | Marc Selner | Suspension de nano-vésicules ioniques et biocide préparé à partir d'une telle suspension |
US10813357B1 (en) | 2015-05-26 | 2020-10-27 | Gojo Industries, Inc. | Compositions and methods with efficacy against spores and other organisms |
CN108136026A (zh) | 2015-06-19 | 2018-06-08 | 全球健康方案有限责任公司 | 包含阳离子杀生物剂的基于凡士林的组合物 |
WO2017019009A1 (fr) | 2015-07-27 | 2017-02-02 | Kimberly-Clark Worldwide, Inc. | Composition désinfectante résiduelle |
CN105106029A (zh) * | 2015-09-10 | 2015-12-02 | 高密市丽美化妆品有限公司 | 新型化妆品防腐剂 |
US20170100383A1 (en) * | 2015-10-13 | 2017-04-13 | Practical Solution, Inc. | Topical formulations for preventing skin infection |
US10493244B2 (en) | 2015-10-28 | 2019-12-03 | Becton, Dickinson And Company | Extension tubing strain relief |
US10188598B1 (en) | 2015-11-25 | 2019-01-29 | Sage Products, Llc | Sterilized chlorhexidine article and method of sterilizing a chlorhexidine article |
SE1650162A1 (en) | 2016-02-09 | 2017-08-10 | Karladani Abbas | Antimicrobial and cleansing composition comprising a polymeric biguanide, EDTA, and surfactants. |
RU2719462C1 (ru) | 2016-06-22 | 2020-04-17 | 3М Инновейтив Пропертиз Компани | Способы и наборы для удаления зубного камня |
CN106214926A (zh) * | 2016-07-29 | 2016-12-14 | 腾科宝迪(厦门)生物科技有限公司 | 一种鼻喷雾剂及其制备方法 |
WO2018075150A1 (fr) | 2016-10-20 | 2018-04-26 | 3M Innovative Properties Company | Procédés et kits pour éliminer le tartre à l'aide d'un ion métallique et d'un bicarbonate |
US11446219B2 (en) | 2016-10-20 | 2022-09-20 | 3M Innovative Properties Company | Methods and kits for removing calculus using a non-enzymatic, hydrogen peroxide decomposition catalyst |
US10941252B2 (en) | 2016-11-03 | 2021-03-09 | 3M Innovative Properties Company | Silicone copolymers, methods of making, and articles |
CN106421217B (zh) * | 2016-11-14 | 2017-12-01 | 广东洛斯特制药有限公司 | 一种苯扎氯铵的溶液及其制备方法 |
WO2018217761A1 (fr) * | 2017-05-23 | 2018-11-29 | Hitchcock Wiley William | Composition antimicrobienne |
CN110769931A (zh) * | 2017-06-17 | 2020-02-07 | 株式会社Acenet | 自由基产生催化剂、自由基的制造方法、氧化反应产物的制造方法、药剂和农畜产用药剂 |
WO2019026992A1 (fr) * | 2017-08-03 | 2019-02-07 | 参天製薬株式会社 | Composition médicinale contenant de la chlorhexidine |
US11744248B2 (en) * | 2017-08-20 | 2023-09-05 | Enviro Specialty Chemicals Inc. | Disinfectant composition for control of clostridium difficile spore |
US11134676B2 (en) * | 2017-08-30 | 2021-10-05 | Nobio Ltd. | Anti-microbial particles and methods of use thereof |
JP7138702B2 (ja) | 2017-09-22 | 2022-09-16 | ベクトン・ディキンソン・アンド・カンパニー | カテーテルロック溶液としての使用のための4%クエン酸三ナトリウム溶液 |
TW201947084A (zh) * | 2018-04-06 | 2019-12-16 | 香港商醫鎧科技(香港)有限公司 | 用於醫療保健環境的耐用抗菌處理之紡織品 |
JP2021521136A (ja) * | 2018-04-09 | 2021-08-26 | ローディア オペレーションズ | 長期間持続する殺菌のための組成物及び方法 |
GB201810925D0 (en) * | 2018-07-03 | 2018-08-15 | Blueberry Therapeutics Ltd | Compositions and methods of treatment |
CN108904859A (zh) * | 2018-07-23 | 2018-11-30 | 衢州玛济克医疗科技有限公司 | 一种痔疮医用敷料及其生产方法 |
CN108837175A (zh) * | 2018-07-23 | 2018-11-20 | 衢州玛济克医疗科技有限公司 | 一种清创医用敷料及其生产方法 |
DE102018220631A1 (de) * | 2018-11-29 | 2020-06-04 | B. Braun Melsungen Ag | Wässrige Zusammensetzung, insbesondere zur Behandlung von Schleimhaut und/oder Wunden |
CN109298101A (zh) * | 2018-12-03 | 2019-02-01 | 山东省食品药品检验研究院 | 一种小麦粉及其制品中间苯二酚的高效液相色谱测定方法 |
CN111265473A (zh) * | 2018-12-04 | 2020-06-12 | 南京从一医药科技有限公司 | 一种具有阻隔异物和杀菌作用的双功能鼻保护凝胶 |
CN113556939A (zh) | 2018-12-27 | 2021-10-26 | 3M创新有限公司 | 具有1,2-链烷二醇的抗微生物组合物 |
JP2022522000A (ja) * | 2019-02-27 | 2022-04-13 | オティカラ,インコーポレーテッド | 鼻、副鼻腔、および鼻咽頭組織の感染および/または炎症を治療するための方法 |
US20220347066A1 (en) | 2019-07-23 | 2022-11-03 | Conopco, Inc., D/B/A Unilever | Water-in-oil emulsion composition for enhanced delivery of water soluble skin benefit agents |
US11766822B2 (en) | 2019-08-20 | 2023-09-26 | 3M Innovative Properties Company | Microstructured surface with increased microorganism removal when cleaned, articles and methods |
JP2022545424A (ja) | 2019-08-20 | 2022-10-27 | スリーエム イノベイティブ プロパティズ カンパニー | 洗浄時の微生物除去が向上した微細構造化表面、物品、及び方法 |
EP4017401A1 (fr) | 2019-08-20 | 2022-06-29 | 3M Innovative Properties Company | Articles médicaux ayant une surface microstructurée présentant une élimination accrue des microorganismes après nettoyage et procédés associés |
EP4045057A4 (fr) | 2019-10-18 | 2023-12-06 | Topikos Scientific, Inc. | Organosilanes antimicrobiens |
US11884845B2 (en) * | 2019-12-03 | 2024-01-30 | Massachusetts Institute Of Technology | Body fluid resistant tissue adhesives |
CN111213674B (zh) * | 2019-12-06 | 2021-07-02 | 鲁东大学 | 一种具有抑菌活性的化合物及其制备方法和应用 |
GB202006794D0 (en) * | 2020-05-07 | 2020-06-24 | Quin Global Uk Ltd | Hand sanitising composition, apparatus and dispensing unit |
EP4153060A1 (fr) | 2020-05-20 | 2023-03-29 | 3M Innovative Properties Company | Articles médicaux à surface microstructurée |
TWI793555B (zh) * | 2020-06-05 | 2023-02-21 | 日商能源前沿公司 | 塗膜及於表面形成有塗膜的物品 |
WO2021260605A1 (fr) * | 2020-06-25 | 2021-12-30 | Samad, Abdul | Films barrières |
KR20220054586A (ko) * | 2020-08-31 | 2022-05-03 | 샐바시온 유에스에이 인크. | 항바이러스 조성물 |
US20230390991A1 (en) | 2020-12-11 | 2023-12-07 | 3M Innovative Properties Company | Method of thermoforming film with structured surface and articles |
CN112724770B (zh) * | 2020-12-25 | 2022-03-29 | 广州慧谷化学有限公司 | 一种抗菌防霉亲水涂料 |
EP4284570A1 (fr) | 2021-01-28 | 2023-12-06 | 3M Innovative Properties Company | Surface microstructurée à élimination accrue des micro-organismes après nettoyage, articles et procédés |
WO2022170147A1 (fr) * | 2021-02-05 | 2022-08-11 | Acp Laboratories Llc | Composition topique pour le traitement de champignons se formant sur le corps d'un utilisateur |
US20240099815A1 (en) | 2021-02-23 | 2024-03-28 | 3M Innovative Properties Company | Medical articles with microstructured surface having increased microorganism removal when cleaned and methods thereof |
US20220370309A1 (en) * | 2021-05-20 | 2022-11-24 | Shielded, Beauty, LLC | Antimicrobial skincare composition and treatment |
EP4401946A1 (fr) | 2021-09-14 | 2024-07-24 | Solventum Intellectual Properties Company | Articles comprenant une surface incurvée microstructurée et leurs méthodes de fabrication |
WO2023047205A1 (fr) | 2021-09-23 | 2023-03-30 | 3M Innovative Properties Company | Méthodes de fabrication d'articles thermoformés lisses |
WO2023105372A1 (fr) | 2021-12-07 | 2023-06-15 | 3M Innovative Properties Company | Surface microstructurée et articles présentant une moindre visibilité des rayures et procédés associés |
KR20230100252A (ko) * | 2021-12-28 | 2023-07-05 | 단국대학교 천안캠퍼스 산학협력단 | 신규한 화합물을 포함하는 생리 식염수 |
WO2024047419A1 (fr) | 2022-08-31 | 2024-03-07 | Solventum Intellectual Properties Company | Articles comprenant une surface incurvée microstructurée, articles d'outillage et procédés |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0287204A2 (fr) * | 1987-02-25 | 1988-10-19 | The Trustees of Columbia University in the City of New York | Emploi de sulfadiazinate d'argent pour l'inhibition de transmission du virus du SIDA |
WO2001013956A2 (fr) * | 1999-08-26 | 2001-03-01 | Ganeden Biotech, Inc. | Utilisation d'huile d'emeu et de ses diverses fractions comme excipient pour des medicaments et des preparations antifongiques, antibacteriennes et antivirales |
US20020045667A1 (en) * | 1999-04-28 | 2002-04-18 | The Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
US6383505B1 (en) * | 2000-11-09 | 2002-05-07 | Steris Inc | Fast-acting antimicrobial lotion with enhanced efficacy |
US20030194412A1 (en) * | 2001-06-05 | 2003-10-16 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
Family Cites Families (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2818390A (en) * | 1954-04-16 | 1957-12-31 | Monsanto Chemicals | Halogenated carbanilides |
GB882742A (en) | 1959-02-19 | 1961-11-22 | Chesebrough Ponds | Anhydrous germicidal compositions |
DE2242187A1 (de) | 1971-08-31 | 1973-03-08 | Ciba Geigy Ag | Heterocyclische verbindungen |
BE788151A (fr) | 1971-08-31 | 1973-02-28 | Ciba Geigy | Thiadiazoles pouvant servir de fongicides pour le traitement des semences et des terres et de substances actives pour medicaments |
SE385007B (sv) | 1971-08-31 | 1976-05-31 | Ciba Geigy Ag | Tiadiazolderivat till anvendning som fungicida medel, som betmedel for utsede och som skydd for organiskt material mot angrepp av skadliga mikroorganismer |
US4010252A (en) * | 1974-12-19 | 1977-03-01 | Colgate-Palmolive Company | Antimicrobial compositions |
US4067997A (en) * | 1975-05-21 | 1978-01-10 | Med-Chem Laboratories | Synergistic microbecidal composition and method |
IL52045A (en) * | 1976-08-25 | 1979-12-30 | Mundipharma Ag | Sprayable germicidal foam compositions |
JPS5366415A (en) | 1976-11-19 | 1978-06-13 | Nobuo Nishiyama | Ointment for activaing and regenerating damaged skin cell |
US4148924A (en) | 1977-06-13 | 1979-04-10 | The Procter & Gamble Company | Dermatological compositions |
WO1981002977A1 (fr) * | 1980-04-25 | 1981-10-29 | Orthana Kemisk Fab As | Solutions sterilisees, preservees, stables, et contenant de la mucine et procede de sterilisation |
KR830005852A (ko) * | 1980-07-18 | 1983-09-14 | 미첼 페터 잭슨 | 피부와 점막의 비루스 감염치료에 적합한 국소치료제의 제조방법 |
CA1199273A (fr) * | 1982-07-15 | 1986-01-14 | Ctibor Schindlery | Compose anti-inflammatoire |
JPS6044539A (ja) | 1983-08-22 | 1985-03-09 | Kawaguchi Kagaku Kogyo Kk | ゴム加工助剤の顆粒状製品の製造法 |
JPS61194034A (ja) * | 1985-02-25 | 1986-08-28 | Teijin Ltd | 経鼻投与用粉末状組成物 |
US4983595A (en) * | 1986-05-22 | 1991-01-08 | Syntex (U.S.A.) Inc. | Aqueous steroid formulations for nasal administration |
JPS63130541A (ja) | 1986-11-18 | 1988-06-02 | Sunstar Inc | 抗菌性組成物 |
AU618517B2 (en) | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
US4894220A (en) * | 1987-01-30 | 1990-01-16 | Colgate-Palmolive Company | Antibacterial antiplaque oral composition |
US5344641A (en) * | 1987-01-30 | 1994-09-06 | Colgate-Palmolive Co. | Antibacterial antiplaque oral composition |
JPH0625090B2 (ja) * | 1987-02-12 | 1994-04-06 | 花王株式会社 | 毛髪化粧料 |
US4931282A (en) * | 1987-11-25 | 1990-06-05 | Minnesota Mining And Manufacturing Company | Pressure-sensitive medical sealant |
US5225473A (en) * | 1987-11-25 | 1993-07-06 | Minnesota Mining And Manufacturing Company | Pressure-sensitive adhesives |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
JPH02140167A (ja) | 1988-11-22 | 1990-05-29 | Saraya Kk | 手指消毒用組成物 |
CA1316623C (fr) * | 1989-04-06 | 1993-04-20 | Pavel Stovicek | Compositions biocides de moulage et d'enduction a base de sels d'ammonium quaternaires de nalkyl x,x, bi (4,4'-hydroxyphenyles) et de sels quaternaires de glycols et de polyglycols comme structures de base des resines |
US5318955A (en) * | 1989-04-07 | 1994-06-07 | Henkel Kommanditgesellschaft Auf Aktien | Use of selected ethers of monofunctional alcohols in drilling fluids |
US5076859A (en) | 1989-12-26 | 1991-12-31 | Aluminum Company Of America | Heat treatment of aluminum-lithium alloys |
US5314694A (en) * | 1990-10-29 | 1994-05-24 | Alza Corporation | Transdermal formulations, methods and devices |
EP0580803B1 (fr) * | 1991-04-10 | 1999-07-07 | CAPELLI, Christopher C. | Compositions antimicrobiennes utiles pour des applications medicales |
US5192802A (en) * | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
DE69223902T2 (de) * | 1991-10-18 | 1998-08-27 | Kuraray Co | Antimikrobielle polymerisierbare Zusammensetzung, das Polymer und daraus hergestellter Gegenstand |
US5336432A (en) | 1992-01-24 | 1994-08-09 | John Petchul | Composition for microemulsion gel having bleaching and antiseptic properties |
US6197346B1 (en) | 1992-04-24 | 2001-03-06 | Brown Universtiy Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
JPH06166623A (ja) * | 1992-09-25 | 1994-06-14 | Toyama Chem Co Ltd | 抗菌性組成物 |
US5429819A (en) * | 1992-10-14 | 1995-07-04 | Matsushita Electric Industrial Co., Ltd. | Antiviral composition |
DE4302812A1 (de) | 1993-02-02 | 1994-08-04 | Bode Chemie Gmbh & Co | Peroxidentwickelnde Desinfektionsmittel oder -antiseptika |
JPH08507078A (ja) * | 1993-02-17 | 1996-07-30 | スミスクライン・ビーチャム・コーポレイション | 治療用ペプチド含有のミクロエマルジョン |
ES2122288T3 (es) | 1993-05-26 | 1998-12-16 | Fresenius Ag | Antiinfeccioso. |
US5482931A (en) * | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
US6238682B1 (en) * | 1993-12-13 | 2001-05-29 | The Procter & Gamble Company | Anhydrous skin lotions having antimicrobial components for application to tissue paper products which mitigate the potential for skin irritation |
US5817325A (en) * | 1996-10-28 | 1998-10-06 | Biopolymerix, Inc. | Contact-killing antimicrobial devices |
JPH09510208A (ja) | 1994-03-11 | 1997-10-14 | ザ、プロクター、エンド、ギャンブル、カンパニー | 酸性活性剤を含有した低pH加水分解安定性化粧品組成物 |
MX9604411A (es) * | 1994-03-28 | 1997-12-31 | Univ Columbia | Composicion para inactivar irritantes en fluidos. |
JP2677775B2 (ja) * | 1994-04-14 | 1997-11-17 | 株式会社東芝 | 再生装置 |
TW438601B (en) * | 1994-05-18 | 2001-06-07 | Janssen Pharmaceutica Nv | New mucoadhesive emulsion compositions and a process for the preparation thereof |
US5547677A (en) * | 1994-05-20 | 1996-08-20 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
US6071866A (en) * | 1994-06-01 | 2000-06-06 | Lever Brothers Company, Division Of Conopco, Inc. | Mild antimicrobial liquid cleansing formulations comprising hydroxy acid buffering compound or compounds as potentiator of antimicrobial effectiveness |
JPH0815132A (ja) | 1994-07-05 | 1996-01-19 | Nippon Laser Denshi Kk | 表面プラズモン発生用光線反射器 |
JP3515821B2 (ja) * | 1994-10-21 | 2004-04-05 | 株式会社資生堂 | 消毒用組成物 |
JP3968131B2 (ja) | 1994-11-28 | 2007-08-29 | サンスター株式会社 | 抗菌製剤 |
US7833543B2 (en) | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
GB9512290D0 (en) | 1995-06-16 | 1995-08-16 | Moorfields Eye Hospital | Uses of polyhexanide |
AU715827B2 (en) * | 1995-06-22 | 2000-02-10 | Minnesota Mining And Manufacturing Company | Stable hydroalcoholic compositions |
US6123933A (en) * | 1995-07-19 | 2000-09-26 | Mitsubishi Chemical Corporation | Hair cosmetic compositions |
TW434023B (en) | 1995-09-18 | 2001-05-16 | Novartis Ag | Preserved ophthalmic composition |
JPH09124459A (ja) * | 1995-10-27 | 1997-05-13 | Kao Corp | 肛門周辺清拭用組成物 |
US6008173A (en) | 1995-11-03 | 1999-12-28 | Colgate-Palmolive Co. | Bar composition comprising petrolatum |
US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
GB9616208D0 (en) * | 1996-08-01 | 1996-09-11 | Smithkline Beecham Plc | Novel Compounds |
AU1530697A (en) | 1996-09-06 | 1998-03-26 | Minnesota Mining And Manufacturing Company | Antimicrobial compositions |
DE69709691T2 (de) * | 1996-10-21 | 2002-08-22 | Morten Sloth Weidner | Pharmazeutische zusammenstellungen mit parthenium integrifolium oder mit einem extrakt oder einer komponente davon, verwendung dieses pflanzenmaterials zur herstellung von medizin und ein verfahren zur extraktherstellung von parthenium integrifolium |
US6338855B1 (en) * | 1996-10-25 | 2002-01-15 | The Procter & Gamble Company | Cleansing articles for skin and/or hair which also deposit skin care actives |
GB2323784B (en) | 1997-04-02 | 2001-09-12 | Reckitt & Colman Inc | Flexible hydrophilic articles having a residual antimicrobial effect |
US6210695B1 (en) * | 1997-06-04 | 2001-04-03 | The Procter & Gamble Company | Leave-on antimicrobial compositions |
US6287577B1 (en) * | 1997-11-12 | 2001-09-11 | The Procter & Gamble Company | Leave-on antimicrobial compositions which provide improved residual benefit versus gram positive bacteria |
KR20010013377A (fr) * | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | Compositions antimicrobiennes comprenant un analogue de l'acide benzoique et un sel metallique |
DE19733684A1 (de) * | 1997-08-04 | 1999-02-11 | Henkel Kgaa | Konservierungsmittelsystem für Körperpflegemittel |
KR20010031363A (ko) * | 1997-10-22 | 2001-04-16 | 젠스 포니카우 | 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도 |
IL122084A (en) | 1997-10-31 | 1999-09-22 | Lurident Ltd | Formulation for personal care with mucoadhesive properties |
US5897872A (en) * | 1997-11-12 | 1999-04-27 | Picciano; Dante J. | Iodine-containing nasal moisturizing saline solution |
US6171611B1 (en) * | 1997-11-12 | 2001-01-09 | Dante J. Picciano | Iodine-containing nasal moisturizing saline and mouthwash solutions |
US6248343B1 (en) * | 1998-01-20 | 2001-06-19 | Ethicon, Inc. | Therapeutic antimicrobial compositions |
US6022551A (en) * | 1998-01-20 | 2000-02-08 | Ethicon, Inc. | Antimicrobial composition |
US20020022660A1 (en) | 1998-01-20 | 2002-02-21 | Hanuman B. Jampani | Deep penetrating antimicrobial compositions |
US20010053775A1 (en) * | 1998-01-30 | 2001-12-20 | Matthias Seidel | Nasal solutions |
US6054143A (en) * | 1998-03-24 | 2000-04-25 | Jones; Alonzo H. | Xylitol delivery |
HUP0101738A3 (en) | 1998-04-03 | 2003-04-28 | Colgate Palmolive Co New York | Improved low residue cosmetic composition |
GB9810803D0 (en) | 1998-05-21 | 1998-07-22 | Boots Co Plc | Topical compositions |
JP3883739B2 (ja) * | 1998-05-22 | 2007-02-21 | 株式会社メニコン | コンタクトレンズ用殺菌液 |
WO1999060998A1 (fr) | 1998-05-27 | 1999-12-02 | Euroceltique S.A. | Preparations pour l'application d'anti-inflammatoires, et plus particulierement d'antiseptiques et/ou d'agents favorisant la guerison des blessures, dans les voies respiratoires superieures et/ou l'oreille |
JP3592080B2 (ja) | 1998-06-08 | 2004-11-24 | 吉田製薬株式会社 | 粘稠な速乾性殺菌消毒剤 |
AU3950199A (en) | 1998-06-22 | 2000-01-10 | Procter & Gamble Company, The | Treated wipe articles |
GB2338649A (en) | 1998-06-25 | 1999-12-29 | Brian Francis Hawtin | Nasal antiseptic compositions |
US20020119579A1 (en) | 1998-07-14 | 2002-08-29 | Peter Wagner | Arrays devices and methods of use thereof |
US6071541A (en) * | 1998-07-31 | 2000-06-06 | Murad; Howard | Pharmaceutical compositions and methods for managing skin conditions |
WO2000009173A1 (fr) * | 1998-08-14 | 2000-02-24 | Coloplast A/S | Compositions stabilisees a activite antibacterienne |
EP1111995B1 (fr) * | 1998-09-11 | 2005-02-09 | Surfacine Development Company, LLC | Compositions antimicrobiennes dermiques topiques |
US20030147925A1 (en) * | 1998-09-11 | 2003-08-07 | Samuel P. Sawan | Topical dermal antimicrobial compositions, methods for generating same, and monitoring methods utilizing same |
NZ512267A (en) * | 1998-11-09 | 2003-11-28 | Ira Jay Newman | Ionic silver complex |
US20040091428A1 (en) | 1999-01-04 | 2004-05-13 | Barry M. Libin | Method of preventing and treating mucosal and dermal conditions |
US6534075B1 (en) * | 1999-03-26 | 2003-03-18 | Ecolab Inc. | Antimicrobial and antiviral compositions and treatments for food surfaces |
US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
US6187327B1 (en) * | 1999-05-19 | 2001-02-13 | Kevin Stack | Antimicrobial sanitizing lotion with skin protection properties |
US6440405B1 (en) * | 1999-06-07 | 2002-08-27 | University Of Delaware | Quaternary ammonium functionalized dendrimers and methods of use therefor |
US6187332B1 (en) * | 1999-06-14 | 2001-02-13 | Wisconsin Alumni Research Foundation | Acidic buffered nasal spray |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
US6723714B2 (en) * | 1999-07-06 | 2004-04-20 | Blansett Pharmacal Co., Inc. | Aqueous solvent for corticosteroids |
US6313246B1 (en) * | 1999-07-07 | 2001-11-06 | Nalco Chemical Company | High molecular weight zwitterionic polymers |
DE50012930D1 (de) * | 1999-07-20 | 2006-07-20 | Beiersdorf Ag | Emulgatorfreie feindisperse systeme vom typ wasser-in-öl |
YU4602A (sh) * | 1999-07-22 | 2005-06-10 | Aventis Pharmaceuticals Inc. | Farmaceutske formulacije zaštićene od dejstva mikroorganizama |
US6211243B1 (en) * | 1999-09-22 | 2001-04-03 | B. Ron Johnson | Methods for treating cold sores with anti-infective compositions |
WO2001028552A2 (fr) | 1999-10-19 | 2001-04-26 | The Procter & Gamble Company | Compositions antimicrobiennes comprenant de l'acide pyroglutamique et des sels metalliques |
EP1231838B1 (fr) | 1999-11-24 | 2009-12-02 | 3M Innovative Properties Company | Desinfectants pour graines, fruits et legumes |
NZ519878A (en) * | 1999-11-29 | 2004-02-27 | Nz Inst For Crop & Food Res | Collagen |
US6315989B1 (en) * | 1999-12-22 | 2001-11-13 | Revlon Consumer Products Corporation | Water in oil microemulsion peroxide compositions for use in coloring hair and related methods |
US6455066B1 (en) | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
US6224898B1 (en) * | 2000-03-23 | 2001-05-01 | The United States Of America As Represented By The Secretary Of The Army | Antimicrobial dendrimer nanocomposites and a method of treating wounds |
US6422778B2 (en) * | 2000-04-03 | 2002-07-23 | 3M Innovative Properties Company | Surgical prep solution applicator system and methods |
US6579906B2 (en) * | 2000-06-09 | 2003-06-17 | University Of Delaware | Dendrimer biocide-silver nanocomposites: their preparation and applications as potent antimicrobials |
AR031108A1 (es) | 2000-06-19 | 2003-09-10 | Colgate Palmolive Co | Un metodo para mejorar la actividad de una sal de aluminio o de aluminio/circonio que contiene especies de aluminio pequenas y grandes, las sales asi obtenidas y los productos antitranspirantes y/o desodorantes preparados con dichas sales mejoradas |
JP4597318B2 (ja) * | 2000-06-21 | 2010-12-15 | ピジョン株式会社 | 防腐抗菌性が改善された水性組成物 |
JP2002012118A (ja) | 2000-06-30 | 2002-01-15 | Mitsuboshi Belting Ltd | エアバッグドア一体型インストルメントパネル及びその製造方法 |
US20020031556A1 (en) * | 2000-07-21 | 2002-03-14 | Lindahl Ake R. | Stabilized hydrogen peroxide composition and method of making a stabilized hydrogen peroxide composition |
FR2812192B1 (fr) * | 2000-07-28 | 2003-01-31 | Oreal | Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils |
US6500861B1 (en) * | 2000-08-23 | 2002-12-31 | Michael D. Wider | Antimicrobial composition and methods of use in the treatment of disease |
FR2813189B1 (fr) | 2000-08-31 | 2003-02-28 | Oreal | Creme cosmetique moussante pour le traitement des peaux grasses |
WO2002028328A1 (fr) * | 2000-10-05 | 2002-04-11 | Seacoast Technologies, Inc. | Dispositif expansible destine a une therapie thermique |
JP5009468B2 (ja) * | 2000-10-18 | 2012-08-22 | 千寿製薬株式会社 | 局所用水性液剤 |
US6462025B2 (en) * | 2000-12-12 | 2002-10-08 | Imaginative Research Associates, Inc. | Antibiotic/benzoyl peroxide dispenser |
US7923469B2 (en) * | 2001-04-30 | 2011-04-12 | Allergen, Inc. | Compositions including vitamin-based surfactants and methods for using same |
WO2002094179A2 (fr) * | 2001-05-23 | 2002-11-28 | J.B. Chemicals & Pharmaceuticals Ltd. | Nouvelles compositions microbicides topiques |
US20030103867A1 (en) | 2001-06-19 | 2003-06-05 | Welch Allyn, Inc. | Compact diagnostic testing device |
US6833478B2 (en) | 2001-07-13 | 2004-12-21 | Sri International | N,N-dinitramide salts as solubilizing agents for biologically active agents |
US6746635B2 (en) * | 2001-08-08 | 2004-06-08 | Brown University Research Foundation | Methods for micronization of hydrophobic drugs |
US20030059378A1 (en) | 2001-09-06 | 2003-03-27 | Libin Barry M. | Method of preventing mucositis |
US6494856B1 (en) * | 2001-09-12 | 2002-12-17 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Swab deliverable actives |
US7030203B2 (en) * | 2001-09-28 | 2006-04-18 | 3M Innovative Properties Company | Water-in-oil emulsions with ethylene oxide groups, compositions, and methods |
US6951642B2 (en) * | 2001-09-28 | 2005-10-04 | 3M Innovative Properties Company | Water-in-oil emulsions with anionic groups, compositions, and methods |
US20030091540A1 (en) | 2001-10-16 | 2003-05-15 | Nawaz Ahmad | Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity |
WO2003105878A1 (fr) | 2002-01-20 | 2003-12-24 | 株式会社鳳凰堂 | Agent antibacterien et composition antibacterienne |
JP2003221320A (ja) * | 2002-01-29 | 2003-08-05 | Lion Corp | 口腔用組成物 |
US20030158128A1 (en) | 2002-02-12 | 2003-08-21 | Ford John P. | Treatment, composition and method using uracil against side-effects of chemotherapy |
AP2005003346A0 (en) | 2002-12-10 | 2005-06-30 | Biosynexus Inc | Topical anti-infective formulations |
US20040120916A1 (en) * | 2002-12-23 | 2004-06-24 | Advanced Medical Optics, Inc. | Contact lens care compositions, methods of use and preparation which protect ocular tissue membrane integrity |
US20040180093A1 (en) * | 2003-03-12 | 2004-09-16 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US20040208908A1 (en) * | 2003-04-16 | 2004-10-21 | The Trustees Of Columbia University In The City Of New York | Antimicrobial medical articles containing a synergistic combination of anti-infective compounds and octoxyglycerin |
US20050058673A1 (en) * | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
CA2538103A1 (fr) | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Composition antimicrobienne synergique comprenant un lipide antimicrobien et un activateur |
US7745509B2 (en) * | 2003-12-05 | 2010-06-29 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US20050123621A1 (en) * | 2003-12-05 | 2005-06-09 | 3M Innovative Properties Company | Silver coatings and methods of manufacture |
US20050123590A1 (en) * | 2003-12-05 | 2005-06-09 | 3M Innovative Properties Company | Wound dressings and methods |
US20060035039A1 (en) * | 2004-08-12 | 2006-02-16 | 3M Innovative Properties Company | Silver-releasing articles and methods of manufacture |
US20060034899A1 (en) * | 2004-08-12 | 2006-02-16 | Ylitalo Caroline M | Biologically-active adhesive articles and methods of manufacture |
US9028852B2 (en) | 2004-09-07 | 2015-05-12 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
US20060051384A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Antiseptic compositions and methods of use |
US8198326B2 (en) * | 2004-09-07 | 2012-06-12 | 3M Innovative Properties Company | Phenolic antiseptic compositions and methods of use |
CA2599653A1 (fr) | 2005-03-10 | 2006-09-21 | 3M Innovative Properties Company | Methodes de reduction d'une contamination microbienne |
MX2007010908A (es) | 2005-03-10 | 2007-12-05 | 3M Innovative Properties Co | Composiciones antimicrobianas que comprenden esteres de acidos hidroxicarboxilicos. |
-
2004
- 2004-09-07 US US10/936,135 patent/US9028852B2/en active Active
-
2005
- 2005-09-06 TW TW094130544A patent/TW200616609A/zh unknown
- 2005-09-07 CA CA2969582A patent/CA2969582A1/fr not_active Abandoned
- 2005-09-07 EP EP05793861.5A patent/EP1786264B1/fr active Active
- 2005-09-07 EP EP17186934.0A patent/EP3275437A1/fr not_active Withdrawn
- 2005-09-07 JP JP2007530494A patent/JP5154933B2/ja not_active Expired - Fee Related
- 2005-09-07 KR KR1020077007998A patent/KR20070102479A/ko not_active Application Discontinuation
- 2005-09-07 MX MX2013001576A patent/MX343725B/es unknown
- 2005-09-07 CA CA2579243A patent/CA2579243C/fr not_active Expired - Fee Related
- 2005-09-07 CN CN2005800370099A patent/CN101437394B/zh not_active Expired - Fee Related
- 2005-09-07 BR BRPI0514939-8A patent/BRPI0514939A/pt not_active Application Discontinuation
- 2005-09-07 AU AU2005282377A patent/AU2005282377B2/en not_active Ceased
- 2005-09-07 WO PCT/US2005/031956 patent/WO2006029255A2/fr active Application Filing
- 2005-09-07 MX MX2007002725A patent/MX2007002725A/es active IP Right Grant
-
2012
- 2012-09-14 JP JP2012202274A patent/JP2013040177A/ja not_active Ceased
-
2015
- 2015-02-09 JP JP2015023289A patent/JP2015129149A/ja active Pending
- 2015-05-05 US US14/703,911 patent/US10016501B2/en active Active
-
2016
- 2016-04-29 US US15/142,110 patent/US20160235848A1/en not_active Abandoned
-
2017
- 2017-07-21 JP JP2017141615A patent/JP2018008969A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0287204A2 (fr) * | 1987-02-25 | 1988-10-19 | The Trustees of Columbia University in the City of New York | Emploi de sulfadiazinate d'argent pour l'inhibition de transmission du virus du SIDA |
US20020045667A1 (en) * | 1999-04-28 | 2002-04-18 | The Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
WO2001013956A2 (fr) * | 1999-08-26 | 2001-03-01 | Ganeden Biotech, Inc. | Utilisation d'huile d'emeu et de ses diverses fractions comme excipient pour des medicaments et des preparations antifongiques, antibacteriennes et antivirales |
US6383505B1 (en) * | 2000-11-09 | 2002-05-07 | Steris Inc | Fast-acting antimicrobial lotion with enhanced efficacy |
US20030194412A1 (en) * | 2001-06-05 | 2003-10-16 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
Non-Patent Citations (1)
Title |
---|
See also references of WO2006029255A2 * |
Also Published As
Publication number | Publication date |
---|---|
CN101437394B (zh) | 2012-10-10 |
AU2005282377B2 (en) | 2011-07-28 |
CA2969582A1 (fr) | 2006-03-16 |
BRPI0514939A (pt) | 2008-07-01 |
JP2018008969A (ja) | 2018-01-18 |
WO2006029255A2 (fr) | 2006-03-16 |
JP2015129149A (ja) | 2015-07-16 |
AU2005282377A1 (en) | 2006-03-16 |
JP2008512389A (ja) | 2008-04-24 |
TW200616609A (en) | 2006-06-01 |
US20060051385A1 (en) | 2006-03-09 |
JP5154933B2 (ja) | 2013-02-27 |
JP2013040177A (ja) | 2013-02-28 |
US20160235848A1 (en) | 2016-08-18 |
KR20070102479A (ko) | 2007-10-18 |
US10016501B2 (en) | 2018-07-10 |
MX343725B (es) | 2016-11-18 |
US9028852B2 (en) | 2015-05-12 |
MX2007002725A (es) | 2007-05-16 |
US20150231248A1 (en) | 2015-08-20 |
WO2006029255A3 (fr) | 2009-04-16 |
CA2579243C (fr) | 2018-09-18 |
EP1786264A4 (fr) | 2012-10-17 |
CN101437394A (zh) | 2009-05-20 |
CA2579243A1 (fr) | 2006-03-16 |
EP1786264B1 (fr) | 2017-11-22 |
EP3275437A1 (fr) | 2018-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10016501B2 (en) | Cationic antiseptic compositions and methods of use | |
US20210060110A1 (en) | Antiseptic compositons and methods of use | |
US8198326B2 (en) | Phenolic antiseptic compositions and methods of use | |
EP2356982B1 (fr) | Compositions antimicrobielles et leur utilisation | |
US9826770B2 (en) | Antimicrobial compositions comprising esters of hydroxycarboxylic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070314 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
DAX | Request for extension of the european patent (deleted) | ||
R17D | Deferred search report published (corrected) |
Effective date: 20090416 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A01N 33/12 20060101ALI20090428BHEP Ipc: A61K 31/14 20060101AFI20090428BHEP Ipc: A01N 25/00 20060101ALI20090428BHEP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602005053121 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A01N0033120000 Ipc: A61K0031140000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120913 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/14 20060101AFI20120907BHEP Ipc: A61P 31/00 20060101ALI20120907BHEP Ipc: A01N 25/00 20060101ALI20120907BHEP Ipc: A01N 33/12 20060101ALI20120907BHEP |
|
17Q | First examination report despatched |
Effective date: 20140221 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20170418 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 947743 Country of ref document: AT Kind code of ref document: T Effective date: 20171215 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602005053121 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20171122 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 947743 Country of ref document: AT Kind code of ref document: T Effective date: 20171122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180222 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180223 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R026 Ref document number: 602005053121 Country of ref document: DE |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
26 | Opposition filed |
Opponent name: L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'E Effective date: 20180822 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20180905 Year of fee payment: 14 |
|
PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20180930 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180907 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180907 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180930 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180930 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180930 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180930 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R100 Ref document number: 602005053121 Country of ref document: DE |
|
PLCK | Communication despatched that opposition was rejected |
Free format text: ORIGINAL CODE: EPIDOSNREJ1 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171122 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20050907 |
|
PLBN | Opposition rejected |
Free format text: ORIGINAL CODE: 0009273 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: OPPOSITION REJECTED |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180322 |
|
27O | Opposition rejected |
Effective date: 20191128 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20190907 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190907 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230530 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230822 Year of fee payment: 19 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602005053121 Country of ref document: DE Owner name: SOLVENTUM INTELLECTUAL PROPERTIES CO. (N.D.GES, US Free format text: FORMER OWNER: 3M INNOVATIVE PROPERTIES COMPANY, ST. PAUL, MN, US |